StudyFinder
Search Results
Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
Search all categories
621 Study Matches
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Incyte Corporation Call Center (US) - medinfo@incyte.com
NCT06585774
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* ≥ 12 years of age at the time of informed consent.
* New-onset moderate or severe cGVHD, as defined by the 2014 NIH Consensus Development Project Criteria for Clinical Trials in cGVHD, requiring systemic therapy.
* History of allo-HCT from any donor HLA type (related or unrelated donor with any degree of HLA matching) using any graft source (bone marrow, peripheral blood stem cells, or cord blood). Recipients of myeloablative, nonmyeloablative, or reduced-intensity conditioning are eligible.
* Adequate hematologic function with ANC ≥ 0.5 × 109/L independent of growth factors for at least 7 days prior to study entry.
* Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
* Received more than 1 prior allo-HCT. Prior autologous HCT is allowed.
* Has overlap cGVHD, defined as simultaneous presence of features or characteristics of aGVHD in a patient with cGVHD.
* Received more than 7 days of systemic corticosteroid treatment for cGVHD or unable to begin a prednisone dose ≥ 1.0 mg/kg per day (or methylprednisolone equivalent) for cGVHD.
* Received previous systemic treatment for cGVHD, including extracorporeal photopheresis.
* Systemic treatment with CNIs or mTOR inhibitors started within 2 weeks prior to C1D1.
* Prior treatment with CSF-1R targeted therapies.
* Active, uncontrolled bacterial, fungal, parasitic, or viral infection.
* Evidence of relapse of the primary hematologic disease or treatment for relapse after the allo-HCT was performed, including DLIs for the treatment of molecular relapse.
* History of acute or chronic pancreatitis.
* Active symptomatic myositis.
* History or current diagnosis of cardiac disease indicating significant risk of safety for participation in the study, such as uncontrolled or significant cardiac disease.
* Severe renal impairment, that is, estimated CrCl \< 30 mL/min measured or calculated by Cockcroft-Gault equation in adults and Schwartz formula in pediatric participants, or endstage renal disease on dialysis.
* Impaired liver function, defined as total bilirubin \> 1.5 × ULN and/or ALT and AST \> 3 × ULN in participants with no evidence of liver cGVHD.
* Pregnant or breastfeeding.
Other protocol-defined Inclusion/Exclusion Criteria may apply. DRUG: INCA034176, DRUG: Placebo, DRUG: Corticosteroids
Chronic Graft-versus-host-disease
cGVHD
I'm interested
Share via email
Show 122 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| ASST degli Spedali Civili di Brescia Brescia, | |
| Akh Und Medizinische Universitat Wien Universitatsklinik Fur Innere Medizin I Vienna, | |
| Alberta's Children Hospital Calgary, Alberta | |
| Amsterdam University Medical Centre Amsterdam, | |
| Anjo Kosei Hospital Aichi-ken, | |
| Aou Policlinico Consorziale Di Bari Bari, | |
| Austin Health Medical Oncology and Clinical Haematology Heidelberg, Victoria | |
| Azienda Ospedaliera Card. G. Panico Tricase, | |
| Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello Palermo, | |
| Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli Naples, | |
| Azienda Ospedaliero Universitaria Policlinico G.Rodolico San Marco Catania, | |
| Azienda Ospedaliero Universitaria delle Marche Ancona, | |
| Azienda Ospedaliero-Universitaria Di Alessandria Ss.Antonio E Biagio E Cesare Arrigo Alessandria, | |
| Azienda Policlinico Umberto 1 Universita Sapienza Di Roma Rome, | |
| Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Milan, | |
| BC Children's Hospital Vancouver, British Columbia | |
| Baptist Cancer Center Memphis, Tennessee | |
| Bristol Haematology and Oncology Centre Bristol, | |
| CHU Amiens PICARDIE - Hopital SUD Amiens, | |
| Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu Nantes, | |
| Centro Ricerche Cliniche di Verona Verona, | |
| Charité Universitätsmedizin Berlin Berlin, | |
| Childrens National Hospital Washington D.C., District of Columbia | |
| Chu de Nice - Hospital L Archet Nice, | |
| Colorado Blood Cancer Institute Denver, Colorado | |
| Corewell Health Hematology Oncology Grand Rapids, Michigan | |
| Dana Farber Cancer Institute Boston, Massachusetts | |
| Emory University-Winship Cancer Institute Atlanta, Georgia | |
| Fujita Health University Hospital Aichi, | |
| Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli Reggio Calabria, | |
| Gunma Saiseikai Maebashi Hospital Maebashi, | |
| Hackensack University Medical Center Hackensack, New Jersey | |
| Henry Ford Hospital Detroit, Michigan | |
| Hiroshima University Hospital Hiroshima, | |
| Hokkaido University Hospital Sapporo, | |
| Hopitaux De Brabois Nancy, | |
| Hospices Civils de Lyon Centre Hospitalier Lyon Sud Pierre-Bénite, | |
| Hospital De La Santa Creu I Sant Pau Barcelona, | |
| Hospital General Universitario Gregorio Marañon Madrid, | |
| Hospital General Universitario Vall D Hebron Barcelona, | |
| Hospital Maisonneuve Rosemont Montreal, Quebec | |
| Hospital Puerta De Hierro Majadahonda, | |
| Hospital Saint Antoine Paris, | |
| Hospital Saint Louis Paris, | |
| Hospital Universitari i Politécnic La Fe Valencia, | |
| Hospital Universitario Donostia Donostia / San Sebastian, | |
| Hospital Universitario Miguel Servet Zaragoza, | |
| Hospital Universitario Virgen del Rocio Seville, | |
| Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria, | |
| I.R.C.C.S. Casa Sollievo Della Sofferenza San Giovanni Rotondo, | |
| IRCCS Azienda Ospedaliera Universitaria San Martino Genova, | |
| Innsbruck University Hospital Innsbruck, | |
| Institut Catala Doncologia Ico - Hospital Duran I Reynals Location L'Hospitalet de Llobregat, | |
| Institut Paoli Calmettes Marseille, | |
| Intermountain Blood and Marrow Transplant Salt Lake City, Utah | |
| Irccs Fondazione Policlinico San Matteo Pavia, | |
| Jefferson University Hospitals Philadelphia, Pennsylvania | |
| John Hopkins Hospital Baltimore, Maryland | |
| Juravinski Cancer Centre Hamilton, Ontario | |
| Klinikum Der Philipps-Universitaet Marburg Marburg, | |
| Kobe City Medical Center General Hospital Kobe, | |
| Kyushu University Hospital Fukuoka, | |
| Landeskrankenhaus Universitatsklinikum Graz Graz, | |
| Maastricht University Medical Center Maastricht, | |
| Manchester University NHS Foundation Trust Manchester, | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Medical University of South Carolina Charleston, South Carolina | |
| Memorial Cancer Institute Pembroke Pines, Florida | |
| Miami Cancer Institute Miami, Florida | |
| National Hospital Organization Kumamoto Medical Center Kumamoto Kumamoto, | |
| Northwestern Memorial Hospital Chicago, Illinois | |
| Nottingham University Hospitals Nottingham, | |
| Okayama University Hospital Okayama, | |
| Ordensklinikum Linz GmbH Elisabethinen Linz, | |
| Oregon Health and Science University Portland, Oregon | |
| Orlando Health Cancer Institute Downtown Orlando Orlando, Florida | |
| Osaka Metropolitan University Hospital Osaka, | |
| Ospedale Pediatrico Bambino Gesu Irccs Rome, | |
| Ospedale San Raffaele - Milano Milan, | |
| Plymouth Hospitals NHS Trust Plymouth, | |
| Princess Margaret Cancer Center Toronto, Ontario | |
| Prisma Health Upstate Greenville, South Carolina | |
| Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia | |
| Queen Elizabeth University Hospital Glasgow, | |
| Rigshospitalet Copenhagen, | |
| Royal Adelaide Hospital Adelaide, | |
| Royal Marsden Hospital London, | |
| Royal Prince Alfred Hospital Sydney, New South Wales | |
| Rutgers Cancer Institute of Nj New Brunswick, New Jersey | |
| St David'S South Austin Medical Center Austin, Texas | |
| St. Anna Childrens Hospital Vienna, | |
| St. James Hospital Dublin, | |
| Stollery Children's Hospital Edmonton, Alberta | |
| Stony Brook University Medical Center Stony Brook, New York | |
| Texas Transplant Institute San Antonio, Texas | |
| The University of Kansas Cancer Center Kansas City, Kansas | |
| Tohoku University Hospital Miyagi, | |
| Tokai University Hospital Isehara Kanagawa, | |
| Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo, | |
| Universitaetsklinikum Bonn, University Hospital Bonn Bonn, | |
| Universitaetsklinikum Erlangen Erlangen, | |
| Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole Toulouse, | |
| Universitatsklinikum Essen Essen, | |
| Universitatsklinikum Halle (Saale) Halle, | |
| Universitatsklinikum Leipzig Leipzig, | |
| Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii Mainz, | |
| University Clinic Carl Gustav Carus Technical University Dresden Dresden, | |
| University College London Hospitals (UCLH) London, | |
| University Hospital Duesseldorf Düsseldorf, | |
| University Hospital Schleswig-Holstein Campus Kiel Kiel, | |
| University Medical Center Rwth Aachen Aachen, | |
| University of Alabama Birmingham Birmingham, Alabama | |
| University of California San Diego Medical Center, Moores Cancer Center La Jolla, California | |
| University of Illinois Chicago, Illinois | |
| University of Michigan Ann Arbor, Michigan | |
| University of Rochester Medical Center Rochester, New York | |
| University of Southern California Los Angeles, California | |
| Universitätsklinikum Münster Münster, | |
| Vancouver General Hospital Vancouver, | |
| Virginia Commonwealth University Massey Cancer Center Richmond, Virginia | |
| Wake Forest Baptist Medical Center Winston-Salem, North Carolina | |
| West Virginia University Cancer Institute Morgantown, West Virginia |
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Toll Free Number - Trialsites@msd.com
NCT06890884
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues.
* Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale.
* Has received no prior treatment for their DLBCL.
* Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART).
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization.
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
* Has a history of transformation of indolent disease to DLBCL.
* Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma.
* Has Ann Arbor Stage I DLBCL.
* Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication.
* Has clinically significant pericardial or pleural effusion.
* Has ongoing Grade \>1 peripheral neuropathy.
* Has a demyelinating form of Charcot-Marie-Tooth disease.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Has ongoing corticosteroid therapy.
* Known additional malignancy that is progressing or has required active treatment within the past 2 years.
* Known active central nervous system (CNS) lymphoma.
* Has active autoimmune disease that has required systemic treatment in the past 2 years.
* Has active infection requiring systemic therapy.
* Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection.
* Has history of stem cell/solid organ transplant. BIOLOGICAL: Zilovertamab vedotin, BIOLOGICAL: Rituximab, DRUG: Cyclophosphamide, DRUG: Doxorubicin, BIOLOGICAL: Rituximab Biosimilar, DRUG: Prednisone, DRUG: Prednisolone, BIOLOGICAL: Polatuzumab vedotin, DRUG: Rescue Medication
Lymphoma, Large B-Cell, Diffuse
I'm interested
Share via email
Show 125 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AZ Delta ( Site 0303) Roeselare, West-Vlaanderen | |
| AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0306) Mechelen, Antwerpen | |
| Aichi Cancer Center ( Site 1007) Nagoya, Aichi-ken | |
| Alliance Cancer Specialists (ACS) ( Site 8010) Sellersville, Pennsylvania | |
| Arcispedale Santa Maria Nuova ( Site 0706) Reggio Emilia, | |
| Atlantic Health Morristown Medical Center ( Site 0163) Morristown, New Jersey | |
| Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO ( Site 0702) Palermo, | |
| Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 0703) Alessandria, | |
| Baptist Health Hardin ( Site 0154) Elizabethtown, Kentucky | |
| Baptist Health Lexington ( Site 0127) Lexington, Kentucky | |
| Baptist MD Anderson Cancer Center ( Site 0176) Jacksonville, Florida | |
| Bass Medical Group ( Site 0123) Walnut Creek, California | |
| Beacon Cancer Care ( Site 0142) Post Falls, Idaho | |
| Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130) Boca Raton, Florida | |
| Bozeman Health Deaconess Hospital ( Site 0183) Bozeman, Montana | |
| Bristol Haematology and Oncology Centre ( Site 0908) Bristol, Bristol, City of | |
| CHU HELORA asbl ( Site 0304) Mons, Brabant Wallon | |
| Cancer Care Associates Of York ( Site 0174) York, Pennsylvania | |
| Christie Hospital NHS Trust ( Site 0901) Manchester, | |
| Churchill Hospital ( Site 0903) Oxford, Oxfordshire | |
| City of Hope - Phoenix ( Site 0202) Goodyear, Arizona | |
| City of Hope Comprehensive Cancer Center ( Site 0191) Duarte, California | |
| Clatterbridge Cancer Centre - Liverpool ( Site 0911) Liverpool, | |
| Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199) Mayfield Heights, Ohio | |
| Cleveland Clinic Main ( Site 0101) Cleveland, Ohio | |
| Clinical Research Alliance ( Site 0122) Westbury, New York | |
| Cliniques Universitaires Saint-Luc ( Site 0302) Brussels, Bruxelles-Capitale, Region de | |
| Colorado West Healthcare System-Grand Valley Oncology ( Site 0165) Grand Junction, Colorado | |
| Dana Farber Cancer Institute ( Site 0111) Boston, Massachusetts | |
| Edith Wolfson Medical Center ( Site 0602) Holon, | |
| Erie County Medical Center ( Site 0175) Buffalo, New York | |
| Fairview Hospital-Moll Cancer Center ( Site 0198) Cleveland, Ohio | |
| Fujita Health University Hospital ( Site 1003) Toyoake, Aichi-ken | |
| Genesis Cancer and Blood Institute ( Site 0193) Hot Springs, Arkansas | |
| Georgetown University Medical Center ( Site 0117) Washington D.C., District of Columbia | |
| Guy s & St Thomas NHS Foundation Trust ( Site 0904) London, London, City of | |
| HELIOS Klinikum Wuppertal ( Site 0435) Wuppertal, North Rhine-Westphalia | |
| Haddasah Medical Center ( Site 0601) Jerusalem, | |
| Hammersmith Hospital ( Site 0915) London, London, City of | |
| Hokkaido University Hospital ( Site 1004) Sapporo, Hokkaido | |
| IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0707) Meldola, Forli-Cesena | |
| Illinois Cancer Care ( Site 7005) Peoria, Illinois | |
| Infirmary Cancer Care ( Site 0157) Mobile, Alabama | |
| Intermountain Healthcare - St. George ( Site 0203) St. George, Utah | |
| Intermountain Medical Center ( Site 0182) Murray, Utah | |
| Ironwood Cancer & Research Centers ( Site 0204) Chandler, Arizona | |
| Istituto Clinico Humanitas ( Site 0704) Rozzano, Milano | |
| Istituto Europeo di Oncologia ( Site 0701) Milan, | |
| Kansai Medical University Hospital ( Site 1006) Hirakata, Osaka | |
| Klinikum Stuttgart. Klinik fur Hamatologie. Onkologie. Palliativmedizin und Stammzelltransplantation ( Site 0419) Stuttgart, Baden-Wurttemberg | |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108) New York, New York | |
| Lincoln County Hospital ( Site 0906) Lincoln, Lincolnshire | |
| Louisiana State University Health Sciences Shreveport ( Site 0195) Shreveport, Louisiana | |
| MEDICAL COLLEGE OF WISCONSIN ( Site 0103) Milwaukee, Wisconsin | |
| Mater Misercordiae University Hospital ( Site 0501) Dublin, | |
| Medical Oncology Hematology Consultants (MOHC) ( Site 8007) Newark, Delaware | |
| Medical University of South Carolina ( Site 0153) Charleston, South Carolina | |
| Mid Florida Hematology and Oncology Center ( Site 0152) Orange City, Florida | |
| Minnesota Oncology Hematology (MNO) ( Site 8004) Burnsville, Minnesota | |
| Mission Blood & Cancer Care ( Site 0114) Waukee, Iowa | |
| Mount Sinai Braman Comprehensive Cancer Center ( Site 0140) Miami Beach, Florida | |
| NHO Revive Research Institute, LLC ( Site 0121) Lincoln, Nebraska | |
| Nagasaki University Hospital ( Site 1008) Nagasaki, | |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0803) Warsaw, Masovian Voivodeship | |
| National Cancer Center Hospital ( Site 1009) Chūō, Tokyo | |
| National Hospital Organization Sendai Medical Center ( Site 1005) Sendai, Miyagi | |
| Nippon Medical School Hospital ( Site 1001) Bunkyo, Tokyo | |
| Northwest Cancer Specialists (Compass Oncology) ( Site 8000) Vancouver, Washington | |
| Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185) Louisville, Kentucky | |
| Novant Health Forsyth Medical Center ( Site 0206) Winston-Salem, North Carolina | |
| Novant Health Presbyterian Medical Center ( Site 0177) Charlotte, North Carolina | |
| Ochsner Clinic Foundation ( Site 0189) New Orleans, Louisiana | |
| Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209) Monroe, Louisiana | |
| Otto-Von-Guericke-Universitaet Magdeburg ( Site 0411) Magdeburg, Saxony-Anhalt | |
| Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180) Baton Rouge, Louisiana | |
| Palo Verde Cancer Specialists ( Site 0105) Glendale, Arizona | |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208) Mineola, New York | |
| Pratia MCM Krakow ( Site 0804) Karkow, Lesser Poland Voivodeship | |
| Pratia Onkologia Katowice ( Site 0801) Katowice, Silesian Voivodeship | |
| Providence Oncology and Hematology Clinic Westside ( Site 0179) Portland, Oregon | |
| Providence Portland Medical Center ( Site 0120) Portland, Oregon | |
| Queen Elizabeth Hospital Birmingham ( Site 0912) Birmingham, | |
| Rabin Medical Center ( Site 0607) Petah Tikva, | |
| Rambam Health Care Campus ( Site 0604) Haifa, | |
| Rocky Mountain Cancer Centers (RMCC) ( Site 8001) Aurora, Colorado | |
| Roswell Park Cancer Institute ( Site 0192) Buffalo, New York | |
| Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) Burbank, California | |
| Royal Devon & Exeter Hospital ( Site 0910) Exeter, Devon | |
| SCRI Oncology Partners ( Site 7002) Nashville, Tennessee | |
| SSM Health Dean Medical Group ( Site 0106) Madison, Wisconsin | |
| SUNY Upstate Cancer Center ( Site 0178) Syracuse, New York | |
| Saint Elizabeth Medical Center Edgewood ( Site 0141) Edgewood, Kentucky | |
| Sheba Medical Center ( Site 0603) Ramat Gan, | |
| Shimane University Hospital ( Site 1002) Izumo, Shimane | |
| Soroka Medical Center ( Site 0606) Beersheba, | |
| Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 0807) Wałbrzych, Lower Silesian Voivodeship | |
| St Vincent's University Hospital ( Site 0502) Dublin, Dublin | |
| Stoke Mandeville Hospital ( Site 0917) Aylesbury, Buckinghamshire | |
| Szpital Specjalistyczny im. Jedrzeja Sniadeckiego w Nowym Saczu ( Site 0806) Nowy Sącz, Lesser Poland Voivodeship | |
| Temple University Hospital ( Site 0133) Philadelphia, Pennsylvania | |
| Tennessee Cancer Specialists ( Site 7004) Knoxville, Tennessee | |
| Texas Oncology - Central/South Texas ( Site 8006) Austin, Texas | |
| Texas Oncology - Northeast Texas ( Site 8002) Tyler, Texas | |
| Texas Oncology - San Antonio ( Site 8009) San Antonio, Texas | |
| Texas Oncology - West Texas ( Site 8008) Amarillo, Texas | |
| The James Cook University Hospital ( Site 0909) Middlesbrough, England | |
| The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0145) Tyler, Texas | |
| UZ Leuven ( Site 0301) Leuven, Vlaams-Brabant | |
| Uniklinik Erlangen ( Site 0412) Erlangen, Bavaria | |
| Universita degli Studi di Napoli Federico II ( Site 0705) Naples, | |
| Universitaetsklinikum Schleswig-Holstein - Campus Luebeck ( Site 0425) Lübeck, Schleswig-Holstein | |
| Universitaetsklinikum Wuerzburg ( Site 0401) Würzburg, Bavaria | |
| University Hospital Limerick ( Site 0503) Limerick, | |
| University Hospitals Plymouth NHS Trust ( Site 0905) Plymouth, Devon | |
| University Hospitals of Cleveland ( Site 0155) Cleveland, Ohio | |
| University Of Nebraska Medical Center ( Site 0110) Omaha, Nebraska | |
| University of Chicago Medical Center ( Site 0126) Chicago, Illinois | |
| University of Cincinnati Medical Center ( Site 0156) Cincinnati, Ohio | |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 0139) Iowa City, Iowa | |
| University of North Carolina Medical Center ( Site 0136) Chapel Hill, North Carolina | |
| Uniwersyteckie Centrum Kliniczne ( Site 0802) Gdansk, Pomeranian Voivodeship | |
| VCU Health Adult Outpatient Pavillion ( Site 0138) Richmond, Virginia | |
| Valley Health Systems - Ridgewood Campus ( Site 0125) Paramus, New Jersey | |
| Virginia Cancer Specialists, PC ( Site 8003) Manassas, Virginia | |
| ZIV Medical Center ( Site 0605) Safed, |
E-Mindfulness Approaches for Living After Breast Cancer (HEAL-ABC)
Director Regulatory Affairs - langerj@nrgoncology.org
NCT06748222
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* The participant or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for participants treated in the U.S., authorization permitting release of personal health information.
* The participant must have been greater than or equal to 18 or less than or equal to 50 years of age at the time of breast cancer diagnosis.
* The participant must have a first-time diagnosis of non-metastatic breast cancer which is Stage 0, I, II, or III.
* The participant must have a score of greater than or equal to 5 and less than or equal to 14 on the Patient Health Questionnaire-8 item (PHQ-8).
* Participants must have completed all primary breast cancer treatments at least 6 months prior to and no more than 5 years prior to registration. Note: Primary treatments include surgery, radiation therapy, adjuvant chemotherapy, targeted therapies (e.g., PARP (poly-ADP ribose polymerase) inhibitors, CDK4/6 inhibitors, TDM-1, pertuzumab, or immunotherapy). (Participants may still be taking adjuvant therapy with trastuzumab or adjuvant endocrine therapy or completing minor reconstructive surgery.)
* Participant must be able to understand, speak, read, and write in English or Spanish.
* Participant must be willing to participate in a 6-week program to receive training in mindfulness.
* Participant must be able to use a smartphone, tablet, or other digital device.
* Sex assigned at birth must be female.
Exclusion Criteria:
* Patient Health Questionnaire-8 item (PHQ-8) score of less than 5 or greater than 14 .
* Any history or current evidence of recurrent or metastatic breast cancer.
* Current or past history of another cancer. Participants with a history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible.
* Currently pregnant or planning to become pregnant in the near future.
* Participants who are enrolled in other cancer control or behavioral intervention trials that require frequent assessments or training activities. BEHAVIORAL: Mindfulness (MAPs) Live Online, BEHAVIORAL: Mindfulness (MAPs) Digital App, BEHAVIORAL: Meditation Only Control Group
Breast Cancer, Depression
Breast Cancer, Mindfulness, Meditation, Digital
I'm interested
Share via email
Show 334 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AIS Cancer Center at San Joaquin Community Hospital Bakersfield, California | |
| Adams Cancer Center Gettysburg, Pennsylvania | |
| Addison Gilbert Hospital Gloucester, Massachusetts | |
| Allegiance Health Jackson, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Annie Penn Memorial Hospital Reidsville, North Carolina | Site Public Contact - (stacey.phelps@conehealth.com) |
| Armes Family Cancer Center Findlay, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Arnold Palmer Cancer Center Medical Oncology Norwin N. Huntingdon, Pennsylvania | Site Public Contact - (ClinicalResearchServices@upmc.edu) |
| Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin | |
| Aspirus Medford Hospital Medford, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Regional Cancer Center Wausau, Wisconsin | |
| AtlantiCare Health Park-Cape May Court House Cape May Court House, New Jersey | |
| AtlantiCare Surgery Center Egg Harbor, New Jersey | |
| Baptist Cancer Center-Grenada Grenada, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Bayshore Community Hospital Holmdel, New Jersey | Site Public Contact - (Roster@nrgoncology.org) |
| Beaufort Memorial Hospital Beaufort, South Carolina | Site Public Contact - (kwade@bmhsc.org) |
| Beverly Hospital Beverly, Massachusetts | |
| Blanchard Valley Hospital Findlay, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Bon Secours Memorial Regional Medical Center Mechanicsville, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Richmond Community Hospital Richmond, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Saint Francis Medical Center Midlothian, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Saint Mary's Hospital Richmond, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| CHI Health Good Samaritan Kearney, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Cancer Care Center of O'Fallon O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Care Specialists of Illinois - Decatur Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Carilion Roanoke Memorial Hospital Roanoke, Virginia | |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Cancer Institute Normal Normal, Illinois | Site Public Contact - (Research@Carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Carlisle Regional Cancer Center Carlisle, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Centra Alan B Pearson Regional Cancer Center Lynchburg, Virginia | Site Public Contact - (Kevin.Patel@centrahealth.com) |
| Central Maryland Radiation Oncology in Howard County Columbia, Maryland | |
| Centro Comprensivo de Cancer de UPR San Juan, | Site Public Contact - (Roster@nrgoncology.org) |
| Chester County Hospital West Chester, Pennsylvania | Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu) |
| Cone Health Cancer Center Greensboro, North Carolina | Site Public Contact - (stacey.phelps@conehealth.com) |
| Cone Health Cancer Center at Alamance Regional Burlington, North Carolina | Site Public Contact - (stacey.phelps@conehealth.com) |
| Cone Health Cancer Center at Drawbridge Parkway Greensboro, North Carolina | Site Public Contact - (stacey.phelps@conehealth.com) |
| Cone Health MedCenter Asheboro Asheboro, North Carolina | Site Public Contact - (stacey.phelps@conehealth.com) |
| Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Reed City Hospital Reed City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Cotton O'Neil Cancer Center / Stormont Vail Health Topeka, Kansas | |
| Crossroads Cancer Center Effingham, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Eisenhower Medical Center Rancho Mirage, California | |
| Emory Decatur Hospital Decatur, Georgia | Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org) |
| Emory Johns Creek Hospital Johns Creek, Georgia | Site Public Contact - (m.lisa.hwang@emory.edu) |
| Emory Saint Joseph's Hospital Atlanta, Georgia | |
| Emory University Hospital Midtown Atlanta, Georgia | |
| Emory University Hospital/Winship Cancer Institute Atlanta, Georgia | |
| Enloe Medical Center Chico, California | |
| Ephrata Cancer Center Ephrata, Pennsylvania | |
| Essentia Health Cancer Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Cancer Center-South University Clinic Fargo, North Dakota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Flaget Memorial Hospital Bardstown, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Fremont - Rideout Cancer Center Marysville, California | |
| Garnet Health Medical Center Middletown, New York | Site Public Contact - (jgerlach@garnethealth.org) |
| Geisinger Cancer Center Dickson City Dickson City, Pennsylvania | Site Public Contact - (hemoncctrials@geisinger.edu) |
| Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Gene Upshaw Memorial Tahoe Forest Cancer Center Truckee, California | |
| Glens Falls Hospital Glens Falls, New York | |
| Goshen Center for Cancer Care Goshen, Indiana | Site Public Contact - (cccois@goshenhealth.com) |
| Grady Health System Atlanta, Georgia | |
| Gundersen Lutheran Medical Center La Crosse, Wisconsin | Site Public Contact - (cancerctr@gundersenhealth.org) |
| Halifax Health Cancer Center for Hope - Daytona Beach Daytona Beach, Florida | |
| Heartland Regional Medical Center Saint Joseph, Missouri | Site Public Contact - (Trisha.England2@mymlc.com) |
| Henry Ford Cancer Institute-Downriver Brownstown, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Health Providence Novi Hospital Novi, Michigan | Site Public Contact - (kfife3@hfhs.org) |
| Henry Ford Health Providence Southfield Hospital Southfield, Michigan | Site Public Contact - (kfife3@hfhs.org) |
| Henry Ford Hospital Detroit, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Medical Center-Columbus Novi, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Medical Center-Fairlane Dearborn, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford West Bloomfield Hospital West Bloomfield, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Wyandotte Hospital Wyandotte, Michigan | Site Public Contact - (nhay@hfhs.org) |
| Hunterdon Medical Center Flemington, New Jersey | |
| Illinois CancerCare - Washington Washington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Bloomington Bloomington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Canton Canton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Carthage Carthage, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Dixon Dixon, Illinois | |
| Illinois CancerCare-Eureka Eureka, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Galesburg Galesburg, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Kewanee Clinic Kewanee, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Macomb Macomb, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Ottawa Clinic Ottawa, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Pekin Pekin, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peoria Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peru Peru, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Princeton Princeton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Indu and Raj Soin Medical Center Beavercreek, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Inova Alexandria Hospital Alexandria, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Inova Fair Oaks Hospital Fairfax, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Inova Fairfax Hospital Falls Church, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Inova Loudoun Hospital Leesburg, Virginia | Site Public Contact - (Keary.janet@inova.org) |
| Inova Schar Cancer Institute Fairfax, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Iowa Methodist Medical Center Des Moines, Iowa | |
| Jersey Shore Medical Center Neptune City, New Jersey | |
| John Muir Medical Center-Walnut Creek Walnut Creek, California | Site Public Contact - (clinicalresearch@johnmuirhealth.com) |
| Kaiser Permanente - Panorama City Panorama City, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente Downtown Commons Sacramento, California | Site Public Contact - (kpoct@kp.org) |
| Kaiser Permanente Dublin Dublin, California | |
| Kaiser Permanente Fresno Orchard Plaza Fresno, California | |
| Kaiser Permanente Los Angeles Medical Center Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente Medical Center - Santa Clara Santa Clara, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Medical Center-Vacaville Vacaville, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii | Site Public Contact - (shelley.a.clark@kp.org) |
| Kaiser Permanente Northwest Portland, Oregon | Site Public Contact - (information@kpchr.org) |
| Kaiser Permanente San Leandro San Leandro, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente South Bay Harbor City, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente West Los Angeles Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente- Marshall Medical Offices Redwood City, California | |
| Kaiser Permanente- Modesto MOB II Modesto, California | |
| Kaiser Permanente-Anaheim Anaheim, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Baldwin Park Baldwin Park, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Bellflower Bellflower, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Deer Valley Medical Center Antioch, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Fontana Fontana, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Fremont Fremont, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Fresno Fresno, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Irvine Irvine, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Modesto Modesto, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Oakland Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Ontario Ontario, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Richmond Richmond, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Riverside Riverside, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Roseville Roseville, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-San Diego Zion San Diego, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-San Francisco San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-San Marcos San Marcos, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Santa Rosa Santa Rosa, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Santa Teresa-San Jose San Jose, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-South Sacramento Sacramento, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-South San Francisco South San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Stockton Stockton, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Vallejo Vallejo, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Walnut Creek Walnut Creek, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Woodland Hills Woodland Hills, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser San Rafael-Gallinas San Rafael, California | Site Public Contact - (Kpoct@kp.org) |
| Kettering Medical Center Kettering, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Lahey Hospital and Medical Center Burlington, Massachusetts | Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org) |
| Lahey Medical Center-Peabody Peabody, Massachusetts | Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org) |
| Lake Regional Hospital Osage Beach, Missouri | Site Public Contact - (clinicaltrials@lakeregional.com) |
| Lancaster General Ann B Barshinger Cancer Institute Lancaster, Pennsylvania | Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu) |
| Langlade Hospital and Cancer Center Antigo, Wisconsin | Site Public Contact - (Juli.Alford@aspirus.org) |
| Licking Memorial Hospital Newark, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Lowell General Hospital Lowell, Massachusetts | Site Public Contact - (cancerclinicaltrials@tuftsmedicine.org) |
| Loyola University Medical Center Maywood, Illinois | |
| Marshall Cancer Center Cameron Park, California | Site Public Contact - (cancerservices@marshallmedical.org) |
| Maryland Proton Treatment Center Baltimore, Maryland | Site Public Contact - (info@mdproton.com) |
| Mayo Clinic Health System-Eau Claire Clinic Eau Claire, Wisconsin | |
| Mayo Clinic Health System-Franciscan Healthcare La Crosse, Wisconsin | |
| Mayo Clinic Health Systems-Mankato Mankato, Minnesota | |
| Mayo Clinic Hospital in Arizona Phoenix, Arizona | |
| Mayo Clinic in Florida Jacksonville, Florida | |
| Mayo Clinic in Rochester Rochester, Minnesota | |
| MedStar Franklin Square Medical Center/Weinberg Cancer Institute Baltimore, Maryland | |
| MedStar Georgetown University Hospital Washington D.C., District of Columbia | |
| MedStar Good Samaritan Hospital Baltimore, Maryland | Site Public Contact - (Barbara.rector@medstar.net) |
| MedStar Health Bel Air Medical Campus Bel Air, Maryland | Site Public Contact - (David.j.perry2@medstar.net) |
| MedStar Montgomery Medical Center Olney, Maryland | |
| MedStar Southern Maryland Hospital Center Clinton, Maryland | |
| Medical University of South Carolina Charleston, South Carolina | Site Public Contact - (hcc-clinical-trials@musc.edu) |
| Medstar Washington Hospital Center Washington D.C., District of Columbia | |
| Memorial Hospital Chattanooga, Tennessee | Site Public Contact - (Jeffh@columbusccop.org) |
| Memorial Hospital North Colorado Springs, Colorado | |
| Memorial Hospital of South Bend South Bend, Indiana | |
| Memorial Hospital of Sweetwater County Rock Springs, Wyoming | Site Public Contact - (tharris@sweetwatermemorial.com) |
| Mercy Health - Perrysburg Hospital Perrysburg, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mercy Health - Saint Anne Hospital Toledo, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mercy Hospital Fort Smith Fort Smith, Arkansas | |
| Mercy Hospital South St Louis, Missouri | Site Public Contact - (Danielle.Werle@mercy.net) |
| Mercy Hospital Springfield Springfield, Missouri | |
| Mercy Medical Center - Des Moines Des Moines, Iowa | |
| Mississippi Baptist Medical Center Jackson, Mississippi | Site Public Contact - (ctsucontact@westat.com) |
| Missouri Baptist Medical Center St Louis, Missouri | |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Mount Carmel East Hospital Columbus, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mount Carmel Grove City Hospital Grove City, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mount Sinai Chelsea New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai Hospital New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai Queens Astoria, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai Union Square New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai West New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Munson Medical Center Traverse City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| MyMichigan Medical Center Alpena Alpena, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Gladwin Gladwin, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Gratiot Alma, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Midland Midland, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Mount Pleasant Mount Pleasant, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Saginaw Saginaw, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| MyMichigan Medical Center Tawas Tawas City, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Glenview Outpatient Center Glenview, Illinois | |
| Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois | |
| Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois | Site Public Contact - (cancertrials@northwestern.edu) |
| Northwestern Medicine Oak Brook Oak Brook, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern Medicine Orland Park Orland Park, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| OSF Saint Anthony Medical Center Rockford, Illinois | |
| Ocean University Medical Center Brick, New Jersey | |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa | |
| PROncology San Juan, | Site Public Contact - (info@PRoncology.com) |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| Prisma Health Cancer Institute - Butternut Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Easley Easley, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Eastside Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Faris Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Greer Greer, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Seneca Seneca, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| ProHealth D N Greenwald Center Mukwonago, Wisconsin | Site Public Contact - (research.institute@phci.org) |
| ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin | |
| Providence Medical Foundation - Santa Rosa Santa Rosa, California | |
| Rapid City Regional Hospital Rapid City, South Dakota | Site Public Contact - (research@monument.health) |
| Reading Hospital West Reading, Pennsylvania | |
| Redeemer Health Meadowbrook, Pennsylvania | |
| Riverview Medical Center/Booker Cancer Center Red Bank, New Jersey | |
| Rush MD Anderson Cancer Center Chicago, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rush MD Anderson Cancer Center at Rush Lisle Lisle, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rush MD Anderson Cancer Center at Rush Oak Park Oak Park, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rush-Copley Healthcare Center Yorkville, Illinois | |
| Rush-Copley Medical Center Aurora, Illinois | |
| SIH Cancer Institute Carterville, Illinois | Site Public Contact - (clinical.research@sih.net) |
| SSM Health Good Samaritan Mount Vernon, Illinois | Site Public Contact - (gayla.hall@ssmhealth.com) |
| Saint Ann's Hospital Westerville, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Saint Anthony Regional Hospital Carroll, Iowa | Site Public Contact - (sbenson@iora.org) |
| Saint Charles Health System Bend, Oregon | Site Public Contact - (nosall@stcharleshealthcare.org) |
| Saint Charles Health System-Redmond Redmond, Oregon | |
| Saint Elizabeth Youngstown Hospital Youngstown, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Saint Joseph Hospital East Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Medical Center Hematology and Oncology - Silverdale Silverdale, Washington | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Luke's Hospital Chesterfield, Missouri | Site Public Contact - (Rachel.varner@unitypoint.org) |
| Saint Rita's Medical Center Lima, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin | Site Public Contact - (WI_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin | Site Public Contact - (WI_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Salinas Valley Memorial Salinas, California | Site Public Contact - (tnielsen2@svmh.com) |
| Sanford Broadway Medical Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org) |
| Sanford Roger Maris Cancer Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org) |
| Sechler Family Cancer Center Lebanon, Pennsylvania | Site Public Contact - (doxenberg@wellspan.org) |
| Sinai Hospital of Baltimore Baltimore, Maryland | |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| Southern Ocean County Medical Center Manahawkin, New Jersey | |
| Springfield Clinic Springfield, Illinois | |
| Stamford Hospital/Bennett Cancer Center Stamford, Connecticut | |
| Summit Health - Florham Park Campus Florham Park, New Jersey | Site Public Contact - (mmackenzie@summithealth.com) |
| Summit Medical Group Berkeley Heights, New Jersey | Site Public Contact - (Roster@nrgoncology.org) |
| Tallahassee Memorial HealthCare Tallahassee, Florida | |
| The Don and Sybil Harrington Cancer Center Amarillo, Texas | Site Public Contact - (Gina.Cravey@bsahs.org) |
| The Valley Hospital - Luckow Pavilion Paramus, New Jersey | Site Public Contact - (clinicaltrialsresearch@valleyhealth.com) |
| ThedaCare Cancer Care - Berlin Berlin, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| ThedaCare Cancer Care - New London New London, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| ThedaCare Cancer Care - Oshkosh Oshkosh, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| ThedaCare Cancer Care - Shawano Shawano, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| ThedaCare Cancer Care - Waupaca Waupaca, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| ThedaCare Regional Cancer Center Appleton, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| ThedaCare Regional Medical Center - Neenah Neenah, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| Tidelands Georgetown Memorial Hospital Georgetown, South Carolina | Site Public Contact - (broe@tidelandshealth.org) |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Tufts Medical Center Boston, Massachusetts | Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org) |
| Tufts Medical Center Cancer Center Stoneham Stoneham, Massachusetts | Site Public Contact - (NCCCR@Tuftsmedicalcenter.org) |
| UC Irvine Health Cancer Center-Newport Costa Mesa, California | |
| UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California | Site Public Contact - (ucstudy@uci.edu) |
| UCHealth Memorial Hospital Central Colorado Springs, Colorado | |
| UCHealth University of Colorado Hospital Aurora, Colorado | |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California | Site Public Contact - (ucstudy@uci.edu) |
| UCI Health - Yorba Linda Yorba Linda, California | Site Public Contact - (ucstudy@uci.edu) |
| UF Health Cancer Institute - Gainesville Gainesville, Florida | Site Public Contact - (cancer-center@ufl.edu) |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa | |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa | |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa | |
| UI Healthcare Mission Cancer and Blood - Pella Pella, Iowa | Site Public Contact - (trials@missioncancer.com) |
| UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie, Maryland | |
| UM Capital Region Medical Center Largo, Maryland | Site Public Contact - (Sarah.Larson@umm.edu) |
| UM Saint Joseph Medical Center Towson, Maryland | Site Public Contact - (Jeanmarie.downing@umm.edu) |
| UM Upper Chesapeake Medical Center Bel Air, Maryland | |
| UPMC Cancer Center at UPMC Horizon Farrell, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania | |
| UPMC Hillman Cancer Center - New Castle New Castle, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Hillman Cancer Center - Part of Frick Hospital Mount Pleasant, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Hillman Cancer Center Erie Erie, Pennsylvania | Site Public Contact - (ClinicalResearchServices@upmc.edu) |
| UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Memorial York, Pennsylvania | |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania | Site Public Contact - (klitchfield@PINNACLEHEALTH.org) |
| UPMC-Johnstown/John P. Murtha Regional Cancer Center Johnstown, Pennsylvania | |
| UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania | |
| UPMC-Saint Margaret Pittsburgh, Pennsylvania | |
| UPMC-Shadyside Hospital Pittsburgh, Pennsylvania | |
| UW Cancer Center at ProHealth Care Waukesha, Wisconsin | Site Public Contact - (Chanda.miller@phci.org) |
| University Medical Center New Orleans New Orleans, Louisiana | Site Public Contact - (emede1@lsuhsc.edu) |
| University of Arkansas for Medical Sciences Little Rock, Arkansas | |
| University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Cincinnati Cancer Center-West Chester West Chester, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Iowa Healthcare Cancer Services Quad Cities Bettendorf, Iowa | Site Public Contact - (katherine-daprile@uiowa.edu) |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Maryland Shore Medical Center at Easton Easton, Maryland | Site Public Contact - (Christina.weisenborn@umm.edu) |
| University of Maryland/Greenebaum Cancer Center Baltimore, Maryland | |
| University of Michigan Health - Sparrow Lansing Lansing, Michigan | Site Public Contact - (harsha.trivedi@umhsparrow.org) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania | |
| University of Tennessee - Knoxville Knoxville, Tennessee | |
| VCU Community Memorial Health Center South Hill, Virginia | Site Public Contact - (nemer.elmouallem@vcuhealth.org) |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Health System Ridgewood Campus Ridgewood, New Jersey | Site Public Contact - (clinicaltrialsresearch@valleyhealth.com) |
| Vanderbilt Breast Center at One Hundred Oaks Nashville, Tennessee | |
| Virginia Cancer Institute Richmond, Virginia | Site Public Contact - (smoore@vacancer.com) |
| Washington Hospital Fremont, California | |
| WellSpan Health-York Cancer Center York, Pennsylvania | |
| WellSpan Medical Oncology and Hematology Chambersburg, Pennsylvania | |
| William E Kahlert Regional Cancer Center/Sinai Hospital Westminster, Maryland | |
| Women and Infants Hospital Providence, Rhode Island |
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
ctrrecruit@vcu.edu
NCT07061977
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
* Patients must have locally advanced cervical cancer (LACC) with T3 or T4 disease with or without lymph node involvement:
* IIIA (T3aN0M0)
* IIIB (T3bN0M0)
* IIIC1(T3aN1M0, T3bN1M0)
* IIIC2 (T3aN2M0, T3bN2M0)
* IVA (T4aN0M0, T4aN1M0, T4aN2M0) No prior hysterectomy defined as removal of the entire uterus.
* NOTE: prior partial/subtotal hysterectomy for reasons other than cervical cancer are eligible to participate in the study. No plan to perform a hysterectomy as part of initial cervical cancer therapy.
No paraaortic lymph node (PALN) metastases above the T12/L1 interspace.
* Note: Nodal status can be confirmed by imaging (CT, MRI, or PET/CT), fine needle aspirate/core biopsy, extra peritoneal biopsy, laparoscopic biopsy, or lymphadenectomy.
Radiologic definition of lymph node staging:
* N1:
* One or more pelvic lymph nodes with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
* One or more pelvic lymph nodes with short axis diameter of ≥ 10 mm and standardized uptake value maximum (SUVmax) ≥ 2.5 by fludeoxyglucose (FDG)-PET
* N2:
* One or more para-aortic lymph node with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
* One or more para-aortic lymph node with short axis diameter of ≥ 10 mm and SUVmax ≥ 2.5 by FDG-PET
* No prior definitive surgical, radiation, or systemic therapy for cervical cancer
* No prior immunotherapy
* No prior pelvic radiation therapy for any disease
* Age ≥ 18
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
* Not pregnant and not nursing
* Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3
* Platelets ≥ 100,000 cells/mm\^3
* Hemoglobin ≥ 8 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobulin \[Hgb\] ≥ 8 g/dl is acceptable)
* Creatinine clearance (CrCL) of ≥ 50 mL/min by the Cockcroft-Gault formula
* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
* No active infection requiring parenteral antibiotics
* No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacille Calmette Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed
* No diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior registration
* No active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
* No history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
* No history of allergic reaction to the study agent(s) or compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients) PROCEDURE: Biospecimen Collection, RADIATION: Brachytherapy, DRUG: Carboplatin, PROCEDURE: Chest Radiography, DRUG: Cisplatin, PROCEDURE: Computed Tomography, RADIATION: External Beam Radiation Therapy, RADIATION: Intensity-Modulated Radiation Therapy, PROCEDURE: Magnetic Resonance Imaging, DRUG: Paclitaxel, BIOLOGICAL: Pembrolizumab, PROCEDURE: Positron Emission Tomography
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
I'm interested
Share via email
Show 252 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Asplundh Cancer Pavilion Willow Grove, Pennsylvania | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| Atrium Health Cabarrus/LCI-Concord Concord, North Carolina | |
| Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Aultman Health Foundation Canton, Ohio | Site Public Contact - (ClinicalReserachDept@aultman.com) |
| Avera Cancer Institute Sioux Falls, South Dakota | Site Public Contact - (OncRegulatory@avera.org) |
| Beebe Health Campus Rehoboth Beach, Delaware | Site Public Contact - (research@beebehealthcare.org) |
| Beebe South Coastal Health Campus Millville, Delaware | Site Public Contact - (research@beebehealthcare.org) |
| Billings Clinic Cancer Center Billings, Montana | Site Public Contact - (research@billingsclinic.org) |
| Bronson Methodist Hospital Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Broward Health Medical Center Fort Lauderdale, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| CTCA at Southeastern Regional Medical Center Newnan, Georgia | |
| Camden Clark Medical Center Parkersburg, West Virginia | Site Public Contact - (cancertrialsinfo@hsc.wvu.edu) |
| Cancer Care Specialists of Illinois - Decatur Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Capital Health Medical Center-Hopewell Pennington, New Jersey | Site Public Contact - (clinicaltrials@capitalhealth.org) |
| Carilion Roanoke Memorial Hospital Roanoke, Virginia | |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina | |
| Case Western Reserve University Cleveland, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| City of Hope Antelope Valley Lancaster, California | |
| City of Hope Comprehensive Cancer Center Duarte, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope Corona Corona, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope South Pasadena South Pasadena, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope Upland Upland, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope at Irvine Lennar Irvine, California | |
| Clackamas Radiation Oncology Center Clackamas, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Cleveland Clinic Foundation Cleveland, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Community Medical Center Missoula, Montana | |
| Cooper Hospital University Medical Center Camden, New Jersey | |
| Crossroads Cancer Center Effingham, Illinois | |
| Danbury Hospital Danbury, Connecticut | |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Decatur Memorial Hospital Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Duke University Medical Center Durham, North Carolina | |
| Duke Women's Cancer Care Raleigh Raleigh, North Carolina | |
| East Jefferson General Hospital Metairie, Louisiana | Site Public Contact - (emede1@lsuhsc.edu) |
| Emory Decatur Hospital Decatur, Georgia | Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org) |
| Emory University Hospital Midtown Atlanta, Georgia | |
| Emory University Hospital/Winship Cancer Institute Atlanta, Georgia | |
| Farmington Health Center Farmington, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| Fox Chase Cancer Center Philadelphia, Pennsylvania | |
| Freeman Health System Joplin, Missouri | Site Public Contact - (LJCrockett@freemanhealth.com) |
| Geauga Hospital Chardon, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Gibbs Cancer Center-Gaffney Gaffney, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Gibbs Cancer Center-Pelham Greer, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Helen F Graham Cancer Center Newark, Delaware | Site Public Contact - (lbarone@christianacare.org) |
| Highlands Oncology Group Springdale, Arkansas | Site Public Contact - (research@hogonc.com) |
| Highlands Oncology Group - Fayetteville Fayetteville, Arkansas | Site Public Contact - (research@hogonc.com) |
| Highlands Oncology Group - Rogers Rogers, Arkansas | Site Public Contact - (research@hogonc.com) |
| Hillcrest Hospital Cancer Center Mayfield Heights, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Huntsman Cancer Institute/University of Utah Salt Lake City, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| IRMC Cancer Center Indiana, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| Inova Alexandria Hospital Alexandria, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Inova Fair Oaks Hospital Fairfax, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Inova Fairfax Hospital Falls Church, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Inova Loudoun Hospital Leesburg, Virginia | Site Public Contact - (Keary.janet@inova.org) |
| Inova Schar Cancer Institute Fairfax, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Iowa Methodist Medical Center Des Moines, Iowa | |
| Jersey City Medical Center Jersey City, New Jersey | Site Public Contact - (Roster@nrgoncology.org) |
| Kaiser Permanente - Panorama City Panorama City, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente Los Angeles Medical Center Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente Northwest Portland, Oregon | Site Public Contact - (information@kpchr.org) |
| Kaiser Permanente South Bay Harbor City, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente West Los Angeles Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Bellflower Bellflower, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Irvine Irvine, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-San Diego Zion San Diego, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-San Marcos San Marcos, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Woodland Hills Woodland Hills, California | Site Public Contact - (clinical.trials@kp.org) |
| Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho | |
| Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho | |
| LSU Healthcare Network / Metairie Multi-Specialty Clinic Metairie, Louisiana | Site Public Contact - (emede1@lsuhsc.edu) |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York | Site Public Contact - (CancerTrials@nyulangone.org) |
| Legacy Good Samaritan Hospital and Medical Center Portland, Oregon | Site Public Contact - (cancer@lhs.org) |
| Legacy Meridian Park Hospital Tualatin, Oregon | |
| Legacy Salmon Creek Hospital Vancouver, Washington | |
| Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Lenox Hill Hospital New York, New York | |
| Levine Cancer Institute-Gaston Gastonia, North Carolina | |
| Loyola University Medical Center Maywood, Illinois | |
| MaineHealth Cancer Care Center of York County Sanford, Maine | |
| MaineHealth Coastal Cancer Treatment Center Bath, Maine | Site Public Contact - (Roster@nrgoncology.org) |
| MaineHealth Maine Medical Center - Portland Portland, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| MaineHealth Maine Medical Center- Scarborough Scarborough, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| Manhattan Eye Ear and Throat Hospital New York, New York | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Medical Oncology Hematology Consultants PA Newark, Delaware | Site Public Contact - (lbarone@christianacare.org) |
| Medical University of South Carolina Charleston, South Carolina | Site Public Contact - (hcc-clinical-trials@musc.edu) |
| Memorial Hospital West Pembroke Pines, Florida | |
| Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida | Site Public Contact - (OHR@mhs.net) |
| Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey | |
| Memorial Sloan Kettering Bergen Montvale, New Jersey | |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| Memorial Sloan Kettering Commack Commack, New York | |
| Memorial Sloan Kettering Monmouth Middletown, New Jersey | |
| Memorial Sloan Kettering Nassau Uniondale, New York | |
| Memorial Sloan Kettering Westchester Harrison, New York | |
| Mercy Hospital Coon Rapids, Minnesota | |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Mercy Hospital Springfield Springfield, Missouri | |
| Mercy Medical Center - Des Moines Des Moines, Iowa | |
| Miami Valley Cancer Care and Infusion Greenville, Ohio | |
| Miami Valley Hospital Dayton, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Miami Valley Hospital North Dayton, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Miami Valley Hospital South Centerville, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Midwestern Regional Medical Center Zion, Illinois | |
| Moffitt Cancer Center Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center - McKinley Campus Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at SouthShore Ruskin, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at Wesley Chapel Wesley Chapel, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center-International Plaza Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Weiler Hospital The Bronx, New York | |
| Mount Sinai Chelsea New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai Hospital New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| NYU Langone Hospital - Long Island Mineola, New York | Site Public Contact - (cancertrials@nyulangone.org) |
| Nebraska Methodist Hospital Omaha, Nebraska | |
| Northern Westchester Hospital Mount Kisco, New York | Site Public Contact - (AMellor@northwell.edu) |
| Northwell Health Cancer Institute at Huntington Greenlawn, New York | |
| Northwell Health Imbert Cancer Center Bay Shore, New York | |
| Northwell Health Physician Partners at Flushing Flushing, New York | Site Public Contact - (nhppflushing@northwell.edu) |
| Northwell Health Physicians Partners Radiation Medicine at Queens Forest Hills, New York | |
| Northwell Health/Center for Advanced Medicine Lake Success, New York | |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Oak Brook Oak Brook, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern Medicine Orland Park Orland Park, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| Norwalk Hospital Norwalk, Connecticut | Site Public Contact - (jennifer.long@norwalkhealth.org) |
| Novant Health Presbyterian Medical Center Charlotte, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Ochsner Baptist Medical Center New Orleans, Louisiana | Site Public Contact - (Elisemarie.curry@ochsner.org) |
| Ochsner Medical Center Jefferson New Orleans, Louisiana | Site Public Contact - (Elisemarie.curry@ochsner.org) |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| Oklahoma Cancer Specialists and Research Institute-Tulsa Tulsa, Oklahoma | |
| Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa | |
| Oregon Health and Science University Portland, Oregon | Site Public Contact - (trials@ohsu.edu) |
| Orlando Health Cancer Institute Orlando, Florida | Site Public Contact - (CancerClinicalTrials@orlandohealth.com) |
| Parkland Memorial Hospital Dallas, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| Parkview Regional Medical Center Fort Wayne, Indiana | |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| Phelps Health Delbert Day Cancer Institute Rolla, Missouri | Site Public Contact - (research@phelpshealth.org) |
| Phelps Memorial Hospital Center Sleepy Hollow, New York | |
| Piedmont Hospital Atlanta, Georgia | Site Public Contact - (ORS@piedmont.org) |
| Pocono Medical Center East Stroudsburg, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| ProHealth D N Greenwald Center Mukwonago, Wisconsin | Site Public Contact - (research.institute@phci.org) |
| ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin | |
| ProMedica Flower Hospital Sylvania, Ohio | Site Public Contact - (PCIOncResearch@promedica.org) |
| Providence Newberg Medical Center Newberg, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Portland Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Saint Vincent Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Willamette Falls Medical Center Oregon City, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Queens Cancer Center Rego Park, New York | |
| Roswell Park Cancer Institute Buffalo, New York | Site Public Contact - (askroswell@roswellpark.org) |
| Rush MD Anderson Cancer Center Chicago, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey | |
| Rutgers New Jersey Medical School Newark, New Jersey | |
| Saint Alphonsus Cancer Care Center-Boise Boise, Idaho | Site Public Contact - (stephanie.couch@stjoeshealth.org) |
| Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho | Site Public Contact - (stephanie.couch@stjoeshealth.org) |
| Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Saint Luke's Cancer Center - Allentown Allentown, Pennsylvania | |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Meridian Meridian, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Nampa Nampa, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Hospital - Monroe Campus Stroudsburg, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Saint Luke's Hospital - Upper Bucks Campus Quakertown, Pennsylvania | |
| Saint Luke's Hospital-Anderson Campus Easton, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Saint Luke's University Hospital-Bethlehem Campus Bethlehem, Pennsylvania | |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| Spartanburg Medical Center Spartanburg, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Springfield Clinic Springfield, Illinois | |
| Springfield Memorial Hospital Springfield, Illinois | Site Public Contact - (pallante.beth@mhsil.com) |
| State University of New York Upstate Medical University Syracuse, New York | |
| Stony Brook University Medical Center Stony Brook, New York | |
| Temple University Hospital Philadelphia, Pennsylvania | |
| Thomas Jefferson University Hospital Philadelphia, Pennsylvania | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan | |
| UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California | Site Public Contact - (ucstudy@uci.edu) |
| UC San Diego Moores Cancer Center La Jolla, California | Site Public Contact - (cancercto@ucsd.edu) |
| UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado | |
| UCHealth University of Colorado Hospital Aurora, Colorado | |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California | Site Public Contact - (ucstudy@uci.edu) |
| UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UH Seidman Cancer Center at Saint John Medical Center Westlake, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UHHS-Chagrin Highlands Medical Center Beachwood, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa | |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa | |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa | |
| UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida | |
| UM Sylvester Comprehensive Cancer Center at Coral Springs Coral Springs, Florida | |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida | |
| UM Sylvester Comprehensive Cancer Center at Doral Doral, Florida | Site Public Contact - (kginnity@med.miami.edu) |
| UM Sylvester Comprehensive Cancer Center at Hollywood Hollywood, Florida | |
| UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida | |
| UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida | |
| UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina | Site Public Contact - (cancerclinicaltrials@med.unc.edu) |
| UPMC Cancer Center at UPMC Northwest Seneca, Pennsylvania | |
| UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania | |
| UPMC Hillman Cancer Center Erie Erie, Pennsylvania | Site Public Contact - (ClinicalResearchServices@upmc.edu) |
| UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania | Site Public Contact - (klitchfield@PINNACLEHEALTH.org) |
| UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania | |
| UPMC-Passavant Hospital Pittsburgh, Pennsylvania | |
| UT Southwestern Clinical Center at Richardson/Plano Richardson, Texas | Site Public Contact - (Suzanne.cole@utsouthwestern.edu) |
| UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| UT Southwestern/Simmons Cancer Center-Fort Worth Fort Worth, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| UW Cancer Center at ProHealth Care Waukesha, Wisconsin | Site Public Contact - (Chanda.miller@phci.org) |
| UW Health Carbone Cancer Center Rockford Rockford, Illinois | Site Public Contact - (lkline@uwhealth.org) |
| University Hospitals Parma Medical Center Parma, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| University Medical Center New Orleans New Orleans, Louisiana | Site Public Contact - (emede1@lsuhsc.edu) |
| University of Alabama at Birmingham Cancer Center Birmingham, Alabama | Site Public Contact - (gingerreeves@uabmc.edu) |
| University of Arkansas for Medical Sciences Little Rock, Arkansas | |
| University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Cincinnati Cancer Center-West Chester West Chester, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Kansas Cancer Center Kansas City, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center - Briarcliff Kansas City, Missouri | |
| University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center - North Kansas City, Missouri | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center-Overland Park Overland Park, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida | |
| University of Miami Sylvester Comprehensive Cancer Center at Sole Mia North Miami, Florida | Site Public Contact - (kginnity@med.miami.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| University of New Mexico Cancer Center Albuquerque, New Mexico | Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Utah Sugarhouse Health Center Salt Lake City, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| University of Virginia Cancer Center Charlottesville, Virginia | Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu) |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| Upper Valley Medical Center Troy, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Upstate Cancer Center Radiation Oncology at Oswego Oswego, New York | Site Public Contact - (BinghamE@upstate.edu) |
| Upstate Cancer Center at Hill Radiation Oncology Syracuse, New York | Site Public Contact - (BinghamE@upstate.edu) |
| Upstate Cancer Center at Verona Verona, New York | Site Public Contact - (McDowelE@upstate.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| West Jefferson Medical Center Marrero, Louisiana | Site Public Contact - (emede1@lsuhsc.edu) |
| West Michigan Cancer Center Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| West Virginia University Healthcare Morgantown, West Virginia | Site Public Contact - (cancertrialsinfo@hsc.wvu.edu) |
| Women and Infants Hospital Providence, Rhode Island | |
| Women's Cancer Center of Nevada Las Vegas, Nevada |
mHealth Intervention for Pain Self Management (PsyMINT)
Sun Jung Kim, Ph.D - sjkim2@vcu.edu
NCT07332377
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* In a post-treatment stage with no evidence of disease (complete remission)
* Diagnosed with cancer in the past three years
* Experiencing cancer/treatment-related pain
* ≥ 18 years of age at the time of first diagnosis
* Cognitively able to actively participate in an online-based study
* Able to read, write, and understand English
Exclusion Criteria:
* Individuals who currently use any medication for psychiatric reasons (including stimulants, and mood stabilizers)
* Patients with major psychotic disorders (bipolar disorder or schizophrenia) and/or substance use disorders.
* Those who are currently pregnant or plan to become pregnant in the next three months BEHAVIORAL: Mobile Health (mHealth) Intervention
Pain, Pain Management, Symptom Monitoring, Symptom Management, Cancer Survivorship
cancer survivorship, pain management, mHealth, behavioral intervention, nonpharmacologic intervention, app, digital health
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Henrico, Virginia | Sun Jung Kim, Ph.D - (sjkim2@vcu.edu) |
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer (CURB2)
Pierre-Olivier Gaudreau - p-ogaudreau@ctg.queensu.ca
NCT06686771
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Metastatic disease (stage IV) detected on imaging and histologically and/or cytologically confirmed NSCLC as per the WHO Classification of Tumors and AJCC 8th Edition TNM Classification, without a driver mutation with an actionable first-line targeted therapy, for whom either ICI alone or combination ICI + chemotherapy is indicated
* Oligoprogression on first-line ICI +/- chemotherapy systemic therapy after at least 3 cycles.
* All sites of oligoprogression can be safely treated with SBRT or ablative radiotherapy as determined by radiation treatment preplan, including availability and tolerability of necessary technologies (e.g., active breathing control, MRLinac, fiducial insertion, etc.) and accounting for previous radiotherapy overlap. Safety must be assessed and determined by a radiation oncologist.
* Patients with treated CNS disease who have radiologic and clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible providing that they are asymptomatic and do not require corticosteroids (must have discontinued steroids at least 1 week prior to randomization).
* Candidate for regulatory approved SOC first-line orsecond-line systemic therapy options.
* Participants must be ≥ 18 years of age.
* ECOG performance status of 0, 1 or 2.
* Participants that received prior adjuvant/neoadjuvant/consolidation systemic therapy (including chemotherapy and ICI ) are eligible if at least 6 months have elapsed between the completion of prior therapy and start of first-line treatment for metastatic disease.
* Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior systemic therapy. If participants experienced prior immune-mediated toxicity and have not yet re-initiated ICI therapy, please contact CCTG. Please also contact CCTG if participants have ongoing toxicity ≥ grade 1 felt to be clinically insignificant.
* Previous surgery related to NSCLC in the curative or metastatic disease setting is permitted. Previous major surgery is permitted provided that surgery occurred at least 28 days prior to participant enrollment and that wound healing has occurred.
* Prior external beam radiation related to NSCLC in the metastatic disease setting is permitted provided a minimum of 14 days (2 weeks) have elapsed between the last dose of radiation and date of enrollment. Patients that received prior external beam radiation therapy in the NSCLC curative disease setting (including the primary lesion) are eligible. Oligoprogressive lesions previously treated with external beam radiation are eligible as long they are clinically asymptomatic, and re-treatment is possible according to the investigator.
* Prior conventional, non-stereotactic radiotherapy for palliative purposes is allowed, and if the palliated lesion subsequently progressed but asymptomatic not requiring immediate RT, the lesion can still be counted toward one of the five oligoprogressive lesions.
* For Arm 1, SBRT must be initiated within 3 weeks of participant enrollment.
* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in either English, French, or Spanish.
* Reimbursement of continued SOC ICI and chemotherapy systemic therapies may not be uniform across all sites. In the event that site/investigator is unable to provide access to the drug, participant will not be eligible for this trial.
* Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
* Participants of childbearing potential must have agreed to use a highly effective contraceptive method.
Exclusion Criteria:
* Large-cell neuroendocrine carcinoma (LCNEC), pulmonary carcinoid tumour or mixed small cell and non-small cell lung cancer are not eligible.
* Presence of leptomeningeal disease.
* Pregnancy.
* Serious medical conditions in which radiotherapy of target lesions is contraindicated (e.g., scleroderma, Ataxia Telangiectasia (ATM), interstitial lung disease (ILD), Child-Pugh C liver function).
* Any other condition in which in the judgement of the investigator would make the patient inappropriate for study entry.
* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
* Concomitant medications should only exclude participants from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy; please consult the relevant product monographies.
* Concurrent treatment with other anti-cancer therapy, including investigational agents.
* Live attenuated vaccination administered within 30 days prior to enrollment/randomization. RADIATION: SBRT, OTHER: First or second-line standard of care therapy
Non-small Cell Lung Cancer
I'm interested
Share via email
Show 64 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Alton Memorial Hospital Alton, Illinois | |
| City of Hope Comprehensive Cancer Center Duarte, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope at Irvine Lennar Irvine, California | |
| Coborn Cancer Center at Saint Cloud Hospital Saint Cloud, Minnesota | Site Public Contact - (coborncancercenter@centracare.com) |
| Cross Cancer Institute Edmonton, Alberta | |
| Crossroads Cancer Center Effingham, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Decatur Memorial Hospital Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| HSHS Saint Elizabeth's Hospital O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Lenox Hill Hospital New York, New York | |
| Manhattan Eye Ear and Throat Hospital New York, New York | |
| Memorial Hospital East Shiloh, Illinois | Site Public Contact - (dschwab@wustl.edu) |
| Mercy Hospital Coon Rapids, Minnesota | |
| Miller-Dwan Hospital Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Mount Sinai Chelsea New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai Hospital New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai West New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Nebraska Medicine-Bellevue Bellevue, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| Nebraska Medicine-Village Pointe Omaha, Nebraska | |
| Northwell Health/Center for Advanced Medicine Lake Success, New York | |
| Northwest Wisconsin Cancer Center Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Glenview Outpatient Center Glenview, Illinois | |
| Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois | |
| Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois | Site Public Contact - (cancertrials@northwestern.edu) |
| Northwestern Medicine Oak Brook Oak Brook, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern Medicine Orland Park Orland Park, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa | |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| Queens Cancer Center Rego Park, New York | |
| Saint Francis Medical Center Cape Girardeau, Missouri | Site Public Contact - (sfmc@sfmc.net) |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Meridian Meridian, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Nampa Nampa, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Mary's Hospital and Regional Medical Center Grand Junction, Colorado | Site Public Contact - (ccrp@co-cancerresearch.org) |
| Siteman Cancer Center at Christian Hospital St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at West County Hospital Creve Coeur, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center-South County St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| State University of New York Upstate Medical University Syracuse, New York | |
| Stony Brook University Medical Center Stony Brook, New York | |
| The Don and Sybil Harrington Cancer Center Amarillo, Texas | Site Public Contact - (Gina.Cravey@bsahs.org) |
| Thomas Jefferson University Hospital Philadelphia, Pennsylvania | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa | |
| UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC-Shadyside Hospital Pittsburgh, Pennsylvania | |
| University Health Network-Princess Margaret Hospital Toronto, Ontario | Site Public Contact - (clinical.trials@uhn.on.ca) |
| University of Nebraska Medical Center Omaha, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Rochester Rochester, New York | |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Vanderbilt University/Ingram Cancer Center Nashville, Tennessee | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Pfizer CT.gov Call Center - ClinicalTrials.gov_Inquiries@pfizer.com
NCT07013474
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• 18 years of age or older at screening who are non-hospitalized or hospitalized for observation or with the intent of administering the study intervention.
• Confirmed SARS-CoV-2 infection as determined by RAT (or other locally approved test) collected within 2 days prior to randomization. Initial onset of symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified symptoms attributable to COVID-19 present on the day of randomization.
• Severely immunocompromised due to: * Solid organ or islet cell transplant recipient who is receiving immunosuppressive therapy; * Active hematologic malignancy (eg, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia); * Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or who are receiving immunosuppressive therapy; * Currently receiving or recently received B-cell depleting therapies (eg, rituximab), where the immunosuppressive effect is still ongoing.
Exclusion Criteria:
• Severe COVID-19, or current need for supplemental oxygen for treatment of COVID-19.
• Receiving dialysis or have current kidney failure (ie, eGFR consistently \<15 mL/min/1.73 m2)
• Active liver disease
• History of hypersensitivity or other contraindication to any of the components of the study interventions, as determined by the investigator
• Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
• Life expectancy less than 30 days at study entry due to an underlying condition, in the judgement of the investigator.
• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Has received any other antiviral for the treatment of the current COVID-19 infection
• Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).
• Current or previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
• Prior participation in this trial or any clinical trial of ibuzatrelvir.
• Females who are pregnant, breastfeeding, or who are planning to become pregnant within the timeframe of the study.
• Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
DRUG: ibuzatrelvir, DRUG: remdesivir, DRUG: placebo for ibuzatrelvir, DRUG: placebo for remdesivir
COVID-19 Infection
COVID-19 infection, pneumonia, respiratory tract infections, coronavirus infection, RNA virus infection, lung disease, pneumonia, viral, infections, virus, viral protease inhibitor, protease inhibitor, enzyme inhibitor, severe immunocompromise, anti-viral agents, anti-infectives, ibuzatrelvir, remdesivir, COVID-19
I'm interested
Share via email
Show 139 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AZ Sint-Jan Brugge-Oostende AV Bruges, | |
| Aalborg Universitetshospital, Syd Gistrup, | |
| Aarhus Universitetshospital, Skejby Aarhus, Central Jutland | |
| Acibadem Universitesi Atakent Hastanesi Istanbul, İ̇stanbul | |
| Alexandra General Hospital of Athens Athens, Attikí | |
| Amicis Research Center - Granada Hills Granada Hills, California | |
| Asan Medical Center Seoul, | |
| Aso Iizuka Hospital Iizuka, Fukuoka | |
| BRCR Global Puerto Rico San Juan, | |
| BRCR Medical Center - Ponce Ponce, | |
| BRP- Hialeah Hospital Hialeah, Florida | |
| Baylor Scott & White Health - Center for Advanced Heart and Lung Disease Dallas, Texas | |
| Baylor Scott & White Research Institute - Clinical Trials Office Dallas, Texas | |
| Baylor University Medical Center Dallas, Texas | |
| Brigham and Women's Hospital Boston, Massachusetts | |
| CECIP - Centro de Estudos do Interior Paulista Jaú, São Paulo | |
| CHUAC-Complejo Hospitalario Universitario A Coruña A Coruña, A Coruña [LA Coruña] | |
| CHUVI- Hospital Alvaro Cunqueiro Vigo, Pontevedra [pontevedra] | |
| Canas Medical Center Ponce, | |
| Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand Dijon, | |
| Centro Médico São Francisco Curitiba, Paraná | |
| Chonnam National University Hospital Gwangju, | |
| Clinical Trials Center Boston, Massachusetts | |
| Clinical Trials Hub Boston, Massachusetts | |
| D&H Cancer Research Center LLC Margate, Florida | |
| Duke University - Main Hospital and Clinics Durham, North Carolina | |
| Duke Vaccine and Trials Unit Durham, North Carolina | |
| Duke Vaccine and Trials Unit Durham, North Carolina | |
| Evangelismos General Hospital of Athens Athens, Attikí | |
| FAICIC S. de R.L. de C.V. Veracruz, Veracruz Ignacio de LA Llave | |
| Fakultna Nemocnica Trnava Trnava, Trnava Region | |
| Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica Banská Bystrica, | |
| Far Eastern Memorial Hospital New Taipei City, | |
| Fujita Health University Hospital Aichi, | |
| Fundación Santos y de la Garza Evia I.B.P San Pedro Garza García, Nuevo León | |
| Gachon University Gil Medical Center Incheon, Namdong-gu | |
| Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi Gaziantep, | |
| General Hospital of Athens "Laiko" Athens, Attikí | |
| Georgetown University Medical Center Washington D.C., District of Columbia | |
| Hacettepe Universite Hastaneleri Ankara, | |
| Henry Ford Hospital Detroit, Michigan | |
| Holy Name Medical Center Teaneck, New Jersey | |
| Hope Clinical Research, Inc. Canoga Park, California | |
| Hopital Claude Huriez - CHU de Lille Lille, NORD | |
| Hopital Saint Antoine Paris, | |
| Hopital Saint-Louis Paris, Île-de-France Region | |
| Hospital De La Santa Creu I Sant Pau Barcelona, | |
| Hospital General Universitario Dr. Balmis Alicante, | |
| Hospital Germans Trias I Pujol Badalona, | |
| Hospital Italiano de la Plata La Plata, Buenos Aires | |
| Hospital Nossa Senhora das Gracas Curitiba, Paraná | |
| Hospital Universitari Vall d'Hebron Barcelona, | |
| Hospital Universitario La Paz Madrid, | |
| Hospital Universitario Reina Sofia Córdoba, Andalusia | |
| Hospital Universitario Virgen de Valme Seville, | |
| Hospital de Clínicas de Porto Alegre Porto AlegreRS, | |
| Hospital e Maternidade Celso Pierro Campinas, São Paulo | |
| Houston Methodist Hospital Houston, Texas | |
| Humphreys Diabetes Center Boise, Idaho | |
| Hôpital Bichat - Claude-Bernard Paris, | |
| Ibni Sina Hospital Ankara, | |
| Icesp - Instituto Do Câncer Do Estado de São Paulo São Paulo, | |
| Instituto Médico Río Cuarto Río Cuarto, Córdoba Province | |
| Instituto Nacional de Infectologia Evandro Chagas Rio de Janeiro, | |
| International University of Health and Welfare Narita Hospital Narita, Chiba | |
| Jacobs Medical Center at UC San Diego Health La Jolla, California | |
| Jadestone Clinical Research Silver Spring, Maryland | |
| Johns Hopkins Hospital Baltimore, Maryland | |
| Jules Bordet Institute Anderlecht, | |
| Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, | |
| Karadeniz Technical University Trabzon, | |
| Karolinska Universitetssjukhuset Huddinge Huddinge, | |
| Kendall South Medical Center Miami, Florida | |
| Kocaeli Üniversitesi Kocaeli, | |
| Memorial Hermann Hospital Houston, Texas | |
| Nagasaki University Hospital Nagasaki, | |
| Narodny Onkologicky Ustav Bratislava, | |
| Narodny ustav detskych chorob Bratislava, Bratislava Region | |
| National Center for Global Health and Medicine Shinjuku, Tokyo | |
| National Hospital Organization Kyushu Medical Center Fukuoka, | |
| Nemocnica s poliklinikou Stefana Kukuru Michalovce, a.s. Michalovce, | |
| Northwestern Memorial Hospital Chicago, Illinois | |
| Northwestern University Feinberg School of Medicine Chicago, Illinois | |
| Odense Universitetshospital Odense, Region Syddanmark | |
| Parc de Salut Mar - Hospital del Mar Barcelona, | |
| Profound Research LLC Oceanside, California | |
| Radboudumc Nijmegen, | |
| Revive Research Institute, Inc. Farmington Hills, Michigan | |
| Rigshospitalet Copenhagen, | |
| Rinku General Medical Center Izumisano, Osaka | |
| Saga University Hospital Saga, Saga, | |
| Sakarya Training and Research Hospital Sakarya, | |
| Sanatorio Sagrado Corazón Buenos Aires, | |
| School of Medicine Federal University of Minas Gerais Belo Horizonte, Minas Gerais | |
| Seattle Rheumatology Associates Seattle, Washington | |
| Skylight Health Research, - Burlington Burlington, Massachusetts | |
| Skånes Universitetssjukhus Malmö Malmö, Skåne LÄN [se-12] | |
| St. Luke's Idaho Elks Children's Pavilion Boise, Idaho | |
| Swedish Ambulatory Infusion Center- First Hill Seattle, Washington | |
| Swedish Cancer Institute Treatment Center Seattle, Washington | |
| Swedish Medical Center - First Hill Campus Seattle, Washington | |
| Swedish Medical Center- Innovative Therapeutics & Research Unit Seattle, Washington | |
| Swedish Organ Transplant and Liver Center Seattle, Washington | |
| TRC Pittsburgh, Pennsylvania | |
| TUM Klinikum München, Bavaria | |
| Tachikawa Hospital Tachikawa, Tokyo | |
| Taichung Veterans General Hospital Taichung, | |
| Taipei Veterans General Hospital Taipei, | |
| The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul, | |
| The University of Texas Health Science Center at Houston Houston, Texas | |
| Tokyo Medical University Hachioji Medical Center Tokyo, Hachioji, | |
| UC Davis CTSC Clinical Research Center Sacramento, California | |
| UC San Diego Medical Center - Hillcrest San Diego, California | |
| UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus Aurora, Colorado | |
| UKE Hamburg Hamburg, | |
| UPMC Division of Infectious Disease Clinic Pittsburgh, Pennsylvania | |
| UPMC Hillman Cancer Center Pittsburgh, Pennsylvania | |
| UPMC Presbyterian IDS Pittsburgh, Pennsylvania | |
| UPMC Presbyterian Shadyside Pittsburgh, Pennsylvania | |
| UPMC Shadyside Pittsburgh, Pennsylvania | |
| UPMC Shadyside IDS Pittsburgh, Pennsylvania | |
| UT Physicians Houston, Texas | |
| UZ Brussel Brussels, Brussels Capital | |
| Universitaetsklinikum Koeln Cologne, North Rhine-Westphalia | |
| University General Hospital of Alexandroupoli Alexandroupoli, Anatolikí Makedonía KAI Thráki | |
| University of California Davis Health Sacramento, California | |
| University of California San Diego Health San Diego, California | |
| University of Cincinnati College of Medicine (UC Holmes) Cincinnati, Ohio | |
| University of Cincinnati Medical Center Cincinnati, Ohio | |
| University of Colorado Anschutz Medical Campus Aurora, Colorado | |
| University of Colorado Clinical and Translational Research Center Aurora, Colorado | |
| University of Colorado Hospital Aurora, Colorado | |
| University of Massachusetts Chan Medical School Worcester, Massachusetts | |
| University of Michigan Ann Arbor, Michigan | |
| University of Pittsburgh Medical Center Pittsburgh, Pennsylvania | |
| Université Libre de Bruxelles - Hôpital Erasme Brussels, Bruxelles-capitale, Région de | |
| Velocity Clinical Research, Savannah Savannah, Georgia | |
| West Tennessee Research Institute Jackson, Tennessee | |
| Zenos Clinical Research Dallas, Texas |
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
ctrrecruit@vcu.edu
NCT06532279
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must be planned to receive radiation and concurrent cisplatin chemotherapy as definitive therapy. Patients planned to receive concurrent cisplatin and radiation therapy in the adjuvant setting are not eligible.
* At least two subsites (buccal mucosa, lips, retromolar trigone, floor of mouth, oral tongue, tonsil, soft palate, or hard palate) must have at least 1cc or 1% of the subsite volume receiving \>= 50 Gy. In cases of uncertainty, the enrolling clinician can ensure coverage by inspecting the 50 Gy isodose line and using the table describing the anatomic boundaries of the individual subsites contained within the extended cavity contour. The two or more subsites receiving \>= 50 Gy must be documented by the enrolling physician.
* Pathologically confirmed (histologically or cytologically) squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharynx, or oral cavity.
* P16 and/or human papillomavirus (HPV) status (via polymerase chain reaction \[PCR\] or in situ hybridization \[ISH\]) must be documented for patients with oropharynx cancer.
* No patients with T0/Tx/unknown primary disease.
* No definitive clinical or radiologic evidence of metastatic (M1) disease related to current diagnosis.
* Able to receive intensity-modulated radiation therapy (IMRT) delivered as daily fractions of 2.0 Gy once per weekday with a cumulative radiation dose of 70 Gy.
* Age \>= 18.
* Zubrod performance status of 0-2.
* Potassium ≥ institutional lower limit of normal (LLN) and magnesium ≥ institutional LLN. Oral or intravenous (IV) replacement therapy of potassium or magnesium is permitted if parameters can be met after repletion.
* Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3.
* Platelets \>= 100,000 cells/mm\^3.
* Hemoglobin \>= 9.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 10.0 g/dl is acceptable).
* Adequate renal function defined as creatinine clearance (CrCL) \> 50 mL/min by the Cockcroft-Gault formula.
* Total bilirubin =\< 2 x institutional upper limit of normal (ULN) (not applicable to patients with known Gilbert's syndrome).
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional ULN.
* No prior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer, e.g., breast cancer with irradiation of the supraclavicular fossa/level 4 neck.
* No concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure.
* No prior history of gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed.
* No current treatment of adjuvant post-operative (op) chemoradiation.
* No systemic treatment with inducers or strong inhibitors of cytochrome P450 =\< 4 days before registration. Note: Patients undergoing steroid treatment as a component of the anti-emetic regimen for cisplatin are eligible for the study. Treatment with the antifungal medications, nystatin, fluconazole , miconazole and clotrimazole are allowed.
* No prior induction chemotherapy treatment.
* No prior unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ, basal cell skin carcinoma, resected T1-2N0M0 differentiated thyroid cancers, Ta bladder cancers, or low risk prostate cancer.
* No clinically significant hearing impairment that precludes cisplatin, as per physician assessment.
* No serious cardiovascular disease or cerebrovascular disease in the last 6 months prior to study enrollment; defined as a cerebrovascular accident, myocardial infarction, unstable angina, serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment, or current New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or admission within last 6 months for CHF exacerbation; (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification).
* No valvular heart disease.
* No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to enrollment.
* No history or evidence upon physical/neurological examination of central nervous system disease (e.g., seizures) unrelated to cancer unless adequately controlled by medication.
* No acute bacterial, viral, or fungal infection requiring intravenous antimicrobials within 7 days of enrollment.
* No history of chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration.
* No known personal or family history of long QT Syndrome; no marked baseline prolongation of QT/corrected QT (QTc) interval (i.e., ≥ 2 electrocardiograms \[EKGs\] in prior 3 months of a QTc interval \> 450 milliseconds (ms) for males and \> 470 ms for females using the specific/usual choice by clinical center for correction factor.
* Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities must be reversible to ≤ grade 1 with supplementation.
* No poorly controlled hypertension (systolic blood pressure \[SBP\] \> 160 and/or diastolic blood pressure \[DBP\] \> 95) over 2 repeated measures within 30 days prior to registration.
* No grade \>= 2 oral mucositis per CTCAE version 5.0.
* No grade \>= 2 hypotension per CTCAE v. 5.0.
* No medical necessity for anti-arrhythmics with significant risk of QTc prolongation such as class I and class III anti-arrhythmics. These include but are not limited to amiodarone, quinidine, dofetilide, sotalol, flecainide, and lidocaine.
* No medical necessity for medications listed as prohibited.
* For standard management of oral mucositis, clinicians may consult the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. The only intervention against mucositis that is supported by level I evidence is low-level laser therapy (LLLT). Honey is rated at level II and benzydamine, which isn't available in the United States (US), is rated at level III. There are no other positively rated interventions.
* LLLT is prohibited in this study as its availability remains limited, it is not Food and Drug Administration (FDA) approved in the US, and it is considered investigational in many circumstances requiring enrollment in a dedicated protocol who requirements could conflict with this one. Therefore, institutions that use LLLT should only enroll patients who would not be eligible for (or do not want) that intervention. Honey is not on the list of prohibited medications for this study. Given the MASCC recommendation, benzydamine is allowed, although there is lack of availability in the United States of America (USA). The other listed prohibited medications are not recommended by MASCC and some are potentially harmful, such as glutamine, which is associated with mortality in patients receiving stem cell transplant.
* No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).
* Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. OTHER: Best Practice, PROCEDURE: Biospecimen Collection, DRUG: Cisplatin, PROCEDURE: Computed Tomography, RADIATION: Image Guided Radiation Therapy, RADIATION: Intensity-Modulated Radiation Therapy, PROCEDURE: Magnetic Resonance Imaging, DRUG: MnSOD Mimetic BMX-001, DRUG: Placebo Administration, OTHER: Questionnaire Administration
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
I'm interested
Share via email
Show 149 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Adams Cancer Center Gettysburg, Pennsylvania | |
| Arizona Center for Cancer Care Tempe, Arizona | Site Public Contact - (penny.labriola@arizonaccc.com) |
| Arizona Center for Cancer Care - Gilbert Gilbert, Arizona | Site Public Contact - (penny.labriola@arizonaccc.com) |
| Arizona Center for Cancer Care - Phoenix Phoenix, Arizona | Site Public Contact - (penny.labriola@arizonaccc.com) |
| Arizona Center for Cancer Care - Scottsdale Scottsdale, Arizona | Site Public Contact - (penny.labriola@arizonaccc.com) |
| Arizona Center for Cancer Care-Peoria Peoria, Arizona | |
| Arizona Center for Cancer Care-Surprise Surprise, Arizona | Site Public Contact - (Roster@nrgoncology.org) |
| Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin | |
| Aspirus Regional Cancer Center Wausau, Wisconsin | |
| Atrium Health Cabarrus/LCI-Concord Concord, North Carolina | |
| Atrium Health Cleveland/LCI-Cleveland Shelby, North Carolina | |
| Atrium Health Pineville/LCI-Pineville Charlotte, North Carolina | |
| Atrium Health Stanly/LCI-Albemarle Albemarle, North Carolina | |
| Atrium Health Union/LCI-Union Monroe, North Carolina | |
| Atrium Health University City/LCI-University Charlotte, North Carolina | |
| Aultman Health Foundation Canton, Ohio | Site Public Contact - (ClinicalReserachDept@aultman.com) |
| Baptist Cancer Center-Grenada Grenada, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Health Hardin Elizabethtown, Kentucky | |
| Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Boston Medical Center Boston, Massachusetts | |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| CaroMont Regional Medical Center Gastonia, North Carolina | Site Public Contact - (tammy.cozad@caromonthealth.org) |
| Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina | |
| Chambersburg Hospital Chambersburg, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Dartmouth Cancer Center - North Saint Johnsbury, Vermont | Site Public Contact - (cancer.research.nurse@hitchcock.org) |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Drexel Town Square Health Center Oak Creek, Wisconsin | |
| Duke University Medical Center Durham, North Carolina | |
| Ephrata Cancer Center Ephrata, Pennsylvania | |
| Florida Cancer Specialists - Sarasota Sarasota, Florida | Site Public Contact - (Roster@nrgoncology.org) |
| Florida Cancer Specialists - Sarasota Downtown Sarasota, Florida | |
| Florida Cancer Specialists - Venice Pinebrook Venice, Florida | Site Public Contact - (ClinicalTrials@FLCancer.com) |
| Froedtert Menomonee Falls Hospital Menomonee Falls, Wisconsin | |
| Froedtert West Bend Hospital/Kraemer Cancer Center West Bend, Wisconsin | |
| George Washington University Medical Center Washington D.C., District of Columbia | |
| Greater Baltimore Medical Center Baltimore, Maryland | |
| Hayworth Cancer Center High Point, North Carolina | |
| Illinois CancerCare - Washington Washington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Bloomington Bloomington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Canton Canton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Eureka Eureka, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Galesburg Galesburg, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Kewanee Clinic Kewanee, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Macomb Macomb, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Ottawa Clinic Ottawa, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Pekin Pekin, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peoria Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peru Peru, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Princeton Princeton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Iowa Methodist Medical Center Des Moines, Iowa | |
| Karmanos Cancer Institute at McLaren Greater Lansing Lansing, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| Keck Medicine of USC Buena Park Buena Park, California | |
| Lake Regional Hospital Osage Beach, Missouri | Site Public Contact - (clinicaltrials@lakeregional.com) |
| Lancaster Radiation Therapy Center Lancaster, South Carolina | |
| Langlade Hospital and Cancer Center Antigo, Wisconsin | Site Public Contact - (Juli.Alford@aspirus.org) |
| Levine Cancer Institute-Gaston Gastonia, North Carolina | |
| Levine Cancer Institute-Rock Hill Rock Hill, South Carolina | |
| Los Angeles General Medical Center Los Angeles, California | Site Public Contact - (uscnorrisinfo@med.usc.edu) |
| McFarland Clinic - Ames Ames, Iowa | Site Public Contact - (ksoder@mcfarlandclinic.com) |
| McLaren Cancer Institute-Bay City Bay City, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren Cancer Institute-Central Michigan Mount Pleasant, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren Cancer Institute-Clarkston Clarkston, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren Cancer Institute-Flint Flint, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren Cancer Institute-Lapeer Region Lapeer, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren Cancer Institute-Macomb Mount Clemens, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren Cancer Institute-Northern Michigan Petoskey, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| McLaren-Port Huron Port Huron, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Mercy Hospital Coon Rapids, Minnesota | |
| Mercy Medical Center - Des Moines Des Moines, Iowa | |
| Miller-Dwan Hospital Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Moffitt Cancer Center Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center - McKinley Campus Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at SouthShore Ruskin, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at Wesley Chapel Wesley Chapel, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center-International Plaza Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas | Site Public Contact - (Emily.Carvell@bmhcc.org) |
| Northwest Wisconsin Cancer Center Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Orland Park Orland Park, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| OSF Saint Francis Medical Center Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| OSF Saint Joseph Medical Center Bloomington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa | |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| ProHealth D N Greenwald Center Mukwonago, Wisconsin | Site Public Contact - (research.institute@phci.org) |
| ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin | |
| Renown Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Rock Hill Radiation Therapy Center Rock Hill, South Carolina | |
| Saint Francis Medical Center Cape Girardeau, Missouri | Site Public Contact - (sfmc@sfmc.net) |
| Salina Regional Health Center Salina, Kansas | Site Public Contact - (mleepers@srhc.com) |
| Sarasota Memorial Health Care Center at University Parkway Sarasota, Florida | |
| Sarasota Memorial Hospital Sarasota, Florida | |
| Sarasota Memorial Hospital-Venice N. Venice, Florida | |
| Sechler Family Cancer Center Lebanon, Pennsylvania | Site Public Contact - (doxenberg@wellspan.org) |
| Shaw Cancer Center Edwards, Colorado | |
| Summa Health System - Akron Campus Akron, Ohio | Site Public Contact - (cancerresearch@summahealth.org) |
| UC San Diego Medical Center - Hillcrest San Diego, California | Site Public Contact - (rhabbaba@health.ucsd.edu) |
| UC San Diego Moores Cancer Center La Jolla, California | Site Public Contact - (cancercto@ucsd.edu) |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa | |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa | |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa | |
| UPMC Cancer Center - Monroeville Monroeville, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| UPMC Cancer Center at UPMC Horizon Farrell, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania | Site Public Contact - (ClinicalResearchServices@upmc.edu) |
| UPMC Hillman Cancer Center - New Castle New Castle, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Hillman Cancer Center Erie Erie, Pennsylvania | Site Public Contact - (ClinicalResearchServices@upmc.edu) |
| UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania | Site Public Contact - (klitchfield@PINNACLEHEALTH.org) |
| UPMC-Passavant Hospital Pittsburgh, Pennsylvania | |
| UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania | |
| UPMC-Saint Margaret Pittsburgh, Pennsylvania | |
| UPMC-Shadyside Hospital Pittsburgh, Pennsylvania | |
| USC / Norris Comprehensive Cancer Center Los Angeles, California | |
| USC Norris Oncology/Hematology-Newport Beach Newport Beach, California | |
| UW Cancer Center at ProHealth Care Waukesha, Wisconsin | Site Public Contact - (Chanda.miller@phci.org) |
| University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Cincinnati Cancer Center-West Chester West Chester, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Kansas Cancer Center Kansas City, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of New Mexico Cancer Center Albuquerque, New Mexico | Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania | |
| University of Tennessee - Knoxville Knoxville, Tennessee | |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Wake Forest University Health Sciences Winston-Salem, North Carolina | |
| Wayne State University/Karmanos Cancer Institute Detroit, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| Weisberg Cancer Treatment Center Farmington Hills, Michigan | Site Public Contact - (ctoadmin@karmanos.org) |
| WellSpan Health-York Cancer Center York, Pennsylvania | |
| Zablocki Veterans Administration Medical Center Milwaukee, Wisconsin |
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
ctrrecruit@vcu.edu
NCT06317662
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* All patients must be enrolled on APEC14B1 and consented to eligibility screening (part A) prior to treatment and enrollment on AALL2321
* Infants (aged 365 days or less) on the date of diagnosis are eligible; infants must be \> 36 weeks gestational age at the time of enrollment
* Patients must have newly diagnosed B-acute lymphoblastic leukemia (B-ALL, 2017 World Health Organization \[WHO\] classification), also termed B-precursor ALL, or acute leukemia of ambiguous lineage (ALAL), which includes mixed phenotype acute leukemia. For patients with ALAL, the immunophenotype of the leukemia must comprise at least 50% B lineage
* Diagnostic immunophenotype: Leukemia cells must express CD19
Exclusion Criteria:
* Patients with Down Syndrome
* Patients with secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy
* Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of infant ALL or for any cancer diagnosis prior to the initiation of protocol therapy, with the exception of:
* Steroid pretreatment:
* PredniSONE, prednisoLONE, or methylPREDNISolone for ≤ 72 hours (3 days) in the 7 days prior to enrollment. The dose of predniSONE, prednisoLONE or methylPREDNISolone does not affect eligibility
* Inhaled and topical steroids are not considered pretreatment
* Note: Pretreatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone used during or within 6 hours prior to or after sedation to prevent or treat airway edema. However, prior exposure to ANY steroids that occurred \> 28 days before enrollment does not affect eligibility
* Intrathecal cytarabine or methotrexate:
* An intrathecal dose of cytarabine or methotrexate in the 7 days prior to enrollment does not affect eligibility
* Note: The preference is to defer the diagnostic lumbar puncture with intrathecal chemotherapy to day 1 of induction to allow for cytoreduction of circulating blasts and decrease the potential for central nervous system (CNS) contamination due to a traumatic tap. If done prior to day 1 of induction, these results will be used to determine CNS status
* Hydroxyurea:
* Pretreatment with ≤ 72 hours (3 days) of hydroxyurea in the 7 days prior to enrollment does not affect eligibility
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA) and National Cancer Institute (NCI) requirements for human studies must be met DRUG: Asparaginase Erwinia chrysanthemi, PROCEDURE: Biospecimen Collection, BIOLOGICAL: Blinatumomab, PROCEDURE: Bone Marrow Aspiration, DRUG: Calaspargase Pegol, PROCEDURE: Computed Tomography, DRUG: Cyclophosphamide, DRUG: Cytarabine, DRUG: Daunorubicin, DRUG: Dexamethasone, DRUG: Doxorubicin, PROCEDURE: Echocardiography Test, PROCEDURE: FDG-Positron Emission Tomography, DRUG: Leucovorin, DRUG: Levoleucovorin, PROCEDURE: Lumbar Puncture, PROCEDURE: Magnetic Resonance Imaging, DRUG: Mercaptopurine, DRUG: Methotrexate, DRUG: Methylprednisolone, PROCEDURE: Multigated Acquisition Scan, DRUG: Prednisolone, DRUG: Prednisone, DRUG: Therapeutic Hydrocortisone, DRUG: Thioguanine, DRUG: Venetoclax, DRUG: Vincristine
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
I'm interested
Share via email
Show 111 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AdventHealth Orlando Orlando, Florida | Site Public Contact - (FH.Cancer.Research@flhosp.org) |
| Advocate Children's Hospital-Oak Lawn Oak Lawn, Illinois | |
| Advocate Children's Hospital-Park Ridge Park Ridge, Illinois | Site Public Contact - (helpdesk@childrensoncologygroup.org) |
| Albany Medical Center Albany, New York | |
| Alfred I duPont Hospital for Children Wilmington, Delaware | Site Public Contact - (Allison.bruce@nemours.org) |
| Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Arkansas Children's Hospital Little Rock, Arkansas | |
| Arnold Palmer Hospital for Children Orlando, Florida | Site Public Contact - (Jennifer.spinelli@orlandohealth.com) |
| BI-LO Charities Children's Cancer Center Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Banner Children's at Desert Mesa, Arizona | |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas | Site Public Contact - (burton@bcm.edu) |
| Bronson Methodist Hospital Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| C S Mott Children's Hospital Ann Arbor, Michigan | |
| Carilion Children's Roanoke, Virginia | Site Public Contact - (wpmccarty@carilionclinic.org) |
| Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina | |
| Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia | Site Public Contact - (Olivia.Floyd@choa.org) |
| Children's Hospital Colorado Aurora, Colorado | Site Public Contact - (josh.b.gordon@nsmtp.kp.org) |
| Children's Hospital Medical Center Of Akron Akron, Ohio | |
| Children's Hospital New Orleans New Orleans, Louisiana | |
| Children's Hospital and Medical Center of Omaha Omaha, Nebraska | |
| Children's Hospital of Alabama Birmingham, Alabama | Site Public Contact - (oncologyresearch@peds.uab.edu) |
| Children's Hospital of Orange County Orange, California | Site Public Contact - (oncresearch@choc.org) |
| Children's Hospital of Philadelphia Philadelphia, Pennsylvania | Site Public Contact - (CancerTrials@email.chop.edu) |
| Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania | Site Public Contact - (jean.tersak@chp.edu) |
| Children's Hospital of San Antonio San Antonio, Texas | Site Public Contact - (bridget.medina@christushealth.org) |
| Children's Hospital of Wisconsin Milwaukee, Wisconsin | Site Public Contact - (MACCCTO@mcw.edu) |
| Children's Hospital of the King's Daughters Norfolk, Virginia | Site Public Contact - (CCBDCresearch@chkd.org) |
| Children's Mercy Hospitals and Clinics Kansas City, Missouri | Site Public Contact - (COGResearchGroup@cmh.edu) |
| Children's National Medical Center Washington D.C., District of Columbia | Site Public Contact - (OncCRC_OnCall@childrensnational.org) |
| Cincinnati Children's Hospital Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@cchmc.org) |
| Connecticut Children's Medical Center Hartford, Connecticut | |
| Cook Children's Medical Center Fort Worth, Texas | Site Public Contact - (CookChildrensResearch@cookchildrens.org) |
| Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Dayton Children's Hospital Dayton, Ohio | |
| Dell Children's Medical Center of Central Texas Austin, Texas | Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org) |
| Driscoll Children's Hospital Corpus Christi, Texas | Site Public Contact - (Crystal.DeLosSantos@dchstx.org) |
| Duke University Medical Center Durham, North Carolina | |
| East Carolina University Greenville, North Carolina | Site Public Contact - (eubankss@ecu.edu) |
| East Tennessee Childrens Hospital Knoxville, Tennessee | |
| El Paso Children's Hospital El Paso, Texas | Site Public Contact - (ranjan.bista@ttuhsc.edu) |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Hackensack University Medical Center Hackensack, New Jersey | |
| Johns Hopkins All Children's Hospital St. Petersburg, Florida | Site Public Contact - (Ashley.Repp@jhmi.edu) |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Kaiser Permanente-Oakland Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kapiolani Medical Center for Women and Children Honolulu, Hawaii | |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York | Site Public Contact - (CancerTrials@nyulangone.org) |
| Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Loma Linda University Medical Center Loma Linda, California | |
| Lurie Children's Hospital-Chicago Chicago, Illinois | |
| Maine Children's Cancer Program Scarborough, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| Medical City Dallas Hospital Dallas, Texas | |
| Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida | Site Public Contact - (OHR@mhs.net) |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Methodist Children's Hospital of South Texas San Antonio, Texas | Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com) |
| Miller Children's and Women's Hospital Long Beach Long Beach, California | |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Morristown Medical Center Morristown, New Jersey | |
| NYP/Weill Cornell Medical Center New York, New York | |
| Nemours Children's Clinic - Pensacola Pensacola, Florida | Site Public Contact - (helpdesk@childrensoncologygroup.org) |
| Nemours Children's Clinic-Jacksonville Jacksonville, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| Nemours Children's Hospital Orlando, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| New York Medical College Valhalla, New York | |
| Norton Children's Hospital Louisville, Kentucky | Site Public Contact - (CancerResource@nortonhealthcare.org) |
| Ochsner Medical Center Jefferson New Orleans, Louisiana | Site Public Contact - (Elisemarie.curry@ochsner.org) |
| Prisma Health Richland Hospital Columbia, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio | Site Public Contact - (PCIOncResearch@promedica.org) |
| Providence Alaska Medical Center Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington | Site Public Contact - (HopeBeginsHere@providence.org) |
| Rainbow Babies and Childrens Hospital Cleveland, Ohio | |
| Rhode Island Hospital Providence, Rhode Island | |
| Riley Hospital for Children Indianapolis, Indiana | |
| Roswell Park Cancer Institute Buffalo, New York | Site Public Contact - (askroswell@roswellpark.org) |
| Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey | |
| Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida | Site Public Contact - (jennifer.manns@baycare.org) |
| Saint Joseph's Regional Medical Center Paterson, New Jersey | Site Public Contact - (HallL@sjhmc.org) |
| Saint Jude Children's Research Hospital Memphis, Tennessee | Site Public Contact - (referralinfo@stjude.org) |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Mary's Medical Center West Palm Beach, Florida | |
| Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin | Site Public Contact - (WI_research_admin@hshs.org) |
| Sanford Broadway Medical Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org) |
| Seattle Children's Hospital Seattle, Washington | |
| Sinai Hospital of Baltimore Baltimore, Maryland | |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| State University of New York Upstate Medical University Syracuse, New York | |
| The Children's Hospital at TriStar Centennial Nashville, Tennessee | |
| The Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York | |
| UCSF Benioff Children's Hospital Oakland Oakland, California | Site Public Contact - (PedOncRschOAK@ucsf.edu) |
| UCSF Medical Center-Mission Bay San Francisco, California | Site Public Contact - (cancertrials@ucsf.edu) |
| UF Health Cancer Institute - Gainesville Gainesville, Florida | Site Public Contact - (cancer-center@ufl.edu) |
| UMass Memorial Medical Center - University Campus Worcester, Massachusetts | Site Public Contact - (cancer.research@umassmed.edu) |
| UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina | Site Public Contact - (cancerclinicaltrials@med.unc.edu) |
| UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| University Pediatric Hospital San Juan, | |
| University of California Davis Comprehensive Cancer Center Sacramento, California | |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida | |
| University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota | |
| University of Mississippi Medical Center Jackson, Mississippi | |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Rochester Rochester, New York | |
| University of Virginia Cancer Center Charlottesville, Virginia | Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Vanderbilt University/Ingram Cancer Center Nashville, Tennessee | |
| Wake Forest University Health Sciences Winston-Salem, North Carolina | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Yale University New Haven, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Bonnie Wettersten, MS - bonnie.wettersten@alessatherapeutics.com
NCT06257693
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Age at least 21 years old
• Histologically confirmed adenocarcinoma of the prostate
• Study participant qualified and planning for radical prostatectomy
• At least 1 prostate lesion measurable by MRI greater or equal to 0.5 cm
• Cohort A and Cohort B: Gleason score 3+4 or higher Cohort C: Gleason score 3+3 with high risk features or 3+4
• Study participant must be willing to undergo post-treatment imaging by MRI
• Participants must be able to understand and sign the informed consent form
• ECOG performance status 0 or 1
• Adequate organ function, including absolute neutrophil count (ANC) ≥1000 cells/μL, hemoglobin ≥9 g/dL, platelets ≥100,000 cells/μL, estimated creatinine clearance ≥50 mL/min, bilirubin \<1.5x ULN (\< 3x ULN for documented Gilbert's syndrome)
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Alkaline phosphatase \<2.5x ULN
• The effects of Enolen on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, men must agree to use a highly effective form of contraception or abstinence at the time of study entry and continuing through three months after radical prostatectomy/implant removal. Highly effective forms of contraception include: Vasectomy Condom with spermicide Partner use of one of the following methods: Postmenopausal \>1 year or age \>55y Bilateral tubal ligation Intrauterine devices (IUDs) Hormonal implants (Implanon, Nexplanon, etc.) Combination oral contraceptives Progestin-only injections (Depo-Provera) Hormonal patches Vaginal Ring Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, the treating physician should be informed immediately.
Exclusion Criteria:
• Prior radiotherapy or surgery for prostate cancer
• Ongoing hormonal therapy for prostate cancer or hormone therapy \<3 months prior to the start of treatment
• Prior prostate procedures such as transurethral resection of the prostate, transurethral microwave thermotherapy of the prostate, high-intensity focused ultrasound or minimally invasive Benign Prostate Hyperplasia (BPH) procedure
• Study participant unwilling or unable to undergo MRI, including participants with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.
• Metallic hip implant or any other metallic implant or device that distorts the quality of prostatic MR images.
• Study participants who, because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
• Presence of any metastatic disease.
• No evidence of extracapsular extension of disease.
• Study participants, who in the opinion of the treating clinician, would be at increased risk of refractory urinary retention due to a transperineal procedure such as the Enolen implant.
• History of prostate infection within 2 years.
• No intercurrent medical condition or circumstances that would preclude prostatectomy.
• History of bleeding diathesis or currently on anti-coagulation therapy that cannot be safely discontinued for implant procedure.
• Any condition that, in the opinion of the Principal Investigator, which would impair the participant's ability to comply with study procedures and undergo prostatectomy.
DRUG: enzalutamide
Prostate Adenocarcinoma
I'm interested
Share via email
Show 7 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Atlantic Urology Specialists Myrtle Beach, South Carolina | Taylor Stephenson - (taylor.stephenson@startresearch.com) |
| Aurora Urology Milwaukee, Wisconsin | Greg Anderson - (gregory.anderson@aah.org) |
| Mary Bird Cancer Center Metairie, Louisiana | Mandy Shipp - (mshipp@marybird.com) |
| National Institutes of Health Clinical Center Bethesda, Maryland | Katie Evans, RN - (katie.evans@nih.gov) |
| Northwestern University Chicago, Illinois | Sophia Kallas - (sophia.kallas@northwestern.edu) |
| VA Portland Health Care System Portland, Oregon | Laura Onstad - (laura.onstad@va.gov) |
| Virginia Commonwealth University Henrico, Virginia | Genelle Gaudinez - (gaudinezg@vcu.edu) |
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (ACHIEVE)
Dyne Clinical Trials - clinicaltrials@dyne-tx.com
NCT05481879
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Diagnosis of DM1 with trinucleotide repeat size \>100.
* Age of onset of DM1 muscle symptoms ≥12 years.
* Clinically apparent myotonia equivalent to hand opening time of at least 2 seconds in the opinion of the Investigator.
* Hand grip strength and ankle dorsiflexion strength.
* Able to complete 10-MWRT, stair ascend/descend (MAD cohorts only), and 5×STS at screening without the use of assistive devices such as canes, walkers, or orthoses.
Exclusion Criteria:
* History of major surgical procedure within 12 weeks prior to the start of investigative product administration or an expectation of a major surgical procedure (eg, implantation of cardiac defibrillator) during the study.
* History of anaphylaxis.
* Medical condition other than DM1 that would significantly impact ambulation or participation in functional assessments.
* Treatment with medications that can improve myotonia within a period of 5 half-lives of the medication prior to performing screening assessments.
* Electrocardiogram (ECG) with the corrected QT interval by Fridericia's Formula (QTcF) ≥450 milliseconds (ms) in men and QTcF ≥460 ms in women, PR ≥240 ms, left bundle-branch block, or a conduction defect, which is clinically significant in the opinion of the Investigator.
* Percent predicted forced vital capacity (FVC) \<50%.
* History of tibialis anterior biopsy within 3 months of Day 1 or planning to undergo tibialis anterior biopsies during study period for reasons unrelated to the study.
* Participant has a history of suicide attempt, suicidal behavior, or has any suicidal ideation within 6 months prior to Screening that meets criteria at a level of 4 or 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) or who, in the opinion of the Investigator, is at significant risk to commit suicide.
* Use of glucagon-like peptide 1 (GLP-1) agonist medications including semaglutide, dulaglutide, liraglutide, exenatide, or tirzepatide within a period of 5 half-lives of the medication prior to performing screening assessments.
* Significant weight loss during study participation may impact weight-based dosing, performance on muscle function assessments, and pharmacodynamic (PD) biomarkers.
Note: Other inclusion and exclusion criteria may apply. DRUG: DYNE-101, DRUG: Placebo
Myotonic Dystrophy Type 1 (DM1)
I'm interested
Share via email
Show 20 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| CHU de Nantes Nantes, | Marie-Agnès Sourdril - (marieagnes.sourdril@chu-nantes.fr) |
| Centro Clinico Nemo Milan, | Maribel Evoli - (maribel.evoli@centrocliniconemo.it) |
| Charite - Universitatsmedizin Berlin Berlin, | Susanne Behr-Perst - (susanne.behr-perst@charite.de) |
| Fondazione Policlinico Universitario A Gemelli-Rome Rome, | Maria Pirozzoli - (mariaceleste.pirozzoli@policlinicogemelli.it) |
| Indiana University School of Medicine Indianapolis, Indiana | Patti Hogan, BSN RN, CCRA - (hoganpr@iu.edu) |
| Institut de Myologie Paris, | Asma Balloumi - (a.balloumi@institut-myologie.org) |
| John Walton Muscular Dystrophy Research Centre Newcastle upon Tyne, | Nicola McLarty - (nicola.mclarty1@nhs.net) |
| Ludwig Maximilians University, Munich - Friedrich Baur Institut Munich, | Corinna Wirner-Piotrowski - (Corinna.Wirner@med.uni-muenchen.de) |
| NZCR Auckland Auckland, | Miriam Rodrigues - (MRodrigues@adhb.govt.nz) |
| Neurology Rare Disease Center Denton, Texas | Isabella Herman - (Research@neuromdcenter.com) |
| Radboud Medical Center Nijmegen, | Eline Sanders - (clinicalresearchunit@radboudumc.nl) |
| Salford Royal Hospital Salford, | Bethan Blackledge - (Bethan.blackledge@nca.nhs.uk) |
| St. Vincent's Hospital Fitzroy, Victoria | Alan Lai - (alan.lai@svha.org.au) |
| Stanford University Palo Alto, California | Lidia Choniawko - (lidiacho@stanford.edu) |
| University College London Hospitals London, | Nikoletta Nikolenko - (n.nikolenko@nhs.net) |
| University of Florida College of Medicine Jacksonville, Florida | Debbye Landers - (debralanders@peds.ufl.edu) |
| University of Iowa Iowa City, Iowa | Heena Olade, RN, MSN - (heena-olalde@uiowa.edu) |
| University of Rochester Medical Center Rochester, New York | Jim Hilbert - (james_hilbert@urmc.rochester.edu) |
| Virginia Commonwealth University (VCU) Richmond, Virginia | Jodie Howell - (Jodie.howell@vcuhealth.org) Anarosa Rezeq - (anarosa.rezeq@vcuhealth.org) |
| Washington University in St. Louis St Louis, Missouri | Natalie Goedeker - (ngoedeker@wustl.edu) |
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
Incyte Corporation Call Center (US) - medinfo@incyte.com
NCT07214779
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
* Have platinum-resistant disease.
* Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum containing regimen.
* Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
* Archival FFPE tumor tissue block or slides from a specimen no older than 5 years must be available. If not available, participant must be willing to undergo a pretreatment tumor biopsy.
* Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent chemotherapy is considered an appropriate next therapeutic option.
* Should have received prior treatment with bevacizumab unless there was a contraindication for its use.
* Should have received prior treatment with mirvetuximab soravtansine if the tumor is positive for FRα, unless there is an exception for its use on medical grounds.
* Measurable disease per RECIST v1.1.
Exclusion Criteria:
* Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.
* Have primary platinum-refractory disease, defined as progression on or within 3 months after the last dose of first line platinum-containing therapy.
* Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study treatment.
* Known active CNS metastases and/or carcinomatous meningitis.
* Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years before the first dose of study treatment.
* Clinically significant gastrointestinal abnormalities.
Other protocol-defined Inclusion/Exclusion Criteria may apply. DRUG: INCB123667, DRUG: Investigator's choice of chemotherapy
Ovarian Cancer
INCB123667
I'm interested
Share via email
Show 123 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AZ Groeninge Kortrijk, | |
| Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust Cambridge, | |
| Aichi Cancer Center Chikusa-ku, Nagoya | |
| Arthur J E Child Comprehensive Cancer Centre Calgary, Alberta | |
| Atrium Health Wake Forest Baptist Winston-Salem, North Carolina | |
| Ausl Di Placenza Ospedale Guglielmo Da Saliceto Placenza, | |
| Az Maria Middelares Gent Ghent, | |
| Azienda Ospedaliero-Universitaria Careggi (Aouc) Florence, | |
| Azienda Ospedaliero-Universitaria Orsola-Malpighi - Universita Degli Studi Di Bologna Bologna, | |
| Bc Cancer - Abbotsford Abbotsford, British Columbia | |
| Billings Clinic Billings, Montana | |
| Centre Antoine Laccassagne Nice, | |
| Centre Eugene Marquis Rennes, | |
| Centre Hospitalier Départemental Vendée La Roche-sur-Yon, | |
| Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne, | |
| Centre Hospitalier Universitaire de Grenoble- Hopital Albert Michallon La Tronche, | |
| Centro Di Riferimento Oncologico (Cro Aviano) Aviano, | |
| Ch Davignon - Hopital Henri Duffaut Avignon, | |
| Chris Obrien Lifehouse Camperdown, New South Wales | |
| City of Hope Medical Center Duarte, California | |
| Clatterbridge cancer center Metropolitan Borough of Wirral, | |
| Clinica Universidad de Navarra - Sede Madrid Madrid, | |
| Clinique Pole Sante Leonard de Vinci Chambray-lès-Tours, | |
| Clinique Tivoli Bordeaux, | |
| Cliniques Universitaires St Luc Ucl Brussels, | |
| Comitato Etico Irccs Istituto Oncologico Veneto Di Padova Padua, | |
| Corporacio Sanitaria Universitaria Parc Tauli Sabadell, | |
| Cross Cancer Institute Edmonton, Alberta | |
| Edinburgh Cancer Centre Western General Hospital Edinburgh, | |
| Eoc Bellinzona Bellinzona, | |
| Erasmus Medisch Centrum 1 Rotterdam, South Holland | |
| Erlanger Health, Inc. Chattanooga, Tennessee | |
| Fondazione IRCCS Istituto Nazionale dei Tumori Milan, | |
| Georgia Cancer Center Augusta, Georgia | |
| Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust London, | |
| Hammersmith Hospital - Imperial College Healthcare NHS Trust London, | |
| Hokkaido University Hospital Sapporo, | |
| Hopital Prive Jean Mermoz Lyon, | |
| Hopital Universitaire de Bruxelles (Academisch Ziekenhuis Brussel) Brussels, | |
| Hopitaux Universitaires de Geneve (Hug) (Hopital Cantonal) Geneva, | |
| Hospital Clinic de Barcelona (Hospital Clinic i Provincial) Barcelona, | |
| Hospital Clinico Universitario de Valencia (Instituto de Investigacion Sanitaria Incliva) Valencia, | |
| Hospital Universitario La Paz Madrid, | |
| Hospital Universitario Virgen de Valme Seville, | |
| Hospital Universitario Virgen de la Victoria Málaga, | |
| Hospital Universitario de Alava Alava, | |
| Humanitas San Pio X Milan, | |
| Hyogo Cancer Center Akashi, Hyōgo | |
| Ico Badalona. Hospital Universitario Germans Trias I Pujol Badalona, | |
| Institut Gustave Roussy-Gustave Roussy Cancer Center -Ditep Villejuif, | |
| Institut Paoli Calmettes Marseille, | |
| Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena (Ire) Rome, | |
| Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) - Ospedale San Raffaele (Hsr) (Istituto Milan, | |
| Iwate Medical University Hospital Shiwa-gun, Iwate | |
| Jewish General Hospital Montreal, | |
| Jikei University Hospital Tokyo, | |
| Kantonsspital Frauenfeld Frauenfeld, | |
| Kantonsspital Graubunden Chur, Kanton Graubünden | |
| Klinikum Kassel Kassel, | |
| Kurume University Hospital Kurume, | |
| Levine Cancer Center Charlotte, North Carolina | |
| Lmu Klinikum- Medizinische Klinik Und Poliklinik Iii Innere Medizin, Haematologie Und Onkologie München, | |
| London Health Sciences Centre London, Ontario | |
| Maine Center for Cancer Medicine Scarborough, Maine | |
| Mazowiecki Szpital Wojewodzki, Siedleckie Centrum Onkologii Limbourg, | |
| Mazowiecki Szpital Wojewódzki Im. W. Jana Pawa Ii W Siedlcach Sp. Z O.O. Siedleckie Centrum Onkologi Siedlce, | |
| McGill University Health Centre Research Institute Montreal, Quebec | |
| Mercy Hospital St. Louis - David C. Pratt Cancer Center St Louis, Missouri | |
| Musgrove Park Hospital Taunton, Somerset | |
| National Cancer Center Hospital Tokyo, | |
| Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis Amsterdam, | |
| Northampton General Hospital Northampton, | |
| Northshore University Health System-Evanston Hospital Evanston, Illinois | |
| Novant Presbyterian Hospital Charlotte, North Carolina | |
| Okayama University Hospital Okayama, | |
| Oncology Associates of Oregon, P.C. Eugene, Oregon | |
| Ordine Mauriziano - Ospedale Umberto I Di Torino Torino, | |
| Osaka International Cancer Institute Osaka, | |
| Ospedale Ferrero Verduno, | |
| Ospedale Manzoni Lecco, | |
| Ospedale Santa Maria Ca Foncello Treviso, | |
| Ospedale Santa Maria delle Croci Ravenna, | |
| Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore Rome, | |
| Princess Margaret Cancer Center Toronto, Ontario | |
| Providence Cancer Institute Franz Clinic Portland, Oregon | |
| Radboud University Medical Center Nijmegen, | |
| Royal Marsden Hospital London, | |
| Royal Surrey County Hospital Guildford, Surrey | |
| Saitama Medical University International Medical Center Hidaka, | |
| Sanford Cancer Center-Sioux Falls Sioux Falls, South Dakota | |
| Sapporo Medical University Hospital Sapporo, Hokkaid | |
| Shikoku Cancer Center Matsuyama, | |
| Shizuoka Cancer Center Nagaizumi-cho,Sunto-gun, | |
| Ss Antonio & Biagio and C. Arrigo Hospital Alessandria, | |
| St James'S University Hospital - Leeds Teaching Hospitals Nhs Trust Leeds, | |
| St. James Hospital Dublin, | |
| St. Vincent's University Hospital Dublin, | |
| Tenon - Aphp Paris, | |
| Texas Oncology-Abilene Abilene, Texas | |
| The Cancer Institute Hospital of JFCR Koto-ku, Tokyo | |
| The Christie NHS Foundation Trust Manchester, | |
| Tohoku University Hospital Miyagi, | |
| U.O.C. Di Oncologia Ed Ematologia Oncologica Di Mirano-Dolo Mirano, | |
| Universita Degli Studi Di Pavia-Fondazione Irccs Policlinico San Matteo Pavia, | |
| Universitaetsklinikum Tuebingen Tübingen, | |
| Universitair Medisch Centrum Utrecht (UMC Utrecht) Utrecht, | |
| Universitair Ziekenhuis Leuven Leuven, | |
| Universitatsspital Zurich Zurich, | |
| University Clinic Carl Gustav Carus Technical University Dresden Dresden, | |
| University College London Hospitals - University College London Hospitals Nhs Foundation Trust London, | |
| University Medical Center Groningen Groningen, | |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | |
| University of Pittsburgh Medical Center Upmc Mageewomens Hospital Mwh Cancer Center Pittsburgh, Pennsylvania | |
| University of Washington - Fred Hutch Cancer Center Seattle, Washington | |
| Universitätsklinikum Schleswig Holstein Kiel, | |
| Universitätsklinikum Ulm Ulm, | |
| Universitätsmedizin Mannheim Mannheim, | |
| Valkyrie Clinical Trials Los Angeles, California | |
| Velindre University Nhs Trust Cardiff, | |
| ViDia Christliche Kliniken Karlsruhe Karlsruhe, | |
| Virginia Commonwealth University Henrico, Virginia | |
| Wellspan Gynecologic Oncology York, Pennsylvania | |
| Women's Cancer Care Covington, Louisiana |
Atrial Flutter Ablation in the iCMR (VISABL-AFL)
Kate Lindborg - kate.lindborg@imricor.com
NCT05904548
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient indicated for type I atrial flutter ablations with at least 1 documented episode of type I atrial flutter within 6 months (180 days) of enrollment
* Patient 18 years and older
Exclusion Criteria:
* Contraindications for MRI procedures
* Patients who cannot have anti-arrhythmic drugs (class I or class III) prescribed for the treatment of type I atrial flutter stopped on the day of the procedure
* Previous CTI ablation procedures
* Myocardial infarction within 60 days of enrollment
* Current unstable angina
* Cardiac surgery within 90 days of enrollment
* Any cerebral ischemic event (including transient ischemic attacks) within 6 months (180 days) of enrollment
* Thrombocytosis or thrombocytopenia
* Contraindication to anticoagulation therapy
* Currently documented intracardiac thrombus or myxoma
* Implantation of permanent leads of an implantable device in or through the right atrium within 90 days of enrollment
* Prosthetic valve through which the catheter must pass
* Interatrial baffle or patch through which the catheter must pass
* Moderate or severe tricuspid valve regurgitation or stenosis
* Uncompensated congestive heart failure
* Active systemic infection
* Pregnancy or if subject plans to become pregnant during the trial
* Uncontrolled hyperthyroidism
* Any other significant uncontrolled or unstable medical condition
* Enrollment in any concurrent study without Imricor written approval
* Life expectancy of less than or equal to 2 years (730 days) per physician opinion DEVICE: RF Ablation
Atrial Flutter Typical
RF Ablation, interventional Cardiac Magnetic Resonance (iCMR)
I'm interested
Share via email
Show 6 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Amsterdam University Medical Center (AUMC) Amsterdam, | |
| Johns Hopkins University (JHU) Baltimore, Maryland | |
| University Hospital of Vaud (CHUV) Lausanne, | |
| University of Virginia (UVA) Charlottesville, Virginia | |
| Virginia Commonwealth University Henrico, Virginia | Ajay Pillai, M.D. - (ajay.pillai@vcuhealth.org) |
| l'institut Cardiologique Paris Sud (ICPS) Massy, |
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 (BrAAVe)
Trial Transparency email recommended (Toll free for US & Canada) - contact-us@sanofi.com
NCT06844214
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
* For Part A, participants must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
* For Part B, participants must be as follows:
* 10 to 17 years of age inclusive, at the time of signing the informed consent or,
* 18 to 55 years of age inclusive, at the time of signing the informed consent.
* Participants with non-congenital onset DM1
* Participants presenting with signs of DM1 including myotonia and muscle weakness, as diagnosed previously by a clinician based on medical history.
* Participants with genetic diagnosis of DM1 \[cytosine-thymine-guanine (CTG) repeat length ≥50 in one allele from medical history\]
* Participants who can walk independently for at least 10 meters at screening (orthoses and ankle braces allowed).
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
* Participants with neutralizing antibodies against the AAV.SAN011 capsid
* Participants with left ventricular ejection fraction \<50%
* Participants with liver or biliary disease defined as having at least one of the following:
* ALT \>3 x ULN and AST \>3 x ULN
* Alkaline phosphatase \>3 x ULN
* Total bilirubin \>1.5 x ULN (unless has a genetically confirmed diagnosis of Gilbert's syndrome)
* Direct bilirubin ≥1.5 x ULN
* Participants with International normalized ratio \>1.5
* Participants with renal disease defined as:
• Serum creatinine \>1.5 x ULN and/or estimated glomerular filtration rate \<60 mL/min/1.73 m2 as determined by Chronic Kidney Disease Epidemiology Collaboration (2021) for those age ≥18 years and Bedside Schwartz Equation for those \<18 years
* Participants with chronic respiratory insufficiency and on long term/hull-time ventilatory assistance requiring at least 6 hours per day for at least 21 consecutive days.
* Participants with contraindication to corticosteroid or with conditions that could worsen in the presence of corticosteroids, as determined by the Investigator.
* Participants with active hepatitis B or C infection; HBsAg (+), or HCV RNA (+), or current antiviral therapy for either.
* Participants with HBcAb (+) who are not amenable for prophylactic anti-HBV therapy or pre-emptive therapy guided by serial HBV DNA monitoring during the corticosteroids therapy.
* Participants at high risk for tuberculosis reactivation during the corticosteroids therapy as determined by the Investigator.
* Participants with a known HIV infection
* Participants with serious intercurrent illness that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival.
* Participants with recent history of or current drug or alcohol abuse in the past 12 months prior to screening.
* Participants with history of tibialis anterior biopsy within 12 weeks from Day 1 or planning to undergo tibialis anterior biopsies during the duration of this clinical trial.
* Participants with significant developmental delay, intellectual disability, or behavioral neuropsychiatric manifestations as determined by the Investigator.
* Participants with previous systemic corticosteroids treatment at doses of \>5 mg/day within 15 days of Day 1
* Participants with previous treatment with anti-myotonic medication within 15 days of Day 1
* Participants not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
* Participants who have been classified as severe cardiac risk by the Investigator.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial. BIOLOGICAL: SAR446268
Myotonic Dystrophy
I'm interested
Share via email
Show 9 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Columbia University Medical Center - Neurological Institute, 710 W. 168th, 2nd floor, suite 204 - Site Number : 8400003 New York, New York | Jorge Cabrera - (jec2273@cumc.columbia.edu) |
| Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190 - Site Number: 0320001 Buenos Aires, | Ventura Simonovich - (ventura.simonovich@hospitalitaliano.org.ar) |
| Investigational Site Number : 0360001 Brisbane, Queensland | |
| Investigational Site Number : 3760002 Ramat Gan, | |
| Investigational Site Number : 8260002 Newcastle upon Tyne, | |
| The Montreal Neurological Institute and Hospital, 3801 rue University - Site Number: 1240001 Montreal, Quebec | - (nm.neurocru@mcgill.ca) |
| University of Florida, 2004 Mowry Road - Site Number: 8400005 Gainesville, Florida | Melissa Lewis - (melissa.lewis@peds.ufl.edu) |
| University of South Florida - Neuromuscular Research, 13330 USF Laurel Drive - Site Number: 8400001 Tampa, Florida | Sruthi Kommi Reddy - (SKommiReddy@usf.edu) |
| Virginia Commonwealth University Medical Center- Site Number : 8400006 Richmond, Virginia |
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics Global Medical Information - clinicaltrials@unither.com
NCT06388421
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Adults aged 18 years or older
• Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:
• Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
• Autoimmune ILD
• Chronic hypersensitivity pneumonitis
• Nonspecific interstitial pneumonia
• Occupational lung disease
• Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator
• For patients to be eligible for Cohorts 1 to 3: RHC confirmed PH (mean pulmonary artery pressure \>20 mmHg, pulmonary artery wedge pressure ≤15 mmHg, pulmonary vascular resistance \>2 WU).
• For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.
• For patients to be eligible for Cohort 2, they must have initiated Tyvaso/Tyvaso DPI at 1 of the following time points:
• Baseline
• ≤90 days prior to Baseline 6. For patients to be eligible for Cohort 3, they must be receiving Tyvaso/Tyvaso DPI at Baseline and for \>90 days prior to Baseline. 7. For patients to be eligible for Cohort 4: Prior RHC not meeting the definition of PH as described in Inclusion Criterion 3 but has a pulmonary artery wedge pressure ≤15 mmHg. 8. Co-enrollment in other observational or interventional studies is permitted. 9. Patient is willing and able to provide informed consent and complete surveys/questionnaires in English or Spanish.
Exclusion Criteria:
• Confirmed diagnosis of Group 1, 2, 4, or 5 PH a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH.
• Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.
• Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.
OTHER: Prospective study assessments
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
pulmonary hypertension, interstitial lung disease, pulmonary hypertension associated with interstitial lung disease
I'm interested
Share via email
Show 62 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Advent Health Medical Group Advanced Lung Disease Orlando, Florida | |
| Advocate Christ Medical Center Oak Lawn, Illinois | |
| AnMed Health Anderson, South Carolina | |
| Ascension St. Vincent Indianapolis, Indiana | |
| Aurora St. Luke's Medical Center Milwaukee, Wisconsin | |
| Auxilio Mutuo Hospital Guaynabo, Puerto Rico | |
| Banner Health - University Medical Center Phoenix Phoenix, Arizona | |
| Baylor University Medical Center Dallas, Texas | |
| Dartmouth Hitchcock Medical Center Lebanon, New Hampshire | |
| Duke University School of Medicine Durham, North Carolina | |
| East Carolina University Health Greenville, North Carolina | |
| Emory University Atlanta, Georgia | |
| Houston Methodist Houston, Texas | |
| Inova Medical Group Falls Church, Virginia | |
| Intercoastal Medical Group Sarasota, Florida | |
| Intermountain Medical Center Murray, Utah | |
| Legacy Research Institute Portland, Oregon | |
| Loyola University Medical Center Maywood, Illinois | |
| Marshall Health Huntington, West Virginia | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Medical University of South Carolina Charleston, South Carolina | |
| Morristown Medical Center Morristown, New Jersey | |
| NCH Research Institute Naples, Florida | |
| National Jewish Health Denver, Colorado | Beatrice Kwarteng - (KWARTENGB@NJHealth.org) |
| New York Presbyterian Hospital - Weill Cornell Medicine New York, New York | |
| New York University Langone Medical Center New York, New York | |
| Northwell Health Hempstead, New York | |
| Northwestern University Chicago, Illinois | |
| Norton Pulmonary Specialists Louisville, Kentucky | |
| Ohio State Richard M. Ross Heart Hospital Columbus, Ohio | |
| Oklahoma Heart Institute Tulsa, Oklahoma | |
| Oregon Health & Science University Portland, Oregon | |
| Pasquerilla Healthcare Center - Georgetown University Washington D.C., District of Columbia | |
| Pulmonary Associates of Richmond, Inc. Richmond, Virginia | |
| Pulmonix, LLC Greensboro, North Carolina | |
| St. Luke's University Health Network Easton, Pennsylvania | |
| StatCare Pulmonary Consultants and Center for Biomedical Research Knoxville, Tennessee | |
| Summit Health Bend, Oregon | |
| Tampa General Hospital/University of South Florida Health Tampa, Florida | |
| Temple Lung Center Philadelphia, Pennsylvania | |
| Temple University Hospital Philadelphia, Pennsylvania | |
| The Cleveland Clinic Cleveland, Ohio | |
| The University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | |
| Thomas Jefferson University - Sidney Kimmel Medical College Philadelphia, Pennsylvania | |
| UT Southwest Medical Center Heart and Lung Clinic Dallas, Texas | |
| University Medical Center - New Orleans New Orleans, Louisiana | |
| University of Alabama at Birmingham Birmingham, Alabama | |
| University of Cincinnati Medical Center Cincinnati, Ohio | |
| University of Colorado - Anschutz Medical Campus Aurora, Colorado | |
| University of Florida Gainesville, Florida | |
| University of Kansas Medical Center Fairway, Kansas | |
| University of Maryland Medical Center Baltimore, Maryland | |
| University of New Mexico Health Sciences Center Albuquerque, New Mexico | |
| University of North Carolina at Chapel Hill Chapel Hill, North Carolina | |
| University of Pennsylvania Philadelphia, Pennsylvania | |
| University of Texas Health Science Center at Houston Houston, Texas | |
| University of Utah Health Salt Lake City, Utah | |
| University of Wisconsin Hospital and Clinics Madison, Wisconsin | |
| Virginia Commonwealth University Henrico, Virginia | |
| WakeMed Health and Hospital Raleigh, North Carolina | |
| Washington University School of Medicine St Louis, Missouri | |
| Weston Hospital - Cleveland Clinic Florida Weston, Florida |
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
BCC Enroll - BCCEnroll@pennstatehealth.psu.edu
NCT06541262
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Age: Less than 30 years old at initial diagnosis
• Pathology All subjects must have a confirmed diagnosis of tumor type. Phase I: Relapsed/refractory solid tumors: Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma Phase II: * Relapsed/refractory Neuroblastoma * Relapsed/refractory Ewing sarcoma
• Tumor assessment: Disease assessment is required for eligibility and must be done after last dose of previous therapy and prior to first dose of study drug.
• Disease Status: Relapsed/Refractory Neuroblastoma Relapsed disease defined as neuroblastoma that was previously in remission after standard therapy (at least 4 cycles of aggressive multi-drug induction chemotherapy, with or without radiation and surgery, followed by immunotherapy, or according to a standard high-risk treatment/neuroblastoma protocol) and has now relapsed and is in any number of relapses. Refractory disease defined as High-risk neuroblastoma (as defined by INRG) that failed to achieve CR after at least 4 cycles of aggressive multi-drug induction chemotherapy, progression during upfront therapy or with disease remaining after standard immunotherapy. International Neuroblastoma Risk Group Staging System (INRG) High Risk NB defined as one of the following:
• Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M with MYCN amplification
• Age ≥ 547 days and INRG Stage M regardless of biologic features
• Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to Stage M without systemic chemotherapy
• Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to Stage M without systemic chemotherapy Relapsed/refractory Sarcoma Subjects that have relapsed following standard of care therapy or having progressed during standard of care therapy. Standard of care therapy for sarcoma includes multi-agent chemotherapy with local control consisting of either surgery or radiation therapy.
• Measurable or evaluable disease, including at least one of the following: * Measurable tumor by CT or MRI * MIBG or PET that is positive for disease * Bone Marrow biopsy/aspirate that is positive for disease
• Timing from prior therapy: Subjects must have fully recovered from the acute toxic effects of all prior anti- cancer therapy and be within the following timelines:
• Myelosuppressive chemotherapy: Must not have received within 2 weeks of enrollment onto this study.
• Small Molecule Inhibitors (anti-neoplastic agent): At least 2 weeks from the completion of therapy with a small molecule inhibitor.
• Immunotherapy: At least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines, CAR-T cells, anti-GD2 Monoclonal antibodies (ex. naxitamab, dinutuximab, etc.).
• Radiotherapy: At least 30 days since the last treatment except for radiation delivered with palliative intent to a non-target site.
• Stem Cell Transplant: * Allogeneic: No evidence of active graft vs. host disease * Allogeneic/Autologous: ≥ 2 months must have elapsed since transplant.
• MIBG Therapy: At least 6 weeks since treatment with MIBG therapy.
• Subjects must have a Lansky or Karnofsky Performance Scale score of \>/= 50.
• Subjects must have adequate organ function at the time of enrollment: * Cardiac: Subjects must have a QTcF ≤ 480 msc. * Hematological: Hematological recovery as defined by ANC ≥750/μL * Liver: Adequate liver function as defined by AST and ALT \<5x upper limit of normal * Renal: Subjects must have adequate renal function defined as an estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR ≥ 70. The Bedside Schwartz equation is: \[(0.413) X (Height in cm)\] / SCr
• Subjects of childbearing potential must have a negative serum pregnancy test. Subjects of childbearing potential must agree to use effective measures to avoid pregnancy.
• Written informed consent in accordance with institutional and FDA guidelines must be obtained from all subjects (or subjects' legal representative).
Exclusion Criteria:
• Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
• Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the hematological and bone marrow suppression effects of prior therapy.
• Subjects who are currently receiving Vitamin K antagonists (warfarin).
• Subjects who are currently receiving the class of lipid-lowering medications HMG-CoA reductase inhibitors (statins).
• Infection: Subjects who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
• Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.
• Subjects with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the subject's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
• Subjects with any of the following gastrointestinal disorders:
• Active malabsorption (e.g. short gut) syndrome.
• Uncontrolled diarrhea (excess of 4 stools/day)
• Gastritis, ulcerative colitis, Chron's disease or hemorrhagic coloproctitis
• History of gastric or small bowel surgery involving any extent of gastric or small bowel resection
• Lactating subjects are not eligible unless they have agreed to not breastfeed their infants. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the nursing subject with silmitasertib. (NOTE: breast milk cannot be stored for future use while the nursing subject is being treated on study.)
• Subjects with a history of any other malignancy.
DRUG: Silmitasertib, DRUG: Irinotecan, DRUG: Temozolomide, DRUG: Vincristine
Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma
I'm interested
Share via email
Show 21 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| All Children's Hospital Johns Hopkins Medicine St. Petersburg, Florida | Kevin Samnarine - (ksamnar1@jh.edu) |
| Arnold Palmer Hospital for Children Orlando, Florida | Marie Frankos - (marie.frankos@orlandohealth.com) |
| Cardinal Glennon Children's Medical Center St Louis, Missouri | Gina Martin - (gina.martin@health.slu.edu) |
| Children's Medical Center Dallas, Texas | Rachel Nam - (rachel.nam@childrens.com) |
| Children's Mercy Hospitals and Clinics Kansas City, Missouri | Nicole Harvey - (ndharvey@cmh.edu) |
| Hackensack University Medical Center Hackensack, New Jersey | Kellie Daniel - (kellie.danielle@hmhn.org) |
| Hasbro Children's Hospital Providence, Rhode Island | Christopher Bouressa - (cbouressa@lifespan.org) |
| Kapiolani Medical Center for Women and Children Honolulu, Hawaii | Andrea Siu, MPH - (andrea.siu@kapiolani.org) |
| Monroe Carrell Jr. Children's Hospital at Vanderbilt Nashville, Tennessee | Aida Constantinescu - (aida.constantinescu@vumc.org) |
| Nicklaus Children's Hospital Miami, Florida | Aixa Guadarrama - (Aixa.Guadarrama@Nicklaushealth.org) |
| Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine Louisville, Kentucky | Jennifer Miller - (Jennifer.Miller4@nortonhealthcare.org) |
| Penn State Milton S. Hershey Medical Center and Children's Hospital Hershey, Pennsylvania | Suzanne Treadway - (streadway@hmc.psu.edu) |
| Phoenix Children's Hospital Phoenix, Arizona | Brianna Lent - (blent@phoenixchildrens.com) |
| Primary Children's Hospital Salt Lake City, Utah | Group Contact - (Pc-cog@imail.org) |
| Rady Children's Hospital San Diego, California | Megan Saenz - (msaenz@rchsd.org) |
| St. Joseph's Children's Hospital Tampa, Florida | Jennifer Manns, RN - (jennifer.manns@baycare.org) |
| UCSF Benioff Children's Hospital Oakland Oakland, California | Group Contact - (pedsoncrschoak@ucsf.edu) |
| UHC Sainte-Justine Montreal, Quebec | Karyne Daigle - (karyne.daigle.hsj@ssss.quov.qc.ca) |
| University of Alabama/Children's of Alabama Birmingham, Alabama | Bridget Tate - (btate@peds.uab.edu) |
| University of Florida Gainesville, Florida | Ashley Bayne - (abayne@ufl.edu) |
| Virginia Commonwealth University Henrico, Virginia | Mary Madu - (memadu@vcu.edu) |
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
Holly Crandall, BSN - hrking1@iu.edu
NCT07143968
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Adults (≥18 years of age) with documented HIV.
• Documented diagnosis of MASLD established by imaging (ultrasound, CT scan or MRI) or vibration-controlled transient elastography (VCTE) or liver biopsy within 12 months before screening.
• Hepatic fat fraction ≥8% by MRI-PDFF.
• Liver stiffness by VCTE ≥8 kPa and CAP≥263 dB/m
• HIV-1 RNA \<200 copies/mL for ≥6 months on antiretroviral therapy (ART) (must have screening HIV-1 RNA value and one clinical care value within 6 months prior to screening and up to the randomization that meet the criteria).
• Stable ART regimen for ≥3 months prior to screening and stable up to the randomization and no active plans to change ART while on study.
• Willingness to participate in the study.
Exclusion Criteria:
• History of significant alcohol consumption (defined as \>2 drinks/day on average for men, \>1 drinks/day on average for women) for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening
• History of other acute or chronic liver disease, including, but not limited to autoimmune, primary biliary cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis, hepatitis B virus (HBV), and ongoing or recent (within the past 3 years) hepatitis C RNA positivity.
• History of liver transplant.
• Liver biopsy or radiologic imaging consistent with the clinical presence of cirrhosis or portal hypertension at screening.
• Participants whose Visit 2 ALT, AST, or alkaline phosphatase (ALP) values exceed their Visit 1 values by more than 50%.
• Inability to undergo MRI testing
• Uncontrolled T2DM defined as glycated hemoglobin (HbA1c) \>9.5% at screening.
• Any of the following laboratory values at screening:
• ALT or AST \>250 U/L.
• Total bilirubin (TBL) \>1.5 mg/dL and direct bilirubin \> 0.5 mg/dL (unless due to Gilbert's disease or atazanavir use, per the opinion of the site investigator).
• Platelet count \<150,000/mm3.
• Estimated glomerular filtration rate (e-GFR) \<60 mL/min/1.73m2 using the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation
• International normalized ratio (INR) \>1.3.
• Albumin \< 3.6 g/dL
• Liver stiffness measurement (LSM) by VCTE \> 20 kPa
• Further exclusion criteria apply
DRUG: Resmetirom, DRUG: Placebo Control
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
I'm interested
Share via email
Show 10 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Atlantic Clinical Research Institute West Palm Beach, Florida | Amanda Chavez - (achavez@midwaycare.org) |
| Duke University Medical Center Durham, North Carolina | Rebecca Mangus - (rebecca.mangus@duke.edu) |
| Indiana University Indianapolis, Indiana | Lexi Smith - (agoy@iu.edu) |
| Johns Hopkins University Baltimore, Maryland | Sara Mekhael - (sawad3@jhu.edu) |
| Mt Sinai Health System New York, New York | Mark Miller - (mark.miller@mssm.edu) |
| UC San Diego Altman Clinical and Translational Research Institute La Jolla, California | Egbert Mandamba - (emandamba@health.ucsd.edu) |
| UT Health Houston Houston, Texas | Sarah Galloway - (sarah.galloway@uth.tmc.edu) |
| University of Alabama Birmingham Birmingham, Alabama | Kristen Spraggins - (kspraggins@uabmc.edu) |
| University of California, San Francisco San Francisco, California | Rosaura Camberos - (rosaura.camberos@ucsf.com) |
| Virginia Commonwealth University Henrico, Virginia | Dianne Boyce Grogan - (dianne.boycegrogan@vcuhealth.org) |
Assessing Ambulatory and Non-ambulatory Community Mobility in People With Lower Limb Amputation
Paul Kline - klinep@vcu.edu
NCT07387744
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Unilateral or bilateral major lower limb amputation (e.g., proximal to or through the ankle joint)
* \>6 months since LLA Fitted with a prosthetic limb
* Fitted with a prosthetic limb
* Use a wheelchair or scooter for mobility for part of a day at least once per week
Exclusion Criteria:
* Unstable heart condition (including unstable angina, uncontrolled cardiac dysrhythmia, acute myocarditis, hypertension, and acute pericarditis)
* Acute systemic infection Prisoner or institutionalized such that self-determined mobility is restricted
* Prisoner or institutionalized such that self-determined mobility is restricted
* Decisionally challenged individuals (Modified Telephone Interview for Cognitive Status score ≤24)
* Undergoing active cancer treatment
* Participating in prosthetic rehabilitation
* Clinical discretion of the principal investigator to exclude patients who are determined to be unsafe and/or inappropriate to participate in the protocol
* Inability to communicate verbally in English OTHER: Clinical Descriptive Measures related to amputation collected, OTHER: GPS device education/distributed, OTHER: activPAL device education/distributed, OTHER: Questionnaire Assessments completed
Amputation
Lower Limb Amputation (LLA), Global Positioning System (GPS)
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Henrico, Virginia | Paul Kline - (klinep@vcu.edu) |
Nimodipine Variability in SAH (ASH-II)
Sherif H Mahmoud, BSc (Pharm), MSc, PhD, FNCS - smahmoud@ualberta.ca
NCT07065903
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Age 18-85 years
* Diagnosis of aneurysmal SAH
* Provision of informed consent
* Treated with nimodipine
* Presence of intravascular catheter at the time of sampling
Exclusion Criteria:
* Anticipated hospital length of stay \<48 hours
* Non-aneurysmal SAH
* Not treated with nimodipine
* Incarceration
* Delayed presentation to the hospital (\>96 h from SAH onset) Subarachnoid Aneurysm Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal
nimodipine, subarachnoid hemorrhage, pharmacokinetics
I'm interested
Share via email
Show 3 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| University Health Network - Toronto Western Hospital Toronto, Ontario | Victoria McCredie, MBChB PhD FRCP(C) FRCP(UK) - (Victoria.McCredie@uhn.ca) |
| University of Alberta Hospital Edmonton, Alberta | Sherif H Mahmoud, BSc (Pharm), MSc, PhD, FNCS - (smahmoud@ualberta.ca) |
| VCU Medical Center Richmond, Virginia | Gretchen M Brophy, PharmD, BCPS, FCCP, FNCS, MCCM - (gbrophy@vcu.edu) |
His-Bundle Corrective Pacing in Heart Failure (HIS-CRT)
Ann Colasurdo - ann.colasurdo@heart.rochester.edu
NCT05265520
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Age 18 years or older (no upper age limit)
* Optimal medical therapy for heart failure by current guidelines
* Class IIa or IIb guideline-based indication for CRT-D implant in RBBB patients, including one of the following:
* New York Heart Association (NYHA) class II HF symptoms, LVEF ≤ 30% and QRS≥ 150 ms (IIb); OR
* NYHA class III-IV a HF, LVEF ≤ 35%, and QRS duration ≥ 150 ms (IIa); OR
* NYHA class III-IV a HF, LVEF ≤ 35%, and QRS duration 120-149 ms (IIb)
Exclusion Criteria:
* Unable to obtain most recent imaging data from echocardiogram within 1 year prior to date of randomization
* Left bundle branch block (LBBB) or intraventricular conduction delay (IVCD) ECG morphology
* Unable or unwilling to follow study protocol
* Less than 12 months life expectancy at consent
* Pregnancy or planned pregnancy during duration of the study
* On heart transplant list or likely to undergo heart transplant PROCEDURE: His-CRT implantation, PROCEDURE: BIV-CRT implantation
Right Bundle-Branch Block, Heart Failure, His-bundle Pacing, Cardiac Resynchronization Therapy
I'm interested
Share via email
Show 14 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Cedars-Sinai Medical Center Los Angeles, California | |
| Geisinger Wyoming Valley Wilkes-Barre, Pennsylvania | |
| Mission Health Asheville, North Carolina | |
| Mount Sinai Hospital New York, New York | |
| Northwestern Memorial Hospital Chicago, Illinois | |
| Rush University Medical Center Chicago, Illinois | |
| University of Arizona Tucson, Arizona | |
| University of Chicago Chicago, Illinois | |
| University of Pennsylvania Philadelphia, Pennsylvania | |
| University of South Florida Tampa, Florida | |
| University of Vermont Burlington, Vermont | |
| Valley Health System Ridgewood, New Jersey | |
| Virginia Commonwealth University Henrico, Virginia | |
| Weill Cornell Medical College New York, New York |
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech clinical trials patient information - patients@biontech.de
NCT06712355
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study Group \[VALG\]'s two stage classification scheme). For AJCC tumor node metastasis staging system: AJCC 8th edition stage IV (T any, N any, M1a/b/c), or T3\~4 for multiple lung nodules or tumor/nodule volume that cannot be encompassed in a tolerable radiotherapy plan.
* Have not had prior systemic therapy for ES-SCLC. However, participants with prior chemoradiotherapy for limited-stage-SCLC must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible.
* Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion).
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate hematologic and organ function as defined in the protocol.
Exclusion Criteria:
* Have histologically or cytologically confirmed SCLC with combined histologies.
* Have received any of the following therapies or drugs within the noted time intervals prior to study treatment:
* Within 2 weeks: small molecule agents with half-life of \<7 days; radiation outside the thoracic cavity including whole brain radiation. Of note, other local radiation for brain lesions (not whole brain) is allowed; local radiation for bone lesions is allowed. Palliative bone radiation or brain stereotactic radiosurgery would not require a washout period, but participants should recover from radiotherapy-related toxicity.
* Within 4 weeks: radiation involving the thoracic cavity; small molecule targeted agents with half-life of ≥7 days; monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies.
* Have received prior treatment with anti-vascular endothelial growth factor (VEGF) monoclonal antibody, or programmed death (ligand)-1 (PD\[L\]-1)/VEGF bispecific antibody.
* Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of study treatment. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) are allowed.
* Have the following central nervous system metastases:
* Participants with untreated brain metastases that are symptomatic or large (e.g., greater than 2 cm).
* Participants with treated central nervous system (CNS) metastases who are not neurologically stable or on steroids (at a dosage greater than 10 mg/Day of prednisone or an equivalent dose of other corticosteroid) within 7 days before initiating study treatment of this study.
* Participants with known leptomeningeal metastases.
* Have uncontrolled hypertension or poorly controlled diabetes prior to study treatment.
* Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess for which an interval of 6 months must pass before study entry. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.
* Have a significant risk of hemorrhage (per investigator clinical judgment) as defined in the protocol.
* Have superior vena cava syndrome or symptoms of spinal cord compression that requires urgent medical intervention.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply. DRUG: Pumitamig, DRUG: Atezolizumab, DRUG: Etoposide, DRUG: Carboplatin (or cisplatin if carboplatin is not tolerated)
Extensive-Stage Small-Cell Lung Cancer
First-line ES-SCLC, SCLC, Immunotherapy in combination with chemotherapy, Untreated, Bispecific antibody, Programmed death-ligand 1 (PD-L1), Vascular endothelial growth factor (VEGF) A, Immunotherapy, Combination with other investigational agents, Pumitamig, BNT327, Check point inhibitor, Lung cancer, Etoposide, Carboplatin, Cisplatin
I'm interested
Share via email
Show 202 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| ACRC Arizona Clinical Research Center Tucson, Arizona | |
| Acibadem Adana Hospital Adana, | |
| Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust Cambridge, | |
| Affiliated Hospital of Hebei University Baoding, | |
| Ajou University Hospital Suwon, Gyeonggi-do | |
| Akdeniz University Hospital Antalya, | |
| Anhui Provincial Hospital Hefei, | |
| Ankara Bilkent City Hospital Ankara, | |
| Ankara Etlik City Hospital Ankara, | |
| Ankara University Medical Faculty Hospital Mamak, | |
| Asan Medical Center (AMC) Seoul, | |
| Asklepios Fachkliniken Muenchen Gauting Gauting, | |
| Azienda Ospedaliera San Giuseppe Moscati Avellino, | |
| Azienda Socio Sanitaria Territoriale di Cremona Cremona, | |
| Baptist Cancer Center Memphis, Tennessee | |
| Baptist Health Hardin Cancer Center Elizabethtown, Kentucky | |
| Baskent University Adana Turgut Noyan Application and Research Center Adana, | |
| Beijing Chest Hospital,Capital Medical University Beijing, | |
| Beijing Friendship Hospital, Capital Medical University Beijing, | |
| Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center Burlington, Massachusetts | |
| CHU de Caen Caen, | |
| CHU de Rennes, Hopital de Pontchaillou Rennes, | |
| Cairns Hospital Cairns, | |
| Cairns Hospital Cairns, | |
| Calvary Mater Newcastle Waratah, New South Wales | |
| Cancer Care Centers of Brevard, Inc Palm Bay, Florida | |
| Cancer Care Wollongong Pty Limited Wollongong, New South Wales | |
| Cancer Hospital Chinese Academy of Medical Sciences Hebei, | |
| Cancer Hospital of Shantou University Medical College Shantou, | |
| Casa Di Cura Polispecialistica Dott Pederzoli Peschiera del Garda, | |
| Centre Hospitalier Intercommunal Toulon La Seyne Sur Mer (C.H.I.T.S) - Hopital Sainte Musse Toulon, | |
| Centre Hospitalier Universitaire d'Angers (CHU Angers) Angers, | |
| Centro di Riferimento Oncologico Aviano, | |
| Centrul de Oncologie Euroclinic SRL Iași, | |
| Centrul de Oncologie Sf. Nectarie S.R.L (Sf Nectarie Oncology Center) Craiova, | |
| Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) Berlin, | |
| Chongqing University Three Gorges Hospital Wanzhou, | |
| Chungbuk National University Hospital Cheongju-si, | |
| Churchill Hospital - Oxford University Hospitals NHS Foundation Trust Oxford, Oxfordshire | |
| City Hospital Onesti Onești, | |
| Clermont Oncology Center Clermont, Florida | |
| Cleveland Clinic - Akron General Hematology & Oncology Akron, Ohio | |
| Cleveland Clinic - Hillcrest Hospital Mayfield Heights, Ohio | |
| Cleveland Clinic Foundation Cleveland, Ohio | |
| Cleveland Clinic Mercy Hospital Cancer Center Canton, Ohio | |
| Clinica MD Anderson International Madrid, | |
| Coltea Clinical Hospital Bucharest, | |
| Consorcio Hospitalario Provincial de Castellon Castellon, | |
| Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center New York, New York | |
| Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Ankara, | |
| Evangelische Lungenklinik Berlin Berlin, | |
| Fort Wayne Medical Oncology and Hematology, Inc Fort Wayne, Indiana | |
| Frederick Health Hospital- James M Stockman Cancer Institute Frederick, Maryland | |
| Fudan University - Shanghai Cancer Center (FUSCC) Shanghai, | |
| Fujian Provincial Cancer Hospital Fuzhou, | |
| FutureMeds Krakow Krakow, | |
| Gachon University Gil Medical Center Incheon, Namdong-gu | |
| Gazi University, Medical Faculty Hospital Ankara, | |
| Goztepe Prof. Dr. Suleyman Yalcin City Hospital Istanbul, | |
| Guangdong General Hospital Guangzhou, | |
| Guangxi Tumour Hospital Nanning, | |
| Gulhane Training and Research Hospital Ankara, | |
| Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust London, | |
| Gyeongsang National University Hospital (GNUH) Jinju, Gyeongsangnam-do | |
| Hacettepe University Medical Faculty Hospital Ankara, | |
| Harbin Medical University Cancer Hospital Harbin, | |
| Helen G. Nassif Community Cancer Center Cedar Rapids, Iowa | |
| Helios Klinikum Wuppertal-Universitaet Witten-Herdecke Wuppertal, | |
| Hematology Oncology Associates of Fredericksburg, Inc. Fredericksburg, Virginia | |
| Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University) Zhengzhou, | |
| Hospital Clinico Universitario Lozano Blesa de Zaragoza Zaragoza, | |
| Hospital General Universitario Gregorio Maranon (HGUGM) Madrid, | |
| Hospital Regional Universitario de Malaga Málaga, | |
| Hospital Universitario Nuestra Señora de Valme Seville, | |
| Hospital Universitario Vall d'Hebron Barcelona, | |
| Hospital Universitario de Badajoz Badajoz, | |
| Hospital Álvaro Cunqueiro Vigo, | |
| Huddersfield Royal Infirmary - Calderdale and Huddersfield NHS Foundation Trust Huddersfield, North Yorkshire | |
| Hull University Teaching Hospitals NHS Trust Cottingham, | |
| IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) Meldola, | |
| Icon Cancer Centre Kurralta Park Kurralta Park, South Australia | |
| Illinois Cancer Specialists Niles, Illinois | |
| Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest Bordeaux, | |
| Institut Curie - Centre de Recherche Paris, | |
| Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau Saint-Herblain, | |
| Jiamusi Cancer Hospital Jiamusi, | |
| Jiangsu Peoples Hospital Nanjing, | |
| Jilin Cancer Hospital Changchun, Jilin | |
| KOMED Roman Karaszewski I Wspolnicy Spolka Jawna Konin, | |
| Kanagawa Cancer Center Yokohama, | |
| Kettering Medical Center Kettering, Ohio | |
| Klinikum Chemnitz GmbH Chemnitz, | |
| Klinikum Esslingen GmbH Esslingen am Neckar, | |
| Klinikum Kempten-Oberallgau gGmbH Kempten, | |
| Klinikum Nuernberg Nord Nuremberg, | |
| Koc Universitesi Hastanesi (Koc University Hospital) Istanbul, | |
| Kocaeli University Medical Faculty Hospital Kocaeli, | |
| Korea University Guro Hospital Seoul, | |
| Krankenhaus Martha-Maria Halle-Doelau gGmbH Halle, | |
| Kurume University Hospital Kurume, | |
| Linyi Cancer Hospital Linyi, | |
| Liv Hospital Ankara Ankara, | |
| LungenClinic Grosshansdorf GmbH Großhansdorf, | |
| MVZ for oncology and hematology Rhein-Kreis Neuss GmbH Neuss, | |
| Marmara University Pendik Training and Research Hospital Istanbul, | |
| Matsusaka Municipal Hospital Matsusaka, | |
| McFarland Clinic Ames, Iowa | |
| Medical Park Florya Hospital Istanbul, | |
| Medical Point Izmir Hospital Izmir, | |
| Memorial Ankara Hospital Ankara, | |
| Millennium Research and Clinical Development, LLC Houston, Texas | |
| NHO Kinki Chuo Chest Medical Center Sakai, | |
| National Cancer Center Goyang-si, | |
| National Cancer Center Hospital Tokyo, | |
| National Hospital Organization Himeji Medical Center Himeji, | |
| National Hospital Organization Iwakuni Clinical Center Iwakuni, | |
| National Hospital Organization Kyushu Cancer Center Fukuoka, | |
| National Hospital Organization Nagoya Medical Center Nagoya, | |
| National Hospital Organization Shikoku Cancer Center Matsuyama, | |
| National Hospital Organization Yamaguchi-Ube Medical Center Ube, | |
| Nebraska Hematology-Oncology (NHO) Lincoln, Nebraska | |
| New Cross Hospital Wolverhampton, | |
| Niigata Cancer Center Hospital Niigata, | |
| Ninewells Hospital and Medical School - Tayside Health Board Dundee, Scotland | |
| Northern Centre for Cancer Care - The Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne, Northumberland | |
| Northern Jiangsu Peoples Hospital (NJPH) Yangzhou, | |
| Nottingham University Hospitals NHS Trust - Nottingham City Hospital Nottingham, Nottinghamshire | |
| Okayama University Hospital Okayama, | |
| Olivia Newton-John Cancer Wellness & Research centre Heidelberg, Victoria | |
| Oncocenter Oncologie Clinica S.R.L Timișoara, | |
| Osaka Prefectural Hospital Organization Osaka International Cancer Institute Osaka, | |
| Ospedale San Luca Lucca, | |
| Parc de Salut Mar - Hospital del Mar Barcelona, | |
| Peking Union Medical College Hospital Beijing, Beijing Municipality | |
| Peninsula & South Eastern Haematology and Oncology Group Frankston, Victoria | |
| Pratia Onkologia Katowice Katowice, | |
| Pratia S.A. , Pratia Poznan Poznan, | |
| Pratia Wroclaw Onkologia Wroclaw, | |
| Praxiskooperation Bonn-Euskirchen-Rheinbach-Wesseling Bonn, | |
| Royal Devon and Exeter Hospital, Royal Devon University Healthcare NHS Foundation Trust Exeter, | |
| Royal Marsden Hospital (RMH) - Royal Marsden NHS Foundation Trust Chelsea, London | |
| Royal Marsden Hospital (Sutton) - Royal Marsden NHS Foundation Trust Sutton, London | |
| Royal North Shore Hospital Saint Leonards, | |
| Royal Preston Hospital - Lancashire Teaching Hospitals NHS Foundation Trust Preston, | |
| Royal Stoke University Hospital - University Hospitals of North Midlands NHS Trust Stoke-on-Trent, Staffordshire | |
| SC Oncopremium Team SRL Baia Mare, | |
| SRH Wald-Kliniken Gera GmbH Gera, | |
| Sakarya University Training and Research Hospital Sakarya, | |
| Samsung Medical Center Seoul, | |
| Sendai Kousei Hospital Miyagi, | |
| Severance Hospital, Yonsei University Health System Seoul, | |
| Seyhan Medical Park Hospital Adana, | |
| Shandong Cancer Hospital and Institute Jinan, | |
| Shandong University - Jinan Central Hospital Jinan, | |
| Shanghai Chest Hospital Shanghai, | |
| Shanxi Provincial Tumor Hospital (Shanxi Oncology Hospital) Taiyuan, | |
| Shenandoah Oncology Winchester, Virginia | |
| Shibukawa Medical Center Shibukawa, | |
| St James'S University Hospital - Leeds Teaching Hospitals Nhs Trust Leeds, | |
| St. Luke's Physician Group - St. Luke's Cancer Care Associates Fountain Hill, Pennsylvania | |
| Staedtisches Klinikum Muenchen Bogenhausen München, | |
| Taizhou Hospital of Zhejiang Province Linhai, | |
| Texas Oncology Cancer Center Sugar Land, Texas | |
| The Catholic University of Korea, St. Vincent's Hospital Suwon, Gyeonggi-do | |
| The Christ Hospital Cancer Center Cincinnati, Ohio | |
| The Christie NHS Foundation Trust Manchester, | |
| The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion Cleveland, Ohio | |
| The First Affiliated Hospital of Henan Medical University Xinxiang, | |
| The First Affiliated Hospital of NanChang University Nanchang, | |
| The First Affiliated Hospital of Soochow University Suzhou, Jiangsu | |
| The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang | |
| The Queen Elizabeth Hospital Woodville, South Australia | |
| The University of Texas MD Anderson Cancer Center Houston, Texas | |
| The first affiliated hospital of bengbu medical college Bengbu, | |
| Tokyo Metropolitan Komagome Hospital Bunkyō City, | |
| Torbay and South Devon NHS Foundation Trust Torquay, South Devon | |
| Trakya University Faculty of Medicine Edirne, | |
| UOMI Cancer Center-Clinica Tres Torres Barcelona, | |
| Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST) Wuhan, | |
| Universidad de Sevilla - Hospital Universitario Virgen Macarena Seville, | |
| Universita Degli Studi Di Milano-Bicocca - Azienda Ospedaliera San Gerardo Di Monza Monza, | |
| Universitaetsklinikum Schleswig-Holstein (UKSH) - Campus Luebeck Lübeck, | |
| Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur) Valencia, | |
| University Hospitals Cleveland Medical Center Cleveland, Ohio | |
| University Medical Center of Johannes Gutenberg-University Mainz Mainz, | |
| University of Tennessee Medical Center Knoxville, Tennessee | |
| Uniwersytecki Szpital Kliniczny nr 4 w Lublinie Lublin, | |
| Uniwersyteckie Centrum Kliniczne Gdansk, | |
| Velindre NHS Trust, Velindre Cancer Centre Cardiff, Wales | |
| Virginia Cancer Specialists Fairfax, Virginia | |
| Virginia Commonwealth University School of Medicine Richmond, Virginia | |
| Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie Olsztyn, | |
| Washington University School of Medicine St Louis, Missouri | |
| Western Health Sunshine Hospital St Albans, Victoria | |
| White Plains Hospital White Plains, New York | |
| Wielkopolskie Centrum Pulmonologii i Tarakochirurgii Poznan, | |
| Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu Przemyśl, | |
| Xiangyang Central Hospital Xiangyang, | |
| Yeditepe University Kosuyolu Hospital Istanbul, | |
| Yunnan Provincial Cancer Hospital Kunming, | |
| Zhejiang Medical University, Zhejiang Cancer Hospital Hangzhou, | |
| Zhongnan Hospital of Wuhan University Wuhan, |
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Study Contact, M.D. - Participate-In-This-Study1@its.jnj.com
NCT05421663
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent
* Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
* Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL), Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma; Received at least 2 prior lines of systemic therapy; Relapsed or refractory disease defined as 1 or more of the following: Stable disease or Progressive disease (PD) as best response to most recent anti-lymphoma therapy OR disease progression or recurrence after a partial response (PR) or complete response (CR) to most recent anti lymphoma therapy; cohort specific requirements as mentioned in protocol
* Measurable disease as defined by Lugano 2014 classification
* Eastern cooperative oncology group (ECOG) performance status of 0 to 2
Exclusion Criteria:
* History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed)
* History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis
* History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder
* Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)
* Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection
* Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia
* Any prior solid organ or allogeneic stem cell transplantation
* Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis BIOLOGICAL: Prizloncabtagene autoleucel (Prizlo-Cel)
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
CD20/CD19
I'm interested
Share via email
Show 33 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Asan Medical Center Seoul, | |
| Calvary Mater Newcastle Hospital Waratah, New South Wales | |
| City of Hope South Pasadena, California | |
| Colorado Blood Cancer Institute Denver, Colorado | |
| Erasmus MC Rotterdam, South Holland | |
| Fiona Stanley Hospital Murdoch, Western Australia | |
| Greco Hainesworth Tennessee Oncology Centers for Research Nashville, Tennessee | |
| Hosp Clinic de Barcelona Barcelona, | |
| Hosp Univ Fund Jimenez Diaz Madrid, | |
| Hosp Univ Vall D Hebron Barcelona, | |
| ICO l'Hospitalet - Hospital Duran i Reynals Barcelona, | |
| Levine Cancer Institute Charlotte, North Carolina | |
| Northwestern University Chicago, Illinois | |
| Odense University Hospital Odense, | |
| Princess Margaret Cancer Centre University Health Network Toronto, Ontario | |
| Rigshospitalet Copenhagen, | |
| Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey | |
| Samsung Medical Center Seoul, | |
| Sarah Cannon Research Institute Nashville, Tennessee | |
| Seoul National University Hospital Seoul, Seoul Teugbyeolsi | |
| St Vincents Hospital Melbourne Fitzroy, Victoria | |
| St. David's South Austin Medical Center Austin, Texas | |
| Swedish Cancer Institute Seattle, Washington | |
| Texas Transplant Institute San Antonio, Texas | |
| The Alfred Hospital Melbourne, Victoria | |
| The Christie NHS Foundation Trust Christie Hospital Manchester, | |
| UMC Utrecht Utrecht, | |
| University College London Hospitals London, | |
| University Hospitals Cleveland Medical Center Cleveland, Ohio | |
| University of Iowa Hospital and Clinics Iowa City, Iowa | |
| University of Kentucky Medical Center Lexington, Kentucky | |
| University of Pittsburgh Medical Center Pittsburgh, Pennsylvania | |
| VCU Medical Center Richmond, Virginia |
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
Amber Paulus, PhD - amber.Paulus@vcuhealth.org
NCT07415876
Show full eligibility criteria
Hide eligibility criteria
Prospective
Inclusion Criteria:
* Age ≥18 years
* Undergoing a clinically indicated biopsy
* Able to provide informed consent
* Willing to provide a urine sample and allow access to relevant clinical
Retrospective Inclusion Criteria:
* Age ≥18 years
* Biopsy-confirmed rejection (positive histology)
* Donor-derived cell-free DNA\<1% result at time of biopsy
* Availability of stored urine sample collected at time of biopsy
Exclusion Criteria (applies to both arms):
* Individuals under 18 years of age
* Individuals unable to provide informed consent (for prospective enrollment)
* Pregnant women
* Prisoners
* Adults unable to consent OTHER: Retrospective Cohort Enrollment, OTHER: Prospective Cohort Enrollment
Kidney Transplant Rejection
CXCL10, CXCR3+T cells, ccfDNA, dd-cfDNA, ABMR, TCMR
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Henrico, Virginia | Amber Paulus - (Amber.Paulus@vcuhealth.org) Gelila Abebe - (gelila.abebe@vcuhealth.org) |
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
Arnethea Sutton, Ph.D - careslab@vcu.edu
NCT07426913
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* 18 years of age or older
* Able to speak and read in English
* Actively receiving Trastuzumab or an anthracycline-based treatment
* Diagnosed with stages 0-III Breast Cancer
Exclusion Criteria:
\- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis) BEHAVIORAL: Cardiovascular Health Education and Gaming through Virtual Reality
Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
virtual reality, breast cancer, antracyclines, trastuzumab, VCU, Virginia Commonwealth University
I'm interested
Share via email
Show 3 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Adult Outpatient Pavilion Richmond, Virginia | Victoria Williams - (williamsv4@vcu.edu) |
| Cellular Immunotherapies and Transplant Department Richmond, Virginia | Victoria Williams - (williamsv4@vcu.edu) |
| VCU Health at Stony Point Richmond, Virginia | Victoria Williams - (williamsv4@vcu.edu) |
Pelacarsen Roll-over Extension Program
Novartis Pharmaceuticals - novartis.email@novartis.com
NCT06875973
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
* Participants who have completed the parent study and received the assigned study treatment at the time of its completion
Exclusion Criteria:
* Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study
* Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation
* Participants who are receiving another investigational drug or device before the open-label treatment period
* Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator
Other protocol-defined inclusion/exclusion criteria may apply. DRUG: Pelacarsen (TQJ230)
Atherosclerotic Cardiovascular Disease
TQJ230, Lp(a), ASCVD
I'm interested
Share via email
Show 97 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| A&A Research Group Inc Miami, Florida | Belkis Barbon - (bbarbon@aaresearchgroupinc.com) |
| AB Clinical Trials Las Vegas, Nevada | Fungai Siziba-Dubose - (fsdabct@gmail.com) |
| Aa Mrc Llc Flint, Michigan | |
| Aa Mrc Mhs Flint, Michigan | Abuobieda Alawad - (aalawad@aamrc.net) |
| Advanced Clinical Research LLC Bayamón, | Sonia Ortiz Santos - (sortiz@prohealthams.com) |
| Alliance Medical Ministry Raleigh, North Carolina | Luis Molina - (luis.molina@sitebridgeresearch.com) |
| Anderson Medical Research Ft. Washington, Maryland | Ann-Marie Cobb - (andersonmedicalresearch@gmail.com) |
| Angel City Research Inc Los Angeles, California | Maira Jackson - (maira@angelcityresearch.com) |
| Angiocardiac Care of Texas PA Houston, Texas | Alexis Sincere - (ASincere@biopharmainfo.net) |
| Apex Cardiology Research Associates of Jackson Jackson, Tennessee | Pam Gibbons - (pgibbons@researchjackson.com) |
| Ascension Saint Agnes Heart Care Baltimore, Maryland | Morgan Beatty - (mbeatty@scritrials.com) |
| Atlanta Heart Specialists LLC Tucker, Georgia | Hiwot Haile - (hhaile@ahsmed.com) |
| Baptist Health South Miami, Florida | Ruben Dominguez - (Ruben.Dominguez@baptisthealth.net) |
| C and A Clinical Trials Cape Coral, Florida | Sildey Mas Hernandez - (sildey@caclinicaltrial.com) |
| CAIMED Center Ponce, | Nancy Jimenez - (njimenez@psm.edu) |
| CTMD Research Palm Springs, Florida | Doris Rodriguez - (drodriguez@ctmdresearch.com) |
| CV Ins of the South Opelousas, Louisiana | Ariel Quebedeaux - (Ariel.Quebedeaux@cardio.com) |
| California Medical Research Associates Inc Northridge, California | Pulasthi Karunatillaka - (pulasthi.cmra@gmail.com) |
| Capitol Cardiology Associates Lanham, Maryland | Iluyomade Adeusi - (iluyomade@capitolcardiology.com) |
| Cardiology Partners Clinical Research Institute Wellington, Florida | Saaima Farooq - (saaima.farooq@cardiologypartnerspl.com) |
| Cardiology and Medicine Clinic PA Little Rock, Arkansas | Sherry Clements - (sclementsresearch@yahoo.com) |
| Cardiovascular Associates Research Covington, Louisiana | Vicki L Nicely - (thestudygroup@bellsouth.net) |
| Care Access Research Easton, Pennsylvania | Devan Guagenti - (devan.guagenti@careaccess.com) |
| Chicago Clinical Research Inst Chicago, Illinois | Mohammed Hamed Ali Khan - (akhan@ccrii.us) |
| Clinical Research of South Nevada Las Vegas, Nevada | Zeida Gonzalez - (zeidygon.crosn@yahoo.com) |
| Clinical Trials of Texas San Antonio, Texas | |
| Columbus Clinical Services LLC Miami, Florida | Zoraida Bayon - (z.bayon@columbusclinical.net) |
| DBC Research USA Pembroke Pines, Florida | Antonio Marrero - (amarrero@dbcresearch.com) |
| Dallas Heart and Vascular Consultants PA Houston, Texas | Marisol Colon - (marisol@biopharmainfo.net) |
| Dallas Heart and Vascular Consultants PA Houston, Texas | Jessica Mata - (JMata@biopharmainfo.net) |
| Dallas Heart and Vascular Consultants PA Houston, Texas | Sairabano Razzak - (Sairabano@biopharmainfo.net) |
| David Turbay MD PLLC El Paso, Texas | Ricardo Pulido - (rpulido@davidturbaymd.com) |
| Discovery Clinical Trials Pflugerville, Texas | Tracy Fuentes - (operations@discoverytrials.com) |
| Dominion Medical Associates Richmond, Virginia | Richard AJ Jackson - (aj@dominionmedicalinc.com) |
| Dr Yolanda Figueroa Private Pr Humacao, | Noemi Torres Rivas - (yonojo@yahoo.com) |
| Elite Clinical Research Jackson, Mississippi | Candy Thomas - (candycumberland@hotmail.com) |
| Epic Clinical Research Lewisville, Texas | Jessica Powell - (jpowell@allianceclinicalnetwork.com) |
| Excel Medical Clinical Trials LLC Boca Raton, Florida | |
| FXM Clin Res Miramar LLC Miramar, Florida | Raul Hernandez - (raul@eminat.net) |
| Finlay Medical Research Miami, Florida | |
| Flourish Research Winter Park, Florida | |
| Flourish Research Winter Park, Florida | Kristi Norton - (knorton@flourishresearch.com) |
| Heart Care Associates P C Hopewell, Virginia | Orwa Ahmad - (orwahmad@gmail.com) |
| Henry Ford Hospital Detroit, Michigan | Meghan McCarthy - (mmccart8@hfhs.org) |
| Hope Clinical Research Canoga Park, California | Andrea Musi - (amusi@allianceclinicalnetwork.com) |
| Infinite Clinical Research Miami, Florida | Meyling Hernandez - (m.hernandez@infiniteclinicalresearch.com) |
| Inpatient Research Clinical LLC Miami Lakes, Florida | Sergio Ramirez - (sramirez@inpatientresearch.com) |
| Inpatient Research Clinical LLC Miami Lakes, Florida | Dora Gutierrez - (dgutierrez@inpatientresearch.com) |
| International Research Associates, LLC Miami, Florida | Dalia M Alvarez - (dalvarez@intrallc.com) |
| Jamaica Hospital Medical Center Jamaica, New York | Ibrahim Khandakar - (ikhandak@jhmc.org) |
| James A Haley Veterans Hospital Tampa, Florida | Adam Zoble - (Adam.zoble@va.gov) |
| Javara Research Alexandria, Virginia | Nicole Sandiford - (nsandiford@javararesearch.com) |
| Javara Research Alexandria, Virginia | Kiara McFarland Head - (kiara.mcfarland@javararesearch.com) |
| Javara Research Alexandria, Virginia | Aimee Kaczorowski - (aimee.kaczorowski@javararesearch.com) |
| Javara Research Alexandria, Virginia | Aarika Oeleis - (aarika.oeleis@javararesearch.com) |
| Johns Hopkins Univ School of Med Baltimore, Maryland | Christine McLeod - (cmcleod3@jhmi.edu) |
| Johns Hopkins University Baltimore, Maryland | Tanya Burley - (tburley1@jhmi.edu) |
| Las Vegas Endocrinology Henderson, Nevada | Loida Nguyen - (loidan@lasvegasendocrinology.com) |
| Latin Clinical Trial Center Inc San Juan, | Gina Velez - (gvelez@lctcpr.com) |
| Long Beach Clinical Trials Long Beach, California | Bryan De Las Casas - (Bryan@Lbclinicaltrials.com) |
| MD Medical Research Oxon Hill, Maryland | Maria Bartolome - (maria.bartolome@mdmedicalresearch.com) |
| Metropolitan Cardiovascular Consultants Llc Beltsville, Maryland | Sai Preethi Badugu - (sbadugu@metmedicine.com) |
| Monroe Biomedical Research Monroe, North Carolina | Krista Gross - (Krista.gross@monroeresearch.com) |
| Monroe Research Llc West Monroe, Louisiana | Nina Parrott - (ninaparrottlpncrc@monroeresearch.net) |
| Morehouse School of Medicine Atlanta, Georgia | Kaysha Harper - (kharper@msm.edu) |
| NICRs Research Center Garden Grove, California | Aneesha Reddy - (areddy@nicresearch.com) |
| National Heart Institute Beverly Hills, California | Nayeli Aguillon - (naguillon@nationalheartinstitute.org) |
| National Research Institute Hialeah, Florida | Leonor Balbuena - (lbalbuena@nationalri.org) |
| New Tampa Health Tampa, Florida | Niubis Miranda - (miranda@newtampahealthresearch.com) |
| NexGen Research Lima, Ohio | Nicole Steffen - (Nicole.steffen@nexgenresearch.com) |
| North Hills Medical Research Inc Bedford, Texas | |
| Omega Clinical Research Metairie, Louisiana | Tina Messina - (tmessinarn@gmail.com) |
| Overlook Medical Center Summit, New Jersey | Rosmery Montesino - (Rosmery.montesino@atlantichealth.org) |
| Parkway Medical Center Birmingham, Alabama | Susanne Dyer - (jsgdyer@gmail.com) |
| Pharma Tex Research Amarillo, Texas | Salma Villarreal - (sestradaptx@gmail.com) |
| Plano Primary Care Clinic Allen, Texas | Maryum Farooqi - (maryumfarooqi.mf@gmail.com) |
| Proactive Clinical Research Fort Lauderdale, Florida | Beatriz Ramirez - (bramirez@proactivecr.com) |
| Proactive Clinical Research Fort Lauderdale, Florida | |
| Research and Cardiovascular Corp Ponce, | Maria E Diago - (diago_research@yahoo.com) |
| Robert Wood Johnson Medical School New Brunswick, New Jersey | Glaucia Dos Santos-Vaccaro - (gd301@rwjms.rutgers.edu) |
| SW Family Medicine Associates Dallas, Texas | Fatima Abdalrahman - (fatima@swmedicalgroup.com) |
| Sinai Ct for Throm Res and Drug Dev Baltimore, Maryland | Cescelle Barbour - (Cbarbour@lifebridgehealth.org) |
| Sister Life Research Inc Hialeah, Florida | Andrea Orellana - (andrea@sisterliferesearch.com) |
| Southern Clin Research Clinic Zachary, Louisiana | |
| Stanford Health Care San Jose, California | Tamara Bazouzi - (bazouzit@stanford.edu) |
| Stern Cardiovascular Foundation Inc Southaven, Mississippi | Meshun Briscoe - (meshun.briscoe@sterncardio.com) |
| Synexus Clinical Research US Inc Chicago, Illinois | |
| TCV Clinical Studies Linwood, Pennsylvania | Michael Cosgrove - (mcosgrove@tcvclinicalstudies.com) |
| The Heart Institute of East Texas Lufkin, Texas | Ramah Venessa Kirk - (venessa.kirk@sitebridgeresearch.com) |
| University of Calif Irvine Med Cntr Irvine, California | Maryam Ahmed - (maryasa1@hs.uci.edu) |
| University of Texas Health Science Ctr San Antonio, Texas | William Murff - (murff@uthscsa.edu) |
| University of Washington Seattle, Washington | Daniel Isquith - (disquith@uw.edu) |
| VA Caribbean Healthcare System San Juan, | Loriany Alcocer-Rodriguez - (Loriany.Alcocer-Rodriguez@va.gov) |
| VCU Health Richmond, Virginia | Joshua West - (westj6@vcu.edu) |
| Valley Clinical Trials Inc Covina, California | Breanna Culver - (bculver@flourishresearch.com) |
| Virginia Heart Falls Church, Virginia | Deanna Overbeck - (Doverbeck@VirginiaHeart.com) |
| Zenith Clinical Research Hollywood, Florida | Yeny Ramos - (Y.Ramos@zenithclinicalresearch.com) |
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech clinical trials patient information - patients@biontech.de
NCT06712316
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:
* Have systemic treatment naive, histologically or cytologically confirmed diagnosis of Stage IIIB or IIIC (who are not amenable to curative surgery or radiotherapy) or Stage IV NSCLC per the Union Internationale contre le Cancer/American Joint Committee on Cancer staging system, 9th edition.
* Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion).
* Eastern Cooperative Oncology Group Performance Status of 0 or 1.
* Adequate organ function.
Key Exclusion Criteria:
* Have histologically or cytologically confirmed NSCLC with small-cell lung cancer histologic or neuroendocrine component.
* Have received any of the following therapies or drugs within the noted time intervals prior to study treatment:
* Previous chemotherapy (platinum-based) or PD(L)-1 for treating NSCLC in either neo-adjuvant/adjuvant or locally advanced/metastatic setting.
* Participants who received prior treatment with anti-VEGF monoclonal antibody, or PD(L)-1/VEGF bispecific antibody
* Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of study treatment. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (\<=7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) are allowed.
* Have uncontrolled hypertension or poorly controlled diabetic conditions prior to study treatment.
* Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history (within 6 months prior to study entry) or risk of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess or esophageal and gastric varices. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing fistula/perforation.
* Participants with significant risk of hemorrhage (per investigator clinical judgment).
* Have superior vena cava syndrome or symptoms of spinal cord compression.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. DRUG: Pumitamig, DRUG: Pembrolizumab, DRUG: Carboplatin, DRUG: Pemetrexed, DRUG: Paclitaxel
Non-small Cell Lung Cancer
First-line treatment, Combination with chemotherapy, Combination with other investigational agents, Bispecific antibody, Programmed death-ligand 1 (PD-L1), Vascular endothelial growth factor (VEGF) A, Immunotherapy, Programmed Death-1 monoclonal antibodies
I'm interested
Share via email
Show 225 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Acibadem Adana Hospital Adana, | |
| Adana City Training and Research Hospital Adana, | |
| Affiliated Hospital of Hebei University Baoding, | |
| Ageo Central General Hospital Ageo, | |
| Ajou University Hospital Suwon, Gyeonggi-do | |
| Akdeniz University Hospital Antalya, | |
| Alaska Oncology and Hematology, Llc Anchorage, Alaska | |
| Ankara Bilkent City Hospital Ankara, | |
| Asan Medical Center (AMC) Seoul, | |
| Asklepios Fachkliniken Muenchen Gauting Gauting, | |
| Astera Cancer Care East Brunswick, New Jersey | |
| Azienda Ospedaliera San Giuseppe Moscati Avellino, | |
| Azienda Ospedaliero Universitaria Di Bologna Policlinico S. Orsola Malpighi Bologna, | |
| Azienda Socio Sanitaria Territoriale di Cremona (ASST Cremona) Cremona, | |
| Baptist Cancer Center Memphis, Tennessee | |
| Baptist Health Hardin Elizabethtown, Kentucky | |
| Baskent Universitesi Tip Fakultesi Adana Hastanesi Adana, | |
| Beatson West of Scotland Cancer Centre - Greater Glasgow Health Board Glasgow, | |
| Beijing Friendship Hospital, Capital Medical University Beijing, | |
| Beijing Hospital Beijing, Beijing Municipality | |
| Bezmialem Foundation University Medical Faculty Istanbul, | |
| CHU Caen Normandie Caen, | |
| CHU HELORA, Hopital de Mons - Site Kennedy Mons, | |
| CHU de Rennes, Hopital de Pontchaillou Rennes, | |
| Cairns Hospital Cairns, | |
| Cancer And Haematology Centre-The Churchill Hospital-Oxford University Hospitals Oxford, | |
| Cancer Care Wollongong Pty Limited Wollongong, New South Wales | |
| Cancer Hospital of Shantou University Medical College Shantou, | |
| Cancer Research Centre Tbilisi, | |
| Cancer Research SA (CRSA) Adelaide, | |
| Cardiomed Cluj-Napoca, | |
| Casa Di Cura Polispecialistica Dott Pederzoli Peschiera del Garda, | |
| Central West Cancer Care Centre Orange, | |
| Centre Francois Baclesse Caen, | |
| Centre Hospitalier Intercommunal Toulon La Seyne Sur Mer (C.H.I.T.S) - Hospital Font-Pre Toulon, | |
| Centre Hospitalier Intercommunal de Creteil (CHIC) - Centre de ressources et de competences pour la mucoviscidose (C.R.C.M.) Créteil, | |
| Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) - Centre de transplantation d'organes (CTO) Lausanne, | |
| Centre Hospitalier Universitaire d'Angers (CHU Angers) Angers, | |
| Centro di Riferimento Oncologico Aviano, | |
| Centrul de Oncologie Sf. Nectarie S.R.L (Sf Nectarie Oncology Center) Craiova, | |
| Chiangrai Prachanukroh Hospital Chiang Rai, | |
| Chongqing University Three Gorges Hospital Wanzhou, | |
| Chulalongkorn University Bangkok, | |
| Chungbuk National University Hospital Cheongju-si, | |
| Chungnam National University Hospital (CNUH) Daejeon, | |
| Clatterbridge Cancer Centre Metropolitan Borough of Wirral, | |
| Clermont Oncology Center Clermont, Florida | |
| Cleveland Clinic Cleveland, Ohio | |
| Cleveland Clinic - Hillcrest Hospital Mayfield Heights, Ohio | |
| Cleveland Clinic Florida - Martin North Hospital Stuart, Florida | |
| Cleveland Clinic Weston Hospital Weston, Florida | |
| Clinica MD Anderson International Madrid, | |
| Coltea Clinical Hospital Bucharest, | |
| Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas de Gran Canaria, | |
| Consorcio Hospitalario Provincial de Castellon Castellon, | |
| Dicle University Faculty of Medicine Hospital Diyarbakır, | |
| Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Ankara, | |
| Dubbo Hospital Dubbo, | |
| Evangelische Lungenklinik Berlin Berlin, | |
| Faculty of Medicine Vajira Hospital, Navamindradhiraj University Bangkok, | |
| Fletcher Hospital, Inc. dba AdventHealth Hendersonville Hendersonville, North Carolina | |
| Flinders Medical Centre Bedford PK, South Australia | |
| Fondazione Ospedale Isola Tiberina - Gemelli Isola Rome, | |
| Fondazione Policlinico Universitario Campus Bio-Medico Roma, | |
| Fort Wayne Medical Oncology and Hematology, Inc. Fort Wayne, Indiana | |
| Frederick Health Hospital- James M Stockman Cancer Institute Frederick, Maryland | |
| Fundacion Instituto Valenciano de Oncologia Valencia, | |
| GHRMSA Hopital Emile Muller Mulhouse, | |
| Gabrail Cancer Center Research Canton, Ohio | |
| Gachon University Gil Medical Center Incheon, Namdong-gu | |
| Gazi University Faculty of Medicine Yenimahalle, | |
| Gaziantep Sanko University Medical Faculty Gaziantep, | |
| Goztepe Prof. Dr. Suleyman Yalcin City Hospital Istanbul, | |
| Gulhane Training and Research Hospital Ankara, | |
| Gyeongsang National University Hospital (GNUH) Jinju, Gyeongsangnam-do | |
| H. Lee Moffit Cancer center and research institute Tampa, Florida | |
| HRH Princess MahaChakri Sirindhorn Medical Center - Srinakharinwirot University Nakhon Nayok, | |
| Hacettepe University Medicine Faculty Ankara, | |
| Helios Klinikum Wuppertal-Universitaet Witten-Herdecke Wuppertal, | |
| High Technology Hospital MedCenter Ltd Batumi, | |
| Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics Iowa City, Iowa | |
| Hospital General Universitario Gregorio Maranon (HGUGM) Madrid, | |
| Hospital General Universitario de Valencia Valencia, | |
| Hospital Universitari de Lleida Arnau de Villanova Lleida, | |
| Hospital Universitario 12 de Octubre Madrid, | |
| Hospital Universitario De Leon León, | |
| Hospital Universitario Fundacion Jimenez Diaz Madrid, | |
| Hospital Universitario Miguel Servet de Zaragoza Zaragoza, | |
| Hospital Universitario Nuestra Señora de Valme Seville, | |
| Hospital Universitario Puerta de Hierro de Majadahonda Majadahonda, | |
| Hospital Universitario Vall d'Hebron Barcelona, | |
| Hospital Universitario Virgen del Rocio Seville, | |
| Hospital Universitario de Badajoz Badajoz, | |
| Hospital Universitario de Canarias S. Cristobal de La Laguna, Tenerife | |
| Hospital Álvaro Cunqueiro Vigo, | |
| Hull University Teaching Hospitals NHS Trust Cottingham, | |
| ICON Cancer Care - Townsville Townsville, | |
| IRCCS Istituto Romagnolo per lo studio dei Tumori Dino Amadori (IRST) Meldola, | |
| Icon Cancer Centre Kurralta Park Kurralta Park, South Australia | |
| Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest Bordeaux, | |
| Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol Badalona, | |
| Institut Curie - Centre de Recherche Paris, | |
| Institut Gustave Roussy-Gustave Roussy Cancer Center -Ditep Villejuif, | |
| Institut Paoli-Calmettes Marseille, | |
| Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau Saint-Herblain, | |
| Institut de Cancerologie de l'Ouest Paul Papin Angers, | |
| Instytut MSF Sp. z o.o. Lodz, | |
| Integris Cancer Institute of Oklahoma Oklahoma City, Oklahoma | |
| Istinye University Bahcesehir Liv Hospital Istanbul, | |
| Istituti di Ricovero e Cura A Carattere Scientifico (IRCCS) - Istituti Fisioterapici Ospitalieri (IFO) - Istituto Nazionale Tumori Regina Elena (IRE) Roma, | |
| Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele) Milan, | |
| Iwate Medical University Hospital Shiwa-gun, Iwate | |
| Jiangsu Peoples Hospital Nanjing, | |
| Jilin Cancer Hospital Changchun, Jilin | |
| John Muir Clinical Research Center Concord, California | |
| Kantonspital Baden Baden, | |
| Karadeniz Technical University Faculty of Medicine Ortahisar, | |
| Kettering Medical Center Kettering, Ohio | |
| Klinikum Chemnitz gGmbH Chemnitz, | |
| Klinikum Esslingen GmbH Esslingen am Neckar, | |
| Koc Universitesi Hastanesi (Koc University Hospital) Istanbul, | |
| Kocaeli Universitesi Tip Fakultesi Kocaeli, | |
| Korea University Guro Hospital Seoul, | |
| LTD Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic Tbilisi, | |
| Lampang Cancer Hospital Lampang, | |
| Liv Hospital Ankara Ankara, | |
| Llc Todua Clinic Tbilisi, | |
| Lungenfachklinik Immenhausen - Pneumologische Lehrklinik der Universitaet Goettingen Immenhausen, | |
| MVZ for oncology and hematology Rhein-Kreis Neuss GmbH Neuss, | |
| Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC) Hastings, Nebraska | |
| Matsusaka Municipal Hospital Matsusaka, | |
| Medical Park Florya Hospital Istanbul, | |
| Medical Park Seyhan Hospital Seyhan, | |
| Medical Point Izmir Hospital Izmir, | |
| Memorial Ankara Hospital Ankara, | |
| Mersin City Training and Research Hospital Toroslar, | |
| Mid Florida Cancer Centers Orange City, Florida | |
| Millennium Research and Clinical Development, LLC Houston, Texas | |
| Missouri Cancer Associates Columbia, Missouri | |
| Monash University - Monash Health -Monash Medical Centre Melbourne, | |
| Municipal Hospital Ploiesti Ploieşti, | |
| NHO Kinki Chuo Chest Medical Center Sakai, | |
| NZOZ Medpolonia Sp. Z o.o. Poznan, | |
| Nagoya University Hospital Showa-Ku Nagoya, | |
| National Cancer Center Goyang-si, | |
| National Hospital Organization Himeji Medical Center Himeji, | |
| National Hospital Organization Iwakuni Clinical Center Iwakuni, | |
| National Hospital Organization Nagoya Medical Center Nagoya, | |
| National Hospital Organization Shikoku Cancer Center Matsuyama, | |
| National Hospital Organization Tokyo Medical Center Meguro City, | |
| Necmettin Erbakan University Meram Medical Faculty Konya, | |
| New Cross Hospital Wolverhampton, | |
| New Hospitals Tbilisi, | |
| Niigata Cancer Center Hospital Niigata, | |
| Norfolk and Norwich University Hospital - Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich, | |
| Northern Jiangsu Peoples Hospital (NJPH) Yangzhou, | |
| Onco Clinic Consult SA Craiova, | |
| Oncomed Timișoara, | |
| Ondokuz Mayis University Health Practice and Research Hospital Samsun, | |
| Onkologische Tagesklinik Remscheid Remscheid, | |
| Osaka Prefectural Hospital Organization Osaka International Cancer Institute Osaka, | |
| Ospedale San Luca Lucca, | |
| Ovidius Clinical Hospital Ovidiu, | |
| Peking Union Medical College Hospital Beijing, Beijing Municipality | |
| Peninsula & South Eastern Haematology and Oncology Group Frankston, Victoria | |
| Peter MacCallum Cancer Centre Melbourne, Victoria | |
| Physicians Clinic of Iowa Cedar Rapids, Iowa | |
| Praxiskooperation Bonn-Euskirchen-Rheinbach-Wesseling Bonn, | |
| Radiotherapy Center Cluj Cluj-Napoca, | |
| Rajavithi Hospital Ratchathewi, | |
| Royal Adelaide Hospital Adelaide, | |
| Royal Marsden Hospital (RMH) - Royal Marsden NHS Foundation Trust Chelsea, London | |
| Royal Marsden Hospital (Sutton) - Royal Marsden NHS Foundation Trust Sutton, London | |
| Royal Preston Hospital - Lancashire Teaching Hospitals NHS Foundation Trust Preston, | |
| Royal Sussex County Hospital - University Hospitals Sussex NHS Foundation Trust Brighton, | |
| S.C. Medisprof S.R.L, Oncologie medicala Cluj-Napoca, | |
| SC Gral Medical SRL Bucharest, | |
| SRH Wald-Kliniken Gera GmbH Gera, | |
| SSM Health Cancer Care - St. Clare Fenton, Missouri | |
| Sakarya University - Faculty of Medicine Sakarya, | |
| Samsung Medical Center Seoul, | |
| Sendai Kousei Hospital Miyagi, | |
| Severance Hospital, Yonsei University Health System Seoul, | |
| Shandong University - Jinan Central Hospital Jinan, | |
| Shanghai Chest Hospital Shanghai, | |
| Shenandoah Oncology Winchester, Virginia | |
| Shizuoka Cancer Center Nagaizumi-cho,Sunto-gun, | |
| Southampton General Hospital Southampton, | |
| Staedtisches Klinikum Muenchen Bogenhausen München, | |
| Summit Medical Group PA Florham Park, New Jersey | |
| Suny-Stony Brook University Cancer Center Stony Brook, New York | |
| Taizhou Hospital of Zhejiang Province Linhai, | |
| The Catholic University of Korea, St. Vincent's Hospital Suwon, Gyeonggi-do | |
| The Christ Hospital Cancer Center Cincinnati, Ohio | |
| The Christie NHS Foundation Trust Manchester, | |
| The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion Cleveland, Ohio | |
| The First Affiliated Hospital of Soochow University Suzhou, Jiangsu | |
| The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion Paramus, New Jersey | |
| Thoraxklinik-Heidelberg gGmbH Heidelberg, | |
| Tokyo Metropolitan Komagome Hospital Bunkyō City, | |
| UOC Oncoematologia AOU Luigi Vanvitelli Naples, | |
| Uniklinik RWTH Aachen Medizinische Klinik IV Aachen, | |
| Universita di Siena -Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte Siena, | |
| Universitair Ziekenhuis Leuven Leuven, | |
| Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur) Valencia, | |
| University College Hospital London, | |
| University Medical Center of Johannes Gutenberg-University Mainz Mainz, | |
| University Of California - San Diego Moores Cancer Center La Jolla, California | |
| University of Cincinnati Medical Center Cincinnati, Ohio | |
| University of Tennessee Medical Center Knoxville, Tennessee | |
| Universitätsklinikum Erlangen Erlangen, | |
| Uniwersyteckie Centrum Kliniczne (UCK) - Klinika Onkologii i Radioterapii Gdansk, | |
| VCU Massey Cancer Center Richmond, Virginia | |
| VITAZ Sint-Niklaas, | |
| Velindre NHS Trust, Velindre Cancer Centre Cardiff, Wales | |
| Virginia Cancer Specialists Fairfax, Virginia | |
| Wakayama Medical University Hospital Wakayama, | |
| Western Health Sunshine Hospital St Albans, Victoria | |
| Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust Sheffield, | |
| White Plains Hospital White Plains, New York | |
| Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu Przemyśl, | |
| Yeditepe University Kosuyolu Hospital Istanbul, | |
| Yunnan Provincial Cancer Hospital Kunming, | |
| Zhejiang Medical University, Zhejiang Cancer Hospital Hangzhou, | |
| Zhongnan Hospital of Wuhan University Wuhan, |
Alveolar Ridge Preservation (ARP) in the Posterior Maxilla After the Extraction of Maxillary Molars
Iya Ghassib - ghassibi@vcu.edu
NCT07433322
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Intact or \<5mm dehiscence buccally and palatally
* Initial residual bone height (RBH) of at least 6 mm. 3-A minimum distance of 1 mm between root apices and sinus membrane.
Exclusion Criteria
* Medically compromised
* heavy smokers
* young (\<18 yrs.) or those refusing treatment are excluded. OTHER: Ossix mineralized grafting immediately at extraction, OTHER: Delayed grafting at implant placement
Alveolar Bone Loss
Dental Implant, Alveolar Ridge Preservation (ARP), Maxilla
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Henrico, Virginia | Iya Ghassib - (ghassibi@vcu.edu) |
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)
Immunocore Medical Information - medical.information@immunocore.com
NCT06112314
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants must be HLA-A\*02:01-positive
* Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma
* Archived or fresh tumor tissue sample that must be confirmed as adequate
* Participants must have measurable disease per RECIST 1.1
* Participant must have BRAF V600 mutation status determined
* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention
Exclusion Criteria:
* Participants with a history of a malignant disease other than those being treated in this study
* Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis
* Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients
* Participants with clinically significant pulmonary disease or impaired lung function
* Participants with clinically significant cardiac disease or impaired cardiac function
* Participants with active autoimmune disease requiring immunosuppressive treatment
* Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results
* Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma
* Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3 DRUG: Brenetafusp, DRUG: Nivolumab, DRUG: Nivolumab + Relatlimab
Advanced Melanoma
I'm interested
Share via email
Show 211 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| " Azienda Ospedaliera Universitaria Senese - Policlinico Santa Maria Alle Scotte - Clinica Immunoterapia Oncologica" Siena, | |
| A.C.Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE) Liberdade, | Guilherme Cavalcante Pessoa - (guilherme.cavalcante@accamargo.org.br) |
| AKH - Medizinische Universitat Wien Vienna, | |
| AZ Sint-Jan Brugge-Oostende AV-Campus Sint-Jan Bruges, | Angelique Slock - (angelique.slock@azsintjan.be) |
| Allina Health Cancer Institute - Minneapolis Minneapolis, Minnesota | Jonathan Alexander - (jonathan.alexander@allina.com) |
| Ankara Bilkent City Hospital, Oncology Department Çankaya, | |
| Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde" Guadalajara, Jalisco | |
| Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Ambroise-Pare Boulogne-Billancourt, | |
| Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Seine-Saint-Denis - Hopital Avicenne Bobigny, | |
| Austin Hospital Heidelberg, Victoria | |
| Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino Torino, | |
| Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia Perugia, | |
| Azienda Ospedaliero-Universitaria di Modena (AOU Modena) - Policlinico di Modena - Day Hospital Oncologico Modena, | |
| Azienda Sanitaria Locale di Biella (ASL BI) - Ospedale degli Infermi Ponderano, | |
| Beatson West of Scotland Cancer Centre Glasgow, | Dr Pavlina Spiliopoulou, MD - (pavlina.spiliopoulou2@nhs.scot) |
| CEMAIC (Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica Córdoba, | Dra. Laura Nardone - (lauranardone@cemaicsas.com.ar) |
| CHU de Dijon Bourgogne - Hôpital François Mitterrand Dijon, | Meryem DEBBABI - (meryem.debbabi@chu-dijon.fr) Elisabeth CORNOT - (elisabeth.cornot@chu-dijon.fr) |
| Calvary Mater Newcastle Hospital Waratah, New South Wales | MOR Clinical Trials - (Kim.Adler@calvarymater.org.au) |
| Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital (AH) - Oncology Centre Cambridge, | |
| Centre Hospitalier Universitaire de Lille (CHU Lille)-Hopital Claude Huriez Lille, | Pr Laurent Mortier - (laurent.mortier@chu-lille.fr) |
| Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu Nantes, | |
| Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Hopital Charles-Nicolle Rouen, | Orlane DEBOVES - (orlane.deboves@chu-rouen.fr) Raphaëlle DAVESNE - (raphaelle.davesne@chu-rouen.fr) |
| Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Ltda Porto Alegre, Rio Grande do Sul | Alan Azambuja, MD - (cgi.pesquisa@gmail.com) |
| Centro Hospitalar e Universitario de Coimbra EPE (CHUC) Coimbra, | |
| Centro Integral Oncologico Clara Campal (Ciocc) Madrid, | |
| Centro Oncologico Internacional(COI) - Ciudad de Mexico Mexico City, | |
| Centro de Pesquisa Clinica em Oncologia - Oncosite Ijuí, Rio Grande do Sul | Fábio André Franke - (oncositeijui@gmail.com) |
| Centro de Pesquisas Oncologicas (CEPON) Florianópolis, | Camila Donadel - (camila.donadel@cepon.org.br) |
| Centrum Medyczne Pratia Poznań - Skorzewo Skorzewo, | |
| Centrum Onkologii im. Prof. Franciszka Łukaszczyka Bydgoszcz, | |
| Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM) - Klinik fuer Dermatologie Venerologie und Allergologie - Hauttumorcentrum Charite (HTCC) Berlin, | Max Schlaak, MD - (studien-hauttumorcentrum@charite.de) Max Schlaak, MD - (studien-hauttumorcentrum@charite.de) |
| Clinica Viedma Viedma, Río Negro Province | Ruben Kowalyszyn - (kowar@rnonline.com.ar) |
| Cliniques Universitaires Saint-Luc - Institut Roi Albert II Brussels, | Fontaine Florence - (florence.fontaine@saintluc.uclouvain.be) |
| Clínica Adventista Belgrano - Sector Investigación Caba, Buenos Aires | Aldo A. Perfetti - (aaperfetti@yahoo.com.ar) |
| Columbia University Medical Center New York, New York | |
| Complejo Hospitalario Universitario A Coruña (CHUAC) A Coruña, | |
| Complex Oncology Center - Plovdiv Ltd. Plovdiv, | |
| Cross Cancer Institute Edmonton, Alberta | |
| Dana Farber Cancer Institute Boston, Massachusetts | Linnea Drew - (linneam_drew@dfci.harvard.edu) |
| Debreceni Egyetem-Klinikai Kozpont (DEKK) Debrecen, | Dr. Gabriella Emri, MD - (gemri@med.unideb.hu) |
| ESC Norris Comprehensive Cancer Center Los Angeles, California | Sandy Tran - (Sandy.tran@med.usc.edu) |
| Ege Universitesi Tip Fakultesi (Ege University Faculty of Medicine) Bornova, İzmir | Fulden Saraç - (fulden.sarac@atlascro.com.tr) |
| Elbe Kliniken Stade - Hautkrebszentrum Buxtehude Hamburg, | Uta Haisch - (Uta.Haisch@elbekliniken.de) |
| Faculdade de Medicina de Sao Jose do Rio Preto-SP (FAMERP) - Hospital de Base (HB) - Centro Integrado de Pesquisa (CIP) São Paulo, | Thamyres Arroyo - (thamyres.cruz@centrodepesquisacip.com.br) |
| Fakultni Nemocnice Hradec Kralove (FNHK) - Klinika Onkologie a Radioterapie Hradec Králové, | Jindřich Kopecký, PhD - (jindrich.kopecky@fnhk.cz) |
| Fakultni Nemocnice Olomouc (FNOL) Olomouc, | Bohuslav Melichar - (Bohuslav.Melichar@fnol.cz) |
| Fondazione IRCCS - Istituto Nazionale dei Tumori - Milano Milan, | |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs Roma, | |
| Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor Barretos, | |
| Gallipoli Medical Research Foundation (Greenslopes Private Hospital) Greenslopes, Queensland | |
| Georgetown University Washington D.C., District of Columbia | |
| Haukeland University Hospital Bergen, | Cornelia Schuster, MD - (cornelia.schuster@helse-bergen.no) |
| Helios Klinikum Erfurt - Klinik fuer Hautkrankheiten und Allergologie Erfurt, | Prof. Dr. med. Rudolf A Herbst, MD - (rudolf.herbst@helios-gesundheit.de) |
| Helsingin Yliopistollinen Keskussairaala - Cancercentrum Helsinki, | Micaela Hernberg, MD - (micaela.hernberg@hus.fi) |
| Henry Ford Cancer Center - Michigan Detroit, Michigan | Bethany Adams - (badams19@hfhs.org) |
| Hopital Robert Debre Valence, | |
| Hopital de la Timone Marseille, Bouches-du-Rhône | |
| Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud Pierre-Bénite, | |
| Hospital 9 De Julho São Paulo, | Rafael Shimerling - (rafael.schmerling.ext@dasa.com.br) |
| Hospital Clinic de Barcelona Barcelona, | Nadina Fradera - (fradera@recerca.clinic.cat) |
| Hospital Clinico Universitario de Valencia Valencia, | |
| Hospital Duran i Reynals Barcelona, | |
| Hospital General Universitario Gregorio Marañon Madrid, | Isabel Cañete - (icg.hgugm@gmail.com) |
| Hospital Italiano de Buenos Aires (HIBA) Buenos Aires, | |
| Hospital Lusiadas Lisboa (HPP Hospital Dos Lusiadas) Lisbon, | Sofia Torres, MD - (sofia.torres@chln.min-saude.pt) |
| Hospital Regional Universitario de Malaga Málaga, | Irene Rojas - (ensayosch@yahoo.es) |
| Hospital Saint Louis Paris, | |
| Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia São Paulo, São Paulo | Cristiany de Jesus da Siva de Lima - (cristiany.jslima@hsl.org.br) |
| Hospital Universitari Sant Joan de Reus Reus, Tarragona | Francisca Martínez Madueño - (francisca.martinez@salutsantjoan.cat) |
| Hospital Universitari Vall d'Hebron Barcelona, | |
| Hospital Universitario Dexeus Barcelona, | |
| Hospital Universitario Insular de Gran Canaria Las Palmas de Gran Canaria, LAS Palmas | Fatima Guillen Suarez - (uecchuimi.scs@gobiernodecanarias.org) |
| Hospital Universitario La Paz Madrid, | Yolanda Álvarez Pérez - (yolandalapaz@gmail.com) |
| Hospital Universitario Ramon y Cajal Madrid, | |
| Hospital Universitario Reina Sofia Córdoba, Andalusia | - (manuel.sanchez.oncologia@gmail.com) |
| Hospital Universitario Virgen Macarena Seville, | Mónica Suengas - (moni.suengas@gmail.com) |
| Hospital Universitario Virgen de las Nieves (HUVN) Granada, | Isabel Rodriguez - (i_rodriguez_gonzalez@hotmail.es) |
| Hospital Universitario Virgen del Rocio Seville, | |
| Hospital de Clinicas de Porto Alegre (HCPA) Porto Alegre, | Andrea Baldasso Zanon - (abzanon.upco@gmail.com) Sergio Jobim de Azevedo - (sazevedo@hcpa.edu.br) |
| Hospital of Lithuanian University of Health Sciences Kauno Klinikos Kaunas, | Rima Adomaitiene - (rima.deltuvaite@gmail.com) |
| Humanitas Gavazzeni (Cliniche Gavazzeni S.p.A) Bergamo, | |
| IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl (IRST) Meldola, | |
| Inonu Universitesi - Turgut Ozal Tip Merkezi Malatya, | Mustafa Dikilitas - (dikilitasmd@yahoo.com) |
| Institut Gustave Roussy (IGR) Service de Dermatolgie Villejuif, | |
| Instituto Alexander Fleming Caba, | |
| Instituto Américas - Instituto de Educação Pesquisa e Gestão em Saúde Oncosite Rio de Janeiro, | Raphaela Lima, MD - (centrodepesquisa@institutoamericas.org) |
| Instituto Portugues de Oncologio de Lisboa Francisco Gentil EPE (IPO Lisboa) (IPOLFG) Lisbon, | Dr. Patricia Pereira - (pmsilva@ipolisboa.min-saude.pt) |
| Instituto de Investigacion Sanitaria (INCLIVA) (Institute of Health Research Hospital Clinic of Valencia) Valencia, | Inés González Barrallo, MD - (igbarrallo@gmail.com) |
| Instituto do Cancer do Estado de Sao Paulo (ICESP) São Paulo, | |
| Istituto Europeo di Oncologia (IEO) (European Institute of Oncology) Milan, | Raffaella Ghisini - (raffaella.ghisini@ieo.it) |
| Istituto Nazionale Tumori (INT) "Fondazione G. Pascale" di Napoli Napoli, | |
| Istituto Oncologico Veneto (IOV) IRCCS Padua, | |
| Istituto Oncologico Veneto (IOV) IRCCS Padua, | |
| Istituto Tumori Giovanni Paolo II - Ospedale Oncologico di Bari Bari, | |
| Izmir Ekonomi Universitesi Medikal Point Hastanesi Cordaleo, İzmir | Cagatay Arslan, MD - (arslancagatay@yahoo.com) |
| Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Dermatologie, Venerologie und Allergologie Frankfurt, | Dr. Berenice Lang, MD - (berenice.lang@unimedizin-ffm.de) |
| Johannes Wesling Klinikum Minden Minden, | Yenny Angela - (yenny.angela@muehlenkreiskliniken.de) |
| John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey | Oncology Clinical Research Referral Office - (OncologyResearchReferral@hmhn.org) |
| Justus-Liebig-Universitaet Giessen - Klinik fuer Dermatologie und Andrologie Giessen, | |
| Kanser Enstitusu (Hacettepe University Cancer Institute) Altındağ, | |
| Karolinska Universitetssjukhuset Stockholm, | Amanda Hallgren - (amanda.hallgren@regionstockholm.se) |
| Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Warsaw, | Beata Wielgocka - (beata.wielgocka@pib-nio.pl) |
| Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne Gdansk, | Izabela Gudewicz - (izabelagudewicz@gumed.edu.pl) |
| Klinikum Bremen-Ost gGmbH Bremen, | Dr. Miriam Schiff - (miriam.schiff@gesundheitnord.de) |
| Klinikum Dortmund gGmbH - Klinikzentrum Mitte - Hautklinik Dortmund, | |
| Kobenhavns Universitet - Herlev Hospital (Amtssygehuset i Herlev) Herlev, | Inge Marie Svane - (inge.marie.svane@regionh.dk) |
| L'Institute Oncologique Prof. Dr. Ion Chiricuta (IOCN) (The Oncology Institute Prof. Dr. Ion. Chiricuta) Cluj-Napoca, | Dana Iancu - (dana_iancu2004@yahoo.com) |
| LKH - Universitaetsklinikum Graz Graz, | Alexandra Rodlauer-Kriegl - (alexandra.rodlauer-kriegl@medunigraz.at) |
| LMU Klinikum - Klinik und Poliklinik fur Dermatologie und Allergologie Munich, | Prof. Lucie Heinzerling, MD - (DER.onko.studien@med.uni-muenchen.de) |
| Lanssjukhuset Ryhov - Onkologiska Kliniken Jönköping, | Bo Thelin - (bo.thelin@rjl.se) |
| Linear Clinical Research Nedlands, Western Australia | Anke Hoskins - (Anke.Hoskins@health.wa.gov.au) |
| Massachusetts General Hospital Boston, Massachusetts | Kamaneh Montazeri, MD - (kmontazeri@mgh.harvard.edu) |
| Mayo Clinic Florida Jacksonville, Florida | Heidi Turner - (Turner.Heidi@mayo.edu) |
| Medical Park Gaziantep Hastanesi Şehitkamil, Gaziantep | Alper Sevinc, MD - (alpersevinc27@hotmail.com) |
| Medical Park Hastaneler Grubu - I.A.U. VM Medical Park Florya Antalya, Campus | Ali Murat Tatli - (alimurattat@hotmail.com) |
| Medical Park Seyhan Hastanesi Seyhan, | Ahmet Sezer - (drasezer@hotmail.com.tr) |
| Memorial Antalya Hastanesi Kepez, Antalya | Ali Murat Tatli, MD - (alimurattat@hotmail.com) |
| Memorial Saglik Grubu - Memorial Ankara Hastanesi Çankaya, Ankara | Umut Demirci - (drumutdemirci@gmail.com) |
| Memorial Saglik Grubu - Memorial Bahcelievler Hastanesi Bahçelievler, Istanbul | |
| National Cancer Institute Bratislava, | Andreia Cristina de Melo, MD - (andreia.melo@inca.gov.br) |
| National Cancer Institute Regina Elena Roma, | |
| Northwell Health Cancer Institute Lake Success, New York | Sarilee Liz - (sliz@northwell.edu) |
| Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI Chicago, Illinois | |
| Oncocentro Sao Carlos Hospital Fortaleza, | Diogenes Leite - (diogenes.leite@idor.org) |
| Oncopole Claudius Regaud- Institut Universitaire du Cancer de Toulouse Toulouse, Cedex | |
| Ondokuz Mayis Universitesi (OMU) - Tip Facultesi Samsun, | Bahiddin Yilmaz - (yilmazbahiddin80@gmail.com) |
| One Clinical Research - Nedlands Nedlands, Western Australia | Prof. Adnan Khattak - (info@oneclinicalresearch.com.au) |
| Onkologikoa - Kutxaren Institutu Onkologikoa (Instituto Oncologico De Guipuzcoa) San Sebastián, | |
| Orszagos Onkologiai Intezet (National Institute of Oncology) Budapest, | Dr. Tímea Balatoni, MD - (balatoni.timea@oncol.hu) |
| Oslo University Hospital Oslo, Ullernchausseen 70 | Anna Winge-Main - (annwi@ous-hf.no) |
| Paracelsus Medizinischen Privatuniversitaet - SALK - Universitaetsklinik fuer Dermatologie - EB-Haus Austria Salzburg, | |
| Pecsi Tudomanyegyetem (PTE) (University of Pecs) Pécs, | Zsuzsanna Lengyel, MD - (lengyel.zsuzsanna@pte.hu) |
| Peter MacCallum Cancer Centre Melbourne, Victoria | Dr Lavinia Spain - (Enquiries.GMR@gallipoliresearch.org.au) |
| Pirkanmaan Sairaanhoitopiiri (Pirkanmaa Hospital District)-Tampereen Yliopistollinen Sairaala (Tampere University Hospital) Tampere, | Tanja Skyttä, MD - (tanja.skyttä@pirha.fi) |
| Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas - Centro de Pesquisa Clinica (CPC) Porto Alegre, | Virginia Webber - (virginia.webber@cpors.com) |
| Princess Margaret Cancer Centre Toronto, Ontario | Marcus Butler, MD - (marcus.butler@uhn.ca) |
| Prisma Health Cancer Institute Greenville, South Carolina | Lisa Johnson - (Lisa.johnson@prismahealth.org) |
| Queen Elizabeth Hospital Birmingham Birmingham, | |
| Regina Life Clinic Sofia, | |
| Royal Marsden Hospital - Sutton Sutton, Surrey | |
| Sahlgrenska Akademin - Institutionen for Kliniska Vetenskaper (Institute of Clinical Sciences) Gothenburg, | |
| Saint John's Health Center - John Wayne Cancer Institute (JWCI) Santa Monica, California | Maribel Ramirez - (maribel.ramirez1@providence.org) |
| Sanatorio Finochietto Buenos Aires, | Dr. Gabriela Cinat - (gabriela_cinat@yahoo.com.ar) |
| Sanatorium Profesora Arenbergera Prague, | |
| Sarah Cannon Research Institute (SCRI) - London (SCRI-UK) London, | |
| Sarah Cannon Research Institute: USA/TN Nashville, Tennessee | |
| Semmelweis Egyetem Általános Orvostudományi Kar Budapest, | Péter Holló, MD - (hollo.peter@med.semmelweis-univ.hu) |
| Servicio Aragones de Salud - Hospital Universitario Miguel Servet (HUMS) Zaragoza, | |
| Sf Nectarie Oncology Center Craiova, | Augustin Gheorghe - (gusti.gheorghe@yahoo.com) |
| Skanes Universitetssjukhus - Lund - Onkologiska Klinik Lund, | |
| Spartanburg Regional Healthcare System - Spartanburg Medical Center (SMC) Spartanburg, South Carolina | Kristen Ford, RN MSN - (kford@gibbscc.org) |
| St. Elizabeth Healthcare - Edgewood Edgewood, Kentucky | Elizabeth Beatty, CRC - (Elizabeth.Beatty@stelizabeth.com) |
| Stanford Cancer Institute - Stanford Cancer Center Palo Alto Palo Alto, California | |
| Swedish Medical Center - Swedish Cancer Institute (SCI) - First Hill Campus Seattle, Washington | CancerResearch - (cancerresearch@swedish.org) |
| Szegedi Tudomanyegyetem (University of Szeged) Szeged, | Eszter Baltás, MD - (ebaltas@gmail.com) |
| T.C. Saglik Bakanligi - Adana Numune Egitim ve Arastirma Hastanesi (Adana Numune Education and Research Hospital) Yüreğir, Adana | Sevilay Demircioglu - (sevilay.demircioglu@ebmresearch.com) |
| T.C. Saglik Bakanligi - Ankara Etlik sehir Hastanesi Yenimahalle, | Nilay Ertunc Cayan - (nilay.ertunc@medismart.com.tr) |
| T.C. Saglik Bakanligi - SBU Gulhane Egitim ve Arastirma Hastanesi Ankara, | Dr Nuri Karadurmus - (drnkaradurmus@yahoo.com) |
| Tennessee Oncology, PLLC Nashville, Tennessee | Mindy Jordan - (mejordan@tnonc.com) |
| The Angeles Clinic and Research Institute- West Los Angeles Los Angeles, California | Saba Mukarram - (SMukarram@theangelesclinic.org) |
| The Christie NHS Foundation Trust Manchester, | |
| The Clatterbridge Cancer Centre NHS Foundation Trust Liverpool, | Pembe Yeslidag - (pembe.yesildag@nhs.net) |
| The Melanoma & Skin Cancer Institute Denver, Colorado | Brandon Keith - (bkeith@westernstatesncorp.org) |
| The Ohio State University Columbus, Ohio | Sierra Cimafranca - (Sierra.Cimafranca@osumc.edu) |
| The University of Kansas Cancer Center (KUCC) - Westwood Westwood, Kansas | CT Nurse Navigator - (CTNurseNav@kumc.edu) |
| The University of Queensland (UQ) - Princess Alexandra Hospital (PAH) Woolloongabba, | |
| The University of Tennessee - Knoxville (UTK) Knoxville, Tennessee | |
| Thomas Jefferson University Philadelphia, Pennsylvania | Madeleine Martinelli - (Madeleine.martinelli@jefferson.edu) |
| Turun Yliopistollinen Keskussairaala (TYKS) Turku, | Saana-Maaria Virtanen, MD - (saana.maaria.virtanen@varha.fi) |
| UCLA Hematology/Oncology Los Angeles, California | Jessica Crocker - (JCrocker@mednet.ucla.edu) |
| UConn Health-Farmington (University of Connecticut Health Center (UCHC)) Farmington, Connecticut | |
| UNICANCER-Centre Francois Baclesse (CFB) Caen, | Dr Stefan Andreea, MD - (a.stefan@baclesse.unicancer.fr) |
| UPMC Hillman Cancer Center Pittsburgh, Pennsylvania | Kelly Schroder - (schroderka@upmc.edu) |
| UVA Health-UVA Emily Couric Clinical Cancer Center Charlottesville, Virginia | - (uvacancertrials@hscmail.mcc.virginia.edu) |
| UZ Leuven Leuven, | Trial AMO UZ Leuven - (trialamo@uzleuven.be) |
| Uni Hospital Panagyurishte, | Milena Kardaleva - (kardaleva@gmail.com) |
| Universidad Complutense de Madrid (UCM)-Hospital Universitario 12 de Octubre (H12O) Madrid, | Guillermo de Velasco - (gdvelasco.gdv@gmail.com) |
| Universidad de Cantabria (UC) - Hospital Universitario Marques de Valdecilla (HUMV) Santander, Cantabria | Marta Sotelo - (marta.sotelo@scsalud.es) |
| Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA) El Palmar, Murcia | Paula Ruiz Carreño - (dm.oncoarrixaca2@gmail.com) |
| Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Madrid Madrid, | Sara Diaz Sánchez - (sdiazsanch@unav.es) |
| Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona Pamplona, | Eduardo De la Guardia - (edelaguardia@unav.es) |
| UniversitaetsSpital Zuerich - Dermatologische Klinik Zurich, | Prof. Dr. med Reinhard Dummer, MD - (Reinhard.dummer@usz.ch) |
| Universitaetsklinikum Erlangen Erlangen, | Onkologische Studienzentrale der Hautklinik - (onkstudienzentrale.de@uk-erlangen.de) |
| Universitaetsklinikum Essen Essen, | Jessica Bauriedl - (Jessica.bauriedl@uk-essen.de) |
| Universitaetsklinikum Giessen und Marburg GmbH - Marburg Marburg, | |
| Universitaetsklinikum Heidelberg (UKHD) - Hautklinik Heidelberg, | Prof. Jessica Hassel, MD - (NCT.DermaOnko@med.uni-heidelberg.de) |
| Universitaetsklinikum Leipzig - Klinik fuer Dermatologie, Venerologie und Allergologie Leipzig, | Jan Christoph Simon, MD - (Jan.simon@medizin.uni-leipzig.de) |
| Universitaetsklinikum Tuebingen (UKT) - Zentrum fuer Dermatoonkologie - Hautklinik Tübingen, | Teresa Amaral, MD, PhD - (Teresa.amaral@med.uni-tuebingen.de) |
| Universitaetsklinikum Wuerzburg - Klinik und Poliklinik fuer Dermatologie Venerologie und Allergologie Würzburg, | Anja Gesierich, MD - (Gesierich_A@ukw.de) |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz Mainz, | Jennifer Nostadt - (birgit.huebscher@unimedizin-mainz.de) |
| Universitair Ziekenhuis Brussel Brussels, | Loes De Koster - (loes.dekoster@uzbrussel.be) |
| Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur) Valencia, | Maite Giralt - (sconcologia@iislafe.es) |
| Universite Libre de Bruxelles (ULB)-Institut Jules Bordet Anderlecht, | Dr. Langouo - (m.langouofontsa@hubruxelles.be) |
| University Hospital Schleswig-Holstein Kiel, | |
| University Hospital Tsaritsa Yoanna (ISUL) (Queen Giovanna University Hospital) Sofia, | |
| University of Arizona Tucson, Arizona | Terri Katz - (tkatz@arizona.edu) |
| University of California - San Diego La Jolla, California | Katie O'Neil - (croneil@health.ucsd.edu) |
| University of Colorado, Anschutz Medical Campus Aurora, Colorado | Kayla Vondran - (KAYLA.VONDRAN@CUANSCHUTZ.EDU) |
| University of Hamburg Hamburg, | Prof. Dr. Gebhardt - (Studien-htz@uke.de) |
| University of Miami Health System-Sylvester Comprehensive Cancer Center-Miami Miami, Florida | - (CRSCutaneous@miami.edu) |
| University of Oxford Oxford, Oxfordshire | |
| University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre Wollstonecraft, | |
| University of Texas Southwestern Dallas, Texas | Desiree Pierre - (desiree.pierre@utsouthwestern.edu) |
| University of Utah Huntsman Cancer Institute Salt Lake City, Utah | Shantae George - (shantae.george@hci.utah.edu) |
| Universitätsklinikum Carl Gustav Carus Dresden, | |
| Universitätsklinikum St. Pölten Sankt Pölten, | |
| Uppsala Universitet - Akademiska Sjukhuset (Uppsala University Hospital) Uppsala, | |
| Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center) Iași, | Constantin Volovat, MD - (cvolovat@gmail.com) |
| Vilnius University Hospital Santaros Clinics Affiliate National Cancer Center Vilnius, | Aiste Sukstiene - (aiste.sukstiene@nvc.santa.lt) |
| Virginia Commonwealth University (VCU) - Massey Cancer Center Richmond, Virginia | Faith McFadden - (masseyskinca@vcu.edu) |
| Washington University School of Medicine St Louis, Missouri |
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Boehringer Ingelheim - clintriage.rdg@boehringer-ingelheim.com
NCT07220083
Show full eligibility criteria
Hide eligibility criteria
Inclusion criteria:
• Male or female participants ≥12 years old on the day of signing informed consent/assent (Visit 1)
• Weight of ≥40 kg at the screening visit (Visit 1)
• Body mass index (BMI) of ≤40 kg/m² at the screening visit (Visit 1)
• Participants with a diagnosis prior to the screening visit (Visit 1) of either: * Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR * Genetic focal segmental glomerulosclerosis (FSGS) resulting from a gain-of-function mutation in the transient receptor potential cation subfamily C member 6 (TRPC6) gene (based on historical genetic test)
• Urine protein-creatinine ratio (UPCR) ≥1500 mg/g based on the mean of the spot urine sample and first morning void urine sample (both assessed by central laboratory) at the screening visit (Visit 1)
• Estimated glomerular filtration rate (eGFR) * For adult participants (≥18 years): ≥25 mL/min/1.73 m² (chronic kidney disease epidemiology collaboration (CKD-EPI) formula based on combined serum creatinine plus cystatin C) at the screening visit (Visit 1) * For adolescent participants (12 to \<18 years); ≥25 mL/min/1.73 m² based on chronic kidney disease under 25 years (CKiD U25) formula using height and serum cystatin C at the screening visit (Visit 1) Further inclusion criteria apply. Exclusion criteria:
• Known monogenic or syndromic causes of FSGS (with the exception of TRPC6 gain-of-function gene mutations)
• Clinical or histologic evidence of secondary maladaptive or toxic forms of FSGS (based on Investigator's judgement)
• FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)
• A history of organ transplantation or planned organ transplantation during the course of the trial
• Use of intravenous immunosuppressive agents (e.g. cyclophosphamide, rituximab, obinutuzumab) in the last 6 months prior to screening (Visit 1) Further exclusion criteria apply.
• Male or female participants ≥12 years old on the day of signing informed consent/assent (Visit 1)
• Weight of ≥40 kg at the screening visit (Visit 1)
• Body mass index (BMI) of ≤40 kg/m² at the screening visit (Visit 1)
• Participants with a diagnosis prior to the screening visit (Visit 1) of either: * Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR * Genetic focal segmental glomerulosclerosis (FSGS) resulting from a gain-of-function mutation in the transient receptor potential cation subfamily C member 6 (TRPC6) gene (based on historical genetic test)
• Urine protein-creatinine ratio (UPCR) ≥1500 mg/g based on the mean of the spot urine sample and first morning void urine sample (both assessed by central laboratory) at the screening visit (Visit 1)
• Estimated glomerular filtration rate (eGFR) * For adult participants (≥18 years): ≥25 mL/min/1.73 m² (chronic kidney disease epidemiology collaboration (CKD-EPI) formula based on combined serum creatinine plus cystatin C) at the screening visit (Visit 1) * For adolescent participants (12 to \<18 years); ≥25 mL/min/1.73 m² based on chronic kidney disease under 25 years (CKiD U25) formula using height and serum cystatin C at the screening visit (Visit 1) Further inclusion criteria apply. Exclusion criteria:
• Known monogenic or syndromic causes of FSGS (with the exception of TRPC6 gain-of-function gene mutations)
• Clinical or histologic evidence of secondary maladaptive or toxic forms of FSGS (based on Investigator's judgement)
• FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)
• A history of organ transplantation or planned organ transplantation during the course of the trial
• Use of intravenous immunosuppressive agents (e.g. cyclophosphamide, rituximab, obinutuzumab) in the last 6 months prior to screening (Visit 1) Further exclusion criteria apply.
DRUG: BI 764198, DRUG: Placebo
Focal Segmental Glomerulosclerosis
I'm interested
Share via email
Show 271 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| 4th Military Clinical Hospital with a Polyclinic Wroclaw, | Boehringer Ingelheim - (polska@bitrialsupport.com) |
| AIIMS Bhubaneshwar Bhubaneswar, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| ASST Santi Paolo e Carlo Milan, | Boehringer Ingelheim - (italia@bitrialsupport.com) |
| ASST dei Sette Laghi Varese, | Boehringer Ingelheim - (italia@bitrialsupport.com) |
| AZORG Ziekenhuis Aalst, | Boehringer Ingelheim - (belgique@bitrialsupport.com) |
| Aartham Multi Super Speciality Hospital Ahmedabad, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Academic Medical Research Institute - Glendale Los Angeles, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Adana City Hospital Adana, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
| Addenbrooke's Hospital Cambridge, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| Afyon Kocatepe University Hospital Merkez / Afyonkarahisar, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
| Ajou University Hospital Suwon, Gyeonggi-do | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| Akershus universitetssykehus HF Lørenskog, | Boehringer Ingelheim - (norge@bitrialsupport.com) |
| Alabama Kidney Research Alabaster, Alabama | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Amicis Research Center - Balboa Granada Hills, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Amsterdam UMC Locatie AMC Amsterdam, | Boehringer Ingelheim - (nederland@bitrialsupport.com) |
| Ankara Etlik City Hospital Ankara, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
| Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Apogee Clinical Research Huntsville, Alabama | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo, | Boehringer Ingelheim - (italia@bitrialsupport.com) |
| Azienda Universitaria Ospedaliera Consorziale Policlinico Bari Bari, | Boehringer Ingelheim - (italia@bitrialsupport.com) |
| Beijing Tsinghua Changgung Hospital Beijing, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Bradford Institute for Health Research Bradford, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| Buddhist Tzu Chi General Hospital-Hualien-20741 Hualien City, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| Bursa Uludag University Bursa, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
| CEMIC CABA, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| CHU Amiens-Picardie Amiens, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| CHU de Nimes Nîmes, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| CHUC - Centro Hospitalar e Universitário de Coimbra, EPE Coimbra, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| Cardinal Clinical Research, LLC - Shelby Shelby, North Carolina | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| CardioAlem Investigaciones San Isidro, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| Centenario Hospital Miguel Hidalgo Aguascalientes, | Boehringer Ingelheim - (mexico@bitrialsupport.com) |
| Centralny Szpital Kliniczny MON WIM Warsaw, | Boehringer Ingelheim - (polska@bitrialsupport.com) |
| Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi Lodz, | Boehringer Ingelheim - (polska@bitrialsupport.com) |
| Centre Hospitalier Universitaire de Liege Liège, | Boehringer Ingelheim - (belgique@bitrialsupport.com) |
| Centro Medico Dra Laura Maffei Ciudad Autonoma Buenos Aires, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| Centro de Pesquisa Clínica de Nefrologia do ICHC São Paulo, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Chang Gung Memorial Hospital, Linkou Taoyuan City, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| Chiba University Hospital Chiba, Chiba, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| China Medical University Hospital Taichung, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| Cincinnati Children's Hospital Medical Center Cincinnati, Ohio | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Clatterbridge Hospital Bebington, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| Clinica Privada Velez Sarfield Córdoba, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| Clinical Hospital Sveti Duh Zagreb, | Boehringer Ingelheim - (hrvatska@bitrialsupport.com) |
| Clinical Renal Associates Exton, Pennsylvania | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Colorado Kidney Care Denver, Colorado | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Complejo Hospitalario Torrecardenas Almería, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Copenhagen University Hospital, Rigshospitalet København Ø, | Boehringer Ingelheim - (danmark@bitrialsupport.com) |
| DaVita Clinical Research-Las Vegas-67781 Las Vegas, Nevada | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Daido Clinic Aichi, Nagoya, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Danderyds Sjukhus Stockholm, | Boehringer Ingelheim - (sverige@bitrialsupport.com) |
| Dokkyo Medical University Saitama Medical Center Koshigaya, Saitama | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Duke University Medical Center Durham, North Carolina | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Elixia MNA, LLC City of Saint Peters, Missouri | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Emory Children's Center Atlanta, Georgia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Endeavor Health Evanston, Illinois | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Erciyes University Kayseri, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
| Faculty hospital with clinics F.D. Roosevelta Banská Bystrica, | Boehringer Ingelheim - (slovensko@bitrialsupport.com) |
| Far Eastern Memorial Hospital New Taipei City, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| First Affiliated Hospital of Xi'an JiaoTong University Xi'an, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Florida Kidney Physicians - Boca Raton Boca Raton, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Florida Kidney Physicians, LLC - Fort Lauderdale Fort Lauderdale, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Fondazione Salvatore Maugeri Pavia, | Boehringer Ingelheim - (italia@bitrialsupport.com) |
| Fundação Oswaldo Ramos (Hospital do Rim) São Paulo, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Galaxy Lifecare Services Pvt. Ltd. Varanasi, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| George Washington University Medical Faculty Associates Washington D.C., District of Columbia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Government Medical College Kozhikode, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Griffith Health Southport, Queensland | Boehringer Ingelheim - (australia@bitrialsupport.com) |
| Guangdong Provincial People's Hospital Guangzhou, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| HOP Nancy Vandœuvre-lès-Nancy, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| HOP Pellegrin Bordeaux, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| HOP de la Cavale Blanche Brest, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| Health Pharma Professional Research S.A. de C.V. Mexico City, | Boehringer Ingelheim - (mexico@bitrialsupport.com) |
| Helse Stavanger, Stavanger Universitetssykehus Stavanger, | Boehringer Ingelheim - (norge@bitrialsupport.com) |
| Henry Ford Hospital Detroit, Michigan | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Hong Kong Children's Hospital Hong Kong, | Boehringer Ingelheim - (hongkong@bitrialsupport.com) |
| Hopital Edouard Herriot Lyon, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| Hopital Henri Mondor Créteil, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| Hopital Necker Paris, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| Hopital Pasteur Nice, | Boehringer Ingelheim - (france@bitrialsupport.com) |
| Hospital Clinic de Barcelona Barcelona, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Clinico San Carlos Madrid, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Del Mar Barcelona, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Kuala Lumpur Kuala Lumpur, | Boehringer Ingelheim - (malaysia@bitrialsupport.com) |
| Hospital Sant Joan de Deu Barcelona, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Sultan Idris Shah Serdang Kajang, | Boehringer Ingelheim - (malaysia@bitrialsupport.com) |
| Hospital Tuanku Ja'afar Negeri Sembilan, | Boehringer Ingelheim - (malaysia@bitrialsupport.com) |
| Hospital Universitari Vall d'Hebron Barcelona, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Universitario 12 de Octubre Madrid, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Universitario Austral Pilar, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| Hospital Universitario Virgen de las Nieves Granada, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital das Clínicas da Universidade Federal de Pernambuco Recife, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Hospital de Clínicas de Porto Alegre Porto AlegreRS, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Huashan Hospital, Fudan University Shanghai, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Imam Abdulrahman bin Faisal University Dammam, | Boehringer Ingelheim - (saudi@bitrialsupport.com) |
| Inje University Ilsan Paik Hospital Goyang-si, | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| Institute of Science Tokyo Hospital Bunkyoku, Tokyo | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Instituto Nacional de Cardiologia Ignacio Chavez Mexico City, | Boehringer Ingelheim - (mexico@bitrialsupport.com) |
| Instituto Nacional de Cs Médicas y Nutrición S Zubiran Mexico City, | Boehringer Ingelheim - (mexico@bitrialsupport.com) |
| Instituto da Criança e do Adolescente São Paulo, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Institutul Clinic Fundeni Bucharest, | Boehringer Ingelheim - (romania@bitrialsupport.com) |
| JSS Medical College Mysore, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Aichi, Nagoya, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Japanese Red Cross Fukuoka Hospital Fukuoka, Fukuoka, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Johns Hopkins Hospital Baltimore, Maryland | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Joslin Diabetes Center Boston, Massachusetts | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| KEM Hospital and Seth G S Medical College Mumbai, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Kaiser Permanente - French Campus San Francisco, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Kaiser Permanente - Los Angeles Medical Center Los Angeles, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Kaohsiung Chang Gung Memorial Hospital Kaohsiung City, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| Karolinska Universitetssjukhuset Stockholm, | Boehringer Ingelheim - (sverige@bitrialsupport.com) |
| Kasturba Medical College and Hospital Manipal, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Kasugai Municipal Hospital Aichi, Kasugai, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Kidney Associates of Colorado - Denver Denver, Colorado | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Kidney Disease Medical Group Glendale, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| King Fahad Specialist Hospital - Research Center Dammam, | Boehringer Ingelheim - (saudi@bitrialsupport.com) |
| King's College Hospital London, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| Kobe University Hospital Hyogo, Kobe, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Kocaeli University Faculty of Medicine Hospital İzmit, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
| Kurume University Hospital Kurume, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Kyung Hee University Hospital at Gangdong Seoul, | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| LEPL The First University Clinic of Tbilisi State Medical University Tbilisi, | Boehringer Ingelheim - (sakartvelo@bitrialsupport.com) |
| LTD Israeli-Georgian Medical Research Clinic Healthycore Tbilisi, | Boehringer Ingelheim - (sakartvelo@bitrialsupport.com) |
| Lanzhou University Second Hospital Lanzhou, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Leicester General Hospital Leicester, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| M.Iashvili Children's Hospital Tbilisi, | Boehringer Ingelheim - (sakartvelo@bitrialsupport.com) |
| Madras Medical College and Rajiv Gandhi Government General Hospital Chennai, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Maisonneuve-Rosemont Hospital Montreal, Quebec | Boehringer Ingelheim - (canada@bitrialsupport.com) |
| Manila Doctors Hospital Manila, | Boehringer Ingelheim - (pilipinas@bitrialsupport.com) |
| Medical Center "Pulmovision" Sofia, | Boehringer Ingelheim - (balgariya@bitrialsupport.com) |
| Medizinische Hochschule hannover Hanover, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Memorial Health University Hospital Savannah, Georgia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| NYU Langone Nephrology Associates-Mineola Mineola, New York | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nara Prefecture General Medical Center Nara, Nara, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| National Cheng Kung University Hospital Tainan, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| National Hospital Organization Chibahigashi National Hospital Chiba, Chiba, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| National Institute of Clinical Research - Victorville Victorville, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| National Taiwan University Hospital Taipei, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| National University Hospital Singapore, | Boehringer Ingelheim - (singapore@bitrialsupport.com) |
| Nationwide Children's Hospital Columbus, Ohio | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nepean Hospital Kingswood, New South Wales | Boehringer Ingelheim - (australia@bitrialsupport.com) |
| Nephrology Associates of Northern Virginia Fairfax, Virginia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nephrology Associates, Inc East Providence, Rhode Island | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nephrology Physicians - Mishawaka Mishawaka, Indiana | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nephrology of Golden Isles Brunswick, Georgia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nephrotex Research Group Dallas, Texas | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| New York Nephrology and Dialysis Access Surgery, PC Clifton Park, New York | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| New Zealand Clinical Research (NZCR) Christchurch Christchurch, | Boehringer Ingelheim - (newzealand@bitrialsupport.com) |
| Niigata University Medical and Dental Hospital Niigata, Niigata | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Noble Hospital Pvt Ltd Pune, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| North America Research Institute San Dimas, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Northeast Clinical Research Center Bethlehem, Pennsylvania | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Northwest Louisiana Nephrology Shreveport, Louisiana | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Northwestern University Chicago, Illinois | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Nutema Hospital Meerut, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Okayama University Hospital Okayama, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Optimal Clinical Trials North Rosedale, Auckland, | Boehringer Ingelheim - (newzealand@bitrialsupport.com) |
| Oslo Universitetssykehus HF, Ullevål sykehus Oslo, | Boehringer Ingelheim - (norge@bitrialsupport.com) |
| Osmania Medical College & Hospital Hyderabad, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Panoramic Health Riverview, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Paragon Health Nephrology Center - Kalamazoo Kalamazoo, Michigan | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Peking University First Hospital Beijing, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| People's Hospital of Sichuan Province Chengdu, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Policlinico S. Orsola-Malpighi Bologna, | Boehringer Ingelheim - (italia@bitrialsupport.com) |
| Poliklinika Bonifarm Zagreb Zagreb, | Boehringer Ingelheim - (hrvatska@bitrialsupport.com) |
| Primary Children's Hospital Salt Lake City, Utah | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Provecta Researh Network Houston, Texas | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Pusan National University Hospital Seogu, Busan Gwang'yeogsi | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| Queen Elizabeth Hospital Kota Kinabalu, | Boehringer Ingelheim - (malaysia@bitrialsupport.com) |
| Queen Mary Hospital Hong Kong, | Boehringer Ingelheim - (hongkong@bitrialsupport.com) |
| Renal Associates of Baton Rouge Baton Rouge, Louisiana | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Renmin Hospital of Wuhan University Wuhan, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Royal Adelaide Hospital Adelaide, | Boehringer Ingelheim - (australia@bitrialsupport.com) |
| Royal Brisbane and Women's Hospital Herston, Queensland | Boehringer Ingelheim - (australia@bitrialsupport.com) |
| Royal Free Hospital London, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| Royal Melbourne Hospital Parkville, Victoria | Boehringer Ingelheim - (australia@bitrialsupport.com) |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| S.P. Medical College & Associated Group of Hospitals Bikaner, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Saiseikai Yokohamashi Nanbu Hospital Kanagawa, Yokohama, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Salford Royal Salford, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| Samodzielny Publiczny Dzieciecy Szpital Kliniczny Im. Jozefa Polikarpa Brudzinskiego W Warszawie Warsaw, | Boehringer Ingelheim - (polska@bitrialsupport.com) |
| Samsung Medical Center Seoul, | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| Servicios de Oncología Médica Integral, S.A. de C.V. Sucursal Renal Monterrey, | Boehringer Ingelheim - (mexico@bitrialsupport.com) |
| Severance Hospital Seoul, | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| Shanghai General Hospital Shanghai, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Shanxi Provincial People's Hospital Taiyuan, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Shri Mahant Indiresh Hospital Dehradun, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Singapore General Hospital Singapore, | Boehringer Ingelheim - (singapore@bitrialsupport.com) |
| Sir Gangaram Hospital Delhi, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| Skanes universitetssjukhus Lund, | Boehringer Ingelheim - (sverige@bitrialsupport.com) |
| Soltmed Smo Mexico City, | Boehringer Ingelheim - (mexico@bitrialsupport.com) |
| Southeast Kidney Associates - East Point East Point, Georgia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Southeast Renal Research Institute Chattanooga, Tennessee | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Southwest Kidney Institute Surprise, Arizona | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Spitalul Clinic Judetean de urgenta Cluj Cluj-Napoca, | Boehringer Ingelheim - (romania@bitrialsupport.com) |
| Sri Ramchandra Institute Chennai, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| St George Hospital Sydney, | Boehringer Ingelheim - (australia@bitrialsupport.com) |
| St. Clair Nephrology Research, LLC - Shelby Township Utica, Michigan | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Sunway Medical Centre Subang Jaya, | Boehringer Ingelheim - (malaysia@bitrialsupport.com) |
| Synvia Campinas, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Taichung Veterans General Hospital Taichung, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| Taipei Medical University-Shuang Ho Hospital New Taipei City, | Boehringer Ingelheim - (taiwan@bitrialsupport.com) |
| Tan Tock Seng Hospital Singapore, | Boehringer Ingelheim - (singapore@bitrialsupport.com) |
| Taranaki Base Hospital New Plymouth, | Boehringer Ingelheim - (newzealand@bitrialsupport.com) |
| Terapia Renal Domiciliaria Buenos Aires, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| Texas Tech University Health Sciences Center-Amarillo-63885 Amarillo, Texas | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| The First Affiliated Hospital of Baotou Medical College Baotou, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi | Boehringer Ingelheim - (china@bitrialsupport.com) |
| The First Affiliated Hospital of NanChang University Nanchang, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| The First Affiliated Hospital, Zhejiang University Hangzhou, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| The First People's Hospital of Nanning Nanning, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| The Jikei University Hospital Tokyo, Minato-ku, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| The Kidney and Hypertension Center Cincinnati, Ohio | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| The Ohio State University Wexner Medical Center Columbus, Ohio | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| The Second Hospital of Jilin University Changchun, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| The Second Xiangya Hospital of Central South University Changsha, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Tokyo Medical University Hachioji Medical Center Tokyo, Hachioji, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Tokyo Women's Medical University Hospital Tokyo, Shinjuku-ku, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Total Research Group, LLC Miami, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| ULS Braga Braga, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| ULS de Almada -Seixal, E. P. E. - Hospital Garcia de Orta Almada, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| ULS de Amadora/ Sintra, E.P.E. - Hospital Professor Doutor Fernando Fonseca Amadora, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| ULS de Loures-Odivelas, E.P.E Loures, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| ULS de Santa Maria, E.P.E Lisbon, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| ULS de Santo Antônio, E.P.E - Centro Hospitalar Universitário de Santo António Porto, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| ULS de São José Lisbon, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| UZ Leuven Leuven, | Boehringer Ingelheim - (belgique@bitrialsupport.com) |
| Unidade Local de Saúde Lisboa Occidental, E.P.E Lisbon, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| Unidade Local de Saúde da Arrábida,E.P.E Setúbal, | Boehringer Ingelheim - (portugal@bitrialsupport.com) |
| Univ. Gen. Hosp. of Patras Pátrai, | Boehringer Ingelheim - (hellas@bitrialsupport.com) |
| Univ. Hospital Martin Martin, | Boehringer Ingelheim - (slovensko@bitrialsupport.com) |
| Universidade Federal do Ceara Fortaleza, | Boehringer Ingelheim - (brasil@bitrialsupport.com) |
| Universitair Medisch Centrum Groningen Groningen, | Boehringer Ingelheim - (nederland@bitrialsupport.com) |
| Universitatsklinikum Heidelberg Heidelberg, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitetssjukhuset, Linköping Linköping, | Boehringer Ingelheim - (sverige@bitrialsupport.com) |
| Universitetssykehuset Nord-Norge, Tromso Tromsø, | Boehringer Ingelheim - (norge@bitrialsupport.com) |
| University General Hospital of Heraklion Heraklion, | Boehringer Ingelheim - (hellas@bitrialsupport.com) |
| University Hospital Bern Bern, | Boehringer Ingelheim - (suisse@bitrialsupport.com) |
| University Hospital Zurich Zurich, | Boehringer Ingelheim - (suisse@bitrialsupport.com) |
| University Hospital and Comenius University in Bratislava, Derer´s Hospital Bratislava, | Boehringer Ingelheim - (slovensko@bitrialsupport.com) |
| University Malaya Medical Centre Lembah Pantai, | Boehringer Ingelheim - (malaysia@bitrialsupport.com) |
| University of California Los Angeles Los Angeles, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| University of Pennsylvania Philadelphia, Pennsylvania | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| University of Texas Medical Branch at Galveston Galveston, Texas | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Universität Leipzig Leipzig, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitätsklinikum Hamburg, Eppendorf Hamburg, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitätsklinikum Köln (AöR) Cologne, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitätsklinikum Würzburg AÖR Würzburg, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Univerzitna nemocnica L. Pasteura Kosice Košice, | Boehringer Ingelheim - (slovensko@bitrialsupport.com) |
| Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie Szczecin, | Boehringer Ingelheim - (polska@bitrialsupport.com) |
| Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Poznan, | Boehringer Ingelheim - (polska@bitrialsupport.com) |
| Uppsala University Hospital Uppsala, | Boehringer Ingelheim - (sverige@bitrialsupport.com) |
| Utah Kidney Research Institute Salt Lake City, Utah | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Valiance Clinical Research Huntington Park, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Valiance Clinical Research-Tarzana-68237 Tarzana, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Victoria Hospital (LHSC) London, Ontario | Boehringer Ingelheim - (canada@bitrialsupport.com) |
| Virginia Commonwealth University Henrico, Virginia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Virginia Nephrology Arlington, Virginia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Vivantes Klinikum im Friedrichshain Berlin, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Waikato Hospital Hamilton, | Boehringer Ingelheim - (newzealand@bitrialsupport.com) |
| West China Hospital, Sichuan University Chengdu, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| West Coast Kidney Institute Fremont, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| West Virginia University Medicine Morgantown, West Virginia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Wichita Nephrology Group Wichita, Kansas | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Yokohama City University Hospital Kanagawa, Yokohama, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Zealand University Hospita; Roskilde Roskilde, | Boehringer Ingelheim - (danmark@bitrialsupport.com) |
| Zhongda Hospital Southeast University Nanjing, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Zhongshan Hospital Affiliated to Xiamen University Xiamen, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Zydus Hospital - Ahmedabad Ahmedabad, | Boehringer Ingelheim - (india@bitrialsupport.com) |
| hospital Italiano de Buenos Aires Ciudad Autonoma Buenos Aires, | Boehringer Ingelheim - (argentina@bitrialsupport.com) |
| İstanbul Çapa University Istanbul, | Boehringer Ingelheim - (turkiye@bitrialsupport.com) |
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Rachel Wills - cancercontrolprotocols@alliancenctn.org
NCT07091617
Show full eligibility criteria
Hide eligibility criteria
* PATIENTS: Age ≥ 18 years and ≤ 39 years at the time of enrollment
* PATIENTS: AYA cancer patients and survivors. This includes patients at any stage of diagnosis (e.g., newly diagnosed, in treatment, in survivorship) and a cancer diagnosis (including pediatric cancers) at any age ≤ 39 years old. Given targeted therapies for BRCA+ and microsatellite instability (MSI)-high/Lynch Syndrome patients and benefit to relatives, patients with metastatic cancer are included. Any history of cancer, regardless of being in treatment or not
* PATIENTS: Language: In order to complete the mandatory patient-completed measures and receive genetic education and counseling, participants must be able to speak and read English or Spanish
* PATIENTS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members
* PATIENTS: No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician
* PATIENTS: Participants must meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing assessment provided by Penn Telegenetics by the Eligibility Verification Assessment (EVA) chatbot, or paper forms and genetic counselor's review
* NON-PATIENT PARTICIPANT: Non-patient participants eligible for this study include: oncology providers, members of the care team and clinic staff, genetic counselors, and insurers (i.e., people who work in financial services and/or for insurance companies) who participate in oncology care among AYA in community for this study
* NON-PATIENT PARTICIPANT: Age ≥ 18 years
* NON-PATIENT PARTICIPANT: Non-patient participants must be able to speak and read English or Spanish in order to participate in the key informant interviews
OTHER: Telemedicine, OTHER: Genetic Testing, OTHER: Telemedicine, OTHER: Internet-Based Intervention, OTHER: Educational Intervention, BEHAVIORAL: Patient Navigation, OTHER: Interview, OTHER: Survey Administration
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
I'm interested
Share via email
Show 231 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Abbott-Northwestern Hospital Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Alaska Breast Care and Surgery LLC Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alaska Oncology and Hematology LLC Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alaska Women's Cancer Care Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alegent Health Bergan Mercy Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Immanuel Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Lakeside Hospital Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alfred I duPont Hospital for Children Wilmington, Delaware | Site Public Contact - (Allison.bruce@nemours.org) |
| Anchorage Associates in Radiation Medicine Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Arnold Palmer Hospital for Children Orlando, Florida | Site Public Contact - (Jennifer.spinelli@orlandohealth.com) |
| Augusta University Medical Center Augusta, Georgia | Site Public Contact - (ga_cares@augusta.edu) |
| BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri | |
| Bay Area Hospital Coos Bay, Oregon | Site Public Contact - (cherie.cox@bayareahospital.org) |
| Benefis Helena Specialty Center Helena, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Benefis Sletten Cancer Institute Great Falls, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Bethesda North Hospital Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Billings Clinic Cancer Center Billings, Montana | Site Public Contact - (research@billingsclinic.org) |
| Billings Clinic-Cody Cody, Wyoming | Site Public Contact - (research@billingsclinic.org) |
| Bon Secours Memorial Regional Medical Center Mechanicsville, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Saint Francis Medical Center Midlothian, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Saint Mary's Hospital Richmond, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bozeman Health Deaconess Hospital Bozeman, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Broadlawns Medical Center Des Moines, Iowa | |
| CARTI Cancer center Little Rock, Arkansas | Site Public Contact - (Research@CARTI.com) |
| CHI Health Good Samaritan Kearney, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CHI Health Saint Francis Grand Island, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Cancer Care Center of O'Fallon O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Care Northwest - Spokane South Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Northwest-North Spokane Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Northwest-Valley Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Specialists of Illinois - Decatur Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Center at Saint Joseph's Phoenix, Arizona | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Cancer Center of Western Wisconsin New Richmond, Wisconsin | Site Public Contact - (mmcorc@healthpartners.com) |
| Carle BroMenn Medical Center Normal, Illinois | Site Public Contact - (Research@Carle.com) |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Cancer Institute Normal Normal, Illinois | Site Public Contact - (Research@Carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Central Care Cancer Center - Bolivar Bolivar, Missouri | Site Public Contact - (aroland@kccop.org) |
| Central Care Cancer Center - Garden City Garden City, Kansas | Site Public Contact - (aroland@kccop.org) |
| Central Care Cancer Center - Great Bend Great Bend, Kansas | Site Public Contact - (aroland@kccop.org) |
| Centralia Oncology Clinic Centralia, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Clackamas Radiation Oncology Center Clackamas, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| CommonSpirit Cancer Center Mercy Durango, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Anthony Hospital Cancer Center Lakewood, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Commonwealth Cancer Center-Corbin Corbin, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Community Hospital of Anaconda Anaconda, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Community Medical Center Missoula, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Cox Cancer Center Branson Branson, Missouri | |
| CoxHealth South Hospital Springfield, Missouri | |
| Creighton University Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Crossroads Cancer Center Effingham, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Decatur Memorial Hospital Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Lakes Medical Center Wyoming, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Northland Medical Center Princeton, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Southdale Hospital Edina, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Flaget Memorial Hospital Bardstown, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Freeman Health System Joplin, Missouri | Site Public Contact - (LJCrockett@freemanhealth.com) |
| Good Samaritan Hospital - Cincinnati Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Great Falls Clinic Great Falls, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Greater Regional Medical Center Creston, Iowa | |
| HSHS Saint Elizabeth's Hospital O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Heartland Regional Medical Center Saint Joseph, Missouri | Site Public Contact - (Trisha.England2@mymlc.com) |
| Hennepin County Medical Center Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Hi-Line Sletten Cancer Center Havre, Montana | Site Public Contact - (protocols@AllianceNCTN.org) |
| Illinois CancerCare - Washington Washington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Bloomington Bloomington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Canton Canton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Carthage Carthage, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Dixon Dixon, Illinois | |
| Illinois CancerCare-Eureka Eureka, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Galesburg Galesburg, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Kewanee Clinic Kewanee, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Macomb Macomb, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Ottawa Clinic Ottawa, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Pekin Pekin, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peoria Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peru Peru, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Princeton Princeton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Iowa Methodist Medical Center Des Moines, Iowa | |
| Kadlec Clinic Hematology and Oncology Kennewick, Washington | Site Public Contact - (research@kadlecmed.org) |
| Katmai Oncology Group Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Lake Regional Hospital Osage Beach, Missouri | Site Public Contact - (clinicaltrials@lakeregional.com) |
| Lakeview Hospital Stillwater, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Logan Health Medical Center Kalispell, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Longmont United Hospital Longmont, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Matthews Radiation Oncology Center Matthews, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Medical University of South Carolina Charleston, South Carolina | Site Public Contact - (hcc-clinical-trials@musc.edu) |
| Memorial Hospital of Carbondale Carbondale, Illinois | Site Public Contact - (clinical.research@sih.net) |
| Memorial Hospital of Laramie County Cheyenne, Wyoming | Site Public Contact - (protocols@AllianceNCTN.org) |
| Mercy Cancer Center Merced, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Cape Girardeau Cape Girardeau, Missouri | |
| Mercy Cancer Center - Carmichael Carmichael, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Elk Grove Elk Grove, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Rocklin Rocklin, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Sacramento Sacramento, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center-West Lakes Clive, Iowa | |
| Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri | |
| Mercy Hospital Coon Rapids, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mercy Hospital Fort Smith Fort Smith, Arkansas | |
| Mercy Hospital Joplin Joplin, Missouri | Site Public Contact - (esmeralda.carrillo@mercy.net) |
| Mercy Hospital Oklahoma City Oklahoma City, Oklahoma | |
| Mercy Hospital Pittsburg Pittsburg, Kansas | |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Mercy Hospital South St Louis, Missouri | Site Public Contact - (Danielle.Werle@mercy.net) |
| Mercy Hospital Springfield Springfield, Missouri | |
| Mercy Hospital Washington Washington, Missouri | |
| Mercy Infusion Center - Chippewa St Louis, Missouri | |
| Mercy Medical Center Springfield, Massachusetts | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Medical Center - Des Moines Des Moines, Iowa | |
| Mercy Medical Center-West Lakes West Des Moines, Iowa | |
| Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri | |
| Mercy San Juan Medical Center Carmichael, California | Site Public Contact - (ResearchInstituteInquiries@commonspirit.org) |
| Methodist Medical Center of Illinois Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Minnesota Oncology - Burnsville Burnsville, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mission Hope Medical Oncology - Santa Maria Santa Maria, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Missouri Baptist Medical Center St Louis, Missouri | |
| Missouri Baptist Sullivan Hospital Sullivan, Missouri | |
| Monticello Cancer Center Monticello, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Nemours Children's Clinic - Pensacola Pensacola, Florida | Site Public Contact - (ctsucontact@westat.com) |
| Nemours Children's Hospital Orlando, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| New Ulm Medical Center New Ulm, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| North Memorial Medical Health Center Robbinsdale, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Novant Health Cancer Institute - Huntersville Huntersville, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Novant Health Cancer Institute - Kernersville Kernersville, North Carolina | Site Public Contact - (asmarrs@novanthealth.org) |
| Novant Health Cancer Institute - Matthews Matthews, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Novant Health Cancer Institute - Mooresville Mooresville, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Novant Health Cancer Institute - Mount Airy Mount Airy, North Carolina | Site Public Contact - (asmarrs@novanthealth.org) |
| Novant Health Cancer Institute - Rowan Salisbury, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Novant Health Cancer Institute - Thomasville Thomasville, North Carolina | Site Public Contact - (pjordan@novanthealth.org) |
| Novant Health Forsyth Medical Center Winston-Salem, North Carolina | Site Public Contact - (pjordan@novanthealth.org) |
| Novant Health New Hanover Regional Medical Center Wilmington, North Carolina | |
| Novant Health Presbyterian Medical Center Charlotte, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| Novant Health Presbyterian Medical Center Huntersville Huntersville, North Carolina | Site Public Contact - (kashah@novanthealth.org) |
| OSF Saint Anthony's Health Center Alton, Illinois | |
| OSF Saint Francis Hospital and Medical Group Escanaba, Michigan | Site Public Contact - (WI_research_admin@hshs.org) |
| Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Parkland Health Center - Farmington Farmington, Missouri | |
| PeaceHealth Saint John Medical Center Longview, Washington | Site Public Contact - (kmakin-bond@peacehealth.org) |
| PeaceHealth Saint Joseph Medical Center Bellingham, Washington | Site Public Contact - (achapman1@peacehealth.org) |
| PeaceHealth Southwest Medical Center Vancouver, Washington | Site Public Contact - (kmakin-bond@peacehealth.org) |
| PeaceHealth United General Medical Center Sedro-Woolley, Washington | Site Public Contact - (achapman1@peacehealth.org) |
| Penrose-Saint Francis Healthcare Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Phelps Health Delbert Day Cancer Institute Rolla, Missouri | Site Public Contact - (research@phelpshealth.org) |
| Providence Alaska Medical Center Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Providence Hood River Memorial Hospital Hood River, Oregon | Site Public Contact - (canrsrchstudies@provdience.org) |
| Providence Medical Foundation - Santa Rosa Santa Rosa, California | |
| Providence Newberg Medical Center Newberg, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Portland Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Queen of The Valley Napa, California | |
| Providence Regional Cancer Partnership Everett, Washington | Site Public Contact - (marilyn.birchman@providence.org) |
| Providence Regional Cancer System-Aberdeen Aberdeen, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Centralia Centralia, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Lacey Lacey, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California | Site Public Contact - (Najee.Boucher@providence.org) |
| Providence Saint Mary Regional Cancer Center Walla Walla, Washington | Site Public Contact - (Cheryl.Dodd@providence.org) |
| Providence Saint Vincent Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Santa Rosa Memorial Hospital Santa Rosa, California | |
| Providence Willamette Falls Medical Center Oregon City, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Regions Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Rice Memorial Hospital Willmar, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Ridgeview Medical Center Waconia, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Rowan Regional Medical Center Salisbury, North Carolina | Site Public Contact - (nnechiporchik@novanthealth.org) |
| SIH Cancer Institute Carterville, Illinois | Site Public Contact - (clinical.research@sih.net) |
| SSM Health Good Samaritan Mount Vernon, Illinois | Site Public Contact - (gayla.hall@ssmhealth.com) |
| Saint Anthony North Hospital Westminster, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Anthony Regional Hospital Carroll, Iowa | Site Public Contact - (sbenson@iora.org) |
| Saint Charles Health System Bend, Oregon | Site Public Contact - (nosall@stcharleshealthcare.org) |
| Saint Charles Health System-Redmond Redmond, Oregon | |
| Saint Francis Cancer Center Greenville, South Carolina | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Francis Medical Center Cape Girardeau, Missouri | Site Public Contact - (sfmc@sfmc.net) |
| Saint Francis Regional Medical Center Shakopee, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Saint John's Hospital - Healtheast Maplewood, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Saint Joseph Hospital Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Hospital East Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph London London, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Medical Center Hematology and Oncology - Silverdale Silverdale, Washington | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Mount Sterling Mount Sterling, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph's Medical Center Stockton, California | |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Meridian Meridian, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Nampa Nampa, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Mary Corwin Medical Center Pueblo, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Mary's Hospital Centralia, Illinois | |
| Saint Patrick Hospital - Community Hospital Missoula, Montana | Site Public Contact - (amy.hanneman@providence.org) |
| Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin | Site Public Contact - (WI_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin | Site Public Contact - (WI_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri | |
| Sheboygan Physicians Group Sheboygan, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Skagit Regional Health Cancer Care Center Mount Vernon, Washington | Site Public Contact - (rcccclinicalresearch@skagitvalleyhospital.org) |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| Springfield Clinic Springfield, Illinois | |
| Springfield Memorial Hospital Springfield, Illinois | Site Public Contact - (pallante.beth@mhsil.com) |
| Swedish Cancer Institute-Edmonds Edmonds, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Cancer Institute-Issaquah Issaquah, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-Ballard Campus Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-Cherry Hill Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-First Hill Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| The Iowa Clinic PC West Des Moines, Iowa | |
| TriHealth Cancer Institute-Anderson Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| TriHealth Cancer Institute-Westside Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa | |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa | |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa | |
| UI Healthcare Mission Cancer and Blood - Fort Dodge Fort Dodge, Iowa | Site Public Contact - (trials@missioncancer.com) |
| UI Healthcare Mission Cancer and Blood - Pella Pella, Iowa | Site Public Contact - (trials@missioncancer.com) |
| United Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| University of Texas Health Science Center at San Antonio San Antonio, Texas | Site Public Contact - (phoresearchoffice@uthscsa.edu) |
| VCU Community Memorial Health Center South Hill, Virginia | Site Public Contact - (nemer.elmouallem@vcuhealth.org) |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Radiation Oncology Peru, Illinois | |
| Woodland Memorial Hospital Woodland, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |